MXPA01007649A - Alkynyl containing hydroxamic acid compounds as tace inhibitors - Google Patents
Alkynyl containing hydroxamic acid compounds as tace inhibitorsInfo
- Publication number
- MXPA01007649A MXPA01007649A MXPA/A/2001/007649A MXPA01007649A MXPA01007649A MX PA01007649 A MXPA01007649 A MX PA01007649A MX PA01007649 A MXPA01007649 A MX PA01007649A MX PA01007649 A MXPA01007649 A MX PA01007649A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- ynyloxy
- butynyloxy
- hydroxy
- carbon atoms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 109
- 239000002253 acid Substances 0.000 title claims description 135
- 125000000304 alkynyl group Chemical group 0.000 title claims description 10
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title description 4
- 230000001404 mediated Effects 0.000 claims abstract description 8
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims abstract description 5
- -1 2- (4-But-2-ynyloxy-benzenesulfonyl) -N-hydroxy-2-methyl-3- [4- (2-pyridin-1-yl-ethoxy) -phenyl] -propionamide Chemical compound 0.000 claims description 430
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 180
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 92
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 76
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims description 71
- 239000011347 resin Substances 0.000 claims description 59
- 229920005989 resin Polymers 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 55
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 150000002431 hydrogen Chemical class 0.000 claims description 28
- 125000005842 heteroatoms Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 23
- 102100009534 TNF Human genes 0.000 claims description 22
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 19
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 230000000875 corresponding Effects 0.000 claims description 13
- 101710040537 TNF Proteins 0.000 claims description 12
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 11
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical compound C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 claims description 11
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 10
- VSBFNCXKYIEYIS-UHFFFAOYSA-N 9H-xanthene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3OC2=C1 VSBFNCXKYIEYIS-UHFFFAOYSA-N 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000005418 aryl aryl group Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 7
- 125000004429 atoms Chemical group 0.000 claims description 6
- YYOVZJXOBZVIQK-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-N-hydroxy-3-methylbutanamide Chemical compound CC#CCOC1=CC=C(S(=O)C(C(C)C)C(=O)NO)C=C1 YYOVZJXOBZVIQK-UHFFFAOYSA-N 0.000 claims description 5
- GWJBQNZXAWCMRK-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-6-[[2-[(2,2-diphenylacetyl)amino]acetyl]amino]-N-hydroxyhexanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)CCCCNC(=O)CNC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 GWJBQNZXAWCMRK-UHFFFAOYSA-N 0.000 claims description 5
- 210000003169 Central Nervous System Anatomy 0.000 claims description 5
- 229960001171 acetohydroxamic acid Drugs 0.000 claims description 5
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 5
- 200000000018 inflammatory disease Diseases 0.000 claims description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- KTMMYBDZBIJPLY-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-3-methylbutanamide Chemical compound CC#CCOC1=CC=C(S(=O)(=O)C(C(C)C)C(=O)NO)C=C1 KTMMYBDZBIJPLY-UHFFFAOYSA-N 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
- 208000005721 HIV Infections Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010022489 Insulin resistance Diseases 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 4
- ILAOVOOZLVGAJF-UHFFFAOYSA-N 1-methylpyrrole-2-carboxylic acid Chemical compound CN1C=CC=C1C(O)=O ILAOVOOZLVGAJF-UHFFFAOYSA-N 0.000 claims description 3
- SETFXJLLFMSYRI-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenoxy)-N-hydroxyacetamide Chemical compound CC#CCOC1=CC=C(OCC(=O)NO)C=C1 SETFXJLLFMSYRI-UHFFFAOYSA-N 0.000 claims description 3
- YATPINJCZWACOK-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-2-(4-fluorophenyl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1=CC=C(F)C=C1 YATPINJCZWACOK-UHFFFAOYSA-N 0.000 claims description 3
- IWSABXACJQMTBL-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-(oxan-4-yl)acetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1CCOCC1 IWSABXACJQMTBL-UHFFFAOYSA-N 0.000 claims description 3
- RRUDCFGSUDOHDG-UHFFFAOYSA-N Acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- WJPUEGIRFDUQBD-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-6-[(2,2-diphenylacetyl)amino]-N-hydroxyhexanamide Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(=O)NO)CCCCNC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 WJPUEGIRFDUQBD-UHFFFAOYSA-N 0.000 claims description 2
- GWGMYUDABVIUOE-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-6-[[2-(3,4-dichlorophenyl)acetyl]amino]-N-hydroxyhexanamide Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(=O)NO)CCCCNC(=O)CC1=CC=C(Cl)C(Cl)=C1 GWGMYUDABVIUOE-UHFFFAOYSA-N 0.000 claims description 2
- HIBWRSXXRMHOLM-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-N-hydroxyoctanamide Chemical compound CCCCCCC(C(=O)NO)SC1=CC=C(OCC#CC)C=C1 HIBWRSXXRMHOLM-UHFFFAOYSA-N 0.000 claims description 2
- YOUSGMDITBYJFB-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-6-[[2-(1,3-dioxoisoindol-2-yl)acetyl]amino]-N-hydroxyhexanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)CCCCNC(=O)CN1C(=O)C2=CC=CC=C2C1=O YOUSGMDITBYJFB-UHFFFAOYSA-N 0.000 claims description 2
- NTAOZGOZHUUJGN-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-6-[[2-[(2,2-diphenylacetyl)amino]acetyl]amino]-N-hydroxyhexanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)CCCCNC(=O)CNC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 NTAOZGOZHUUJGN-UHFFFAOYSA-N 0.000 claims description 2
- NSFHWMMDSLIZRZ-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-(4-thiophen-2-ylphenyl)acetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1=CC=C(C=2SC=CC=2)C=C1 NSFHWMMDSLIZRZ-UHFFFAOYSA-N 0.000 claims description 2
- OQZJOXZSOHZXBH-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-methyl-3-(4-phenylphenyl)propanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C)(C(=O)NO)CC1=CC=C(C=2C=CC=CC=2)C=C1 OQZJOXZSOHZXBH-UHFFFAOYSA-N 0.000 claims description 2
- FYABASQKYDJSQF-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-methyl-3-pyridin-3-ylpropanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C)(C(=O)NO)CC1=CC=CN=C1 FYABASQKYDJSQF-UHFFFAOYSA-N 0.000 claims description 2
- BXKWXLGTWDFBDG-UHFFFAOYSA-N 4-(4-but-2-ynoxyphenyl)-N-hydroxybutanamide Chemical compound CC#CCOC1=CC=C(CCCC(=O)NO)C=C1 BXKWXLGTWDFBDG-UHFFFAOYSA-N 0.000 claims description 2
- HSWNEKKNBMLTET-UHFFFAOYSA-N C(C#CC)OC1=CC=C(C=C1)S(=O)(=O)C(C(=O)O)CCCC Chemical compound C(C#CC)OC1=CC=C(C=C1)S(=O)(=O)C(C(=O)O)CCCC HSWNEKKNBMLTET-UHFFFAOYSA-N 0.000 claims description 2
- 206010006895 Cachexia Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- AHSUIJIUCZKOSL-UHFFFAOYSA-N N-[5-(4-but-2-ynoxyphenyl)sulfanyl-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)benzamide Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(=O)NO)CCCCNC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 AHSUIJIUCZKOSL-UHFFFAOYSA-N 0.000 claims description 2
- HYLFDNGCOWLWAO-UHFFFAOYSA-N N-[5-(4-but-2-ynoxyphenyl)sulfinyl-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)benzamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)CCCCNC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 HYLFDNGCOWLWAO-UHFFFAOYSA-N 0.000 claims description 2
- 206010040070 Septic shock Diseases 0.000 claims description 2
- 150000007514 bases Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 201000006233 congestive heart failure Diseases 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 231100000915 pathological change Toxicity 0.000 claims description 2
- 230000036285 pathological change Effects 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- BIBRWOGPAHSTEO-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-6-[[2-[(2,2-diphenylacetyl)amino]acetyl]amino]-N-hydroxyhexanamide Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(=O)NO)CCCCNC(=O)CNC(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 BIBRWOGPAHSTEO-UHFFFAOYSA-N 0.000 claims 1
- YUUBFIMJZZUFNO-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-2-(4-fluorophenyl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)C1=CC=C(F)C=C1 YUUBFIMJZZUFNO-UHFFFAOYSA-N 0.000 claims 1
- BMLZCPWNCNXXRV-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-N-hydroxy-6-[[2-(1H-indol-3-yl)acetyl]amino]hexanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)CCCCNC(=O)CC1=CNC2=CC=CC=C12 BMLZCPWNCNXXRV-UHFFFAOYSA-N 0.000 claims 1
- NPIXRIRDKCZNLD-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-(1-oxothian-4-yl)acetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1CCS(=O)CC1 NPIXRIRDKCZNLD-UHFFFAOYSA-N 0.000 claims 1
- ZNXIEKZVWNHBCL-UHFFFAOYSA-N 3-(4-but-2-ynoxyphenoxy)-N-hydroxypropanamide Chemical compound CC#CCOC1=CC=C(OCCC(=O)NO)C=C1 ZNXIEKZVWNHBCL-UHFFFAOYSA-N 0.000 claims 1
- LYHLNFJSHQYIJQ-UHFFFAOYSA-N C(C#CC)OC1=CC=C(C=C1)S(=O)C(C(=O)O)CCCCNC(C(C1=CC=CC=C1)C1=CC=CC=C1)=O Chemical compound C(C#CC)OC1=CC=C(C=C1)S(=O)C(C(=O)O)CCCCNC(C(C1=CC=CC=C1)C1=CC=CC=C1)=O LYHLNFJSHQYIJQ-UHFFFAOYSA-N 0.000 claims 1
- VIGHKRJDXXYCJC-UHFFFAOYSA-N C(C#CC)OC1=CC=C(C=C1)S(=O)C(CCCCNC(=O)C[NH-])C(NO)=O Chemical compound C(C#CC)OC1=CC=C(C=C1)S(=O)C(CCCCNC(=O)C[NH-])C(NO)=O VIGHKRJDXXYCJC-UHFFFAOYSA-N 0.000 claims 1
- 210000000936 Intestines Anatomy 0.000 claims 1
- SDUAVRFGJMIFTR-UHFFFAOYSA-N N-[2-[[5-(4-but-2-ynoxyphenyl)sulfinyl-6-(hydroxyamino)-6-oxohexyl]amino]-2-oxoethyl]-2-(2-phenylethyl)benzamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)CCCCNC(=O)CNC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 SDUAVRFGJMIFTR-UHFFFAOYSA-N 0.000 claims 1
- DPOUJTZNGXOVEL-UHFFFAOYSA-N N-[5-(4-but-2-ynoxyphenyl)sulfonyl-6-(hydroxyamino)-6-oxohexyl]-2-(2-phenylethyl)benzamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)CCCCNC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 DPOUJTZNGXOVEL-UHFFFAOYSA-N 0.000 claims 1
- 101710019698 Olfr5 Proteins 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 10
- 210000000845 Cartilage Anatomy 0.000 abstract description 4
- 230000003412 degenerative Effects 0.000 abstract description 4
- 201000008482 osteoarthritis Diseases 0.000 abstract description 4
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 abstract description 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 2
- 206010011401 Crohn's disease Diseases 0.000 abstract description 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 2
- 201000006704 ulcerative colitis Diseases 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 179
- 238000006243 chemical reaction Methods 0.000 description 102
- 239000007787 solid Substances 0.000 description 77
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 64
- 239000000243 solution Substances 0.000 description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 238000007429 general method Methods 0.000 description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- 239000003921 oil Substances 0.000 description 49
- 235000019198 oils Nutrition 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- 239000000047 product Substances 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 29
- 239000000843 powder Substances 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cells Anatomy 0.000 description 24
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000008079 hexane Substances 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 229940022663 Acetate Drugs 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 239000003981 vehicle Substances 0.000 description 17
- BXAVKNRWVKUTLY-UHFFFAOYSA-N 4-sulfanylphenol Chemical compound OC1=CC=C(S)C=C1 BXAVKNRWVKUTLY-UHFFFAOYSA-N 0.000 description 15
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 15
- 239000003112 inhibitor Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- 150000003573 thiols Chemical class 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 229940088598 Enzyme Drugs 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 239000000969 carrier Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 150000003457 sulfones Chemical class 0.000 description 13
- CTSLXHKWHWQRSH-UHFFFAOYSA-N Oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 12
- 102100003095 TNFRSF1A Human genes 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 150000003568 thioethers Chemical class 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 229960003742 phenol Drugs 0.000 description 11
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 102100018200 MMP1 Human genes 0.000 description 10
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 10
- 238000005804 alkylation reaction Methods 0.000 description 10
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 125000004494 ethyl ester group Chemical group 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 9
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 101700019781 MMP1 Proteins 0.000 description 8
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 229920002892 amber Polymers 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 150000003462 sulfoxides Chemical class 0.000 description 8
- 238000010998 test method Methods 0.000 description 8
- WQINSVOOIJDOLJ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetic acid Chemical compound C1=CC=C2C(=O)N(CC(=O)O)C(=O)C2=C1 WQINSVOOIJDOLJ-UHFFFAOYSA-N 0.000 description 7
- 108009000330 Matrix Metalloproteinases Proteins 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 7
- 239000012230 colorless oil Substances 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 7
- 239000012442 inert solvent Substances 0.000 description 7
- 239000002609 media Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 108010026132 Gelatinases Proteins 0.000 description 6
- 102000013382 Gelatinases Human genes 0.000 description 6
- 102100004962 MMP13 Human genes 0.000 description 6
- 101700084657 MMP13 Proteins 0.000 description 6
- 102100006844 MMP9 Human genes 0.000 description 6
- 101700067851 MMP9 Proteins 0.000 description 6
- 210000004379 Membranes Anatomy 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 150000003141 primary amines Chemical class 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZOUPGSMSNQLUNW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(Cl)=C1 ZOUPGSMSNQLUNW-UHFFFAOYSA-N 0.000 description 5
- LMLJZJGMFKPKNY-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-N-hydroxy-2-phenylacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)C1=CC=CC=C1 LMLJZJGMFKPKNY-UHFFFAOYSA-N 0.000 description 5
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 5
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 206010003246 Arthritis Diseases 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- 206010027476 Metastasis Diseases 0.000 description 5
- OKBMCNHOEMXPTM-UHFFFAOYSA-M Potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 5
- 210000003491 Skin Anatomy 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- NEEDEQSZOUAJMU-UHFFFAOYSA-N but-2-yn-1-ol Chemical compound CC#CCO NEEDEQSZOUAJMU-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- PYHXGXCGESYPCW-UHFFFAOYSA-N diphenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 5
- 125000002534 ethynyl group Chemical class [H]C#C* 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tBuOOH Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- 208000003432 Bone Disease Diseases 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 101710038526 TNFRSF1A Proteins 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- HAXCQSPZTUOZKN-UHFFFAOYSA-N ethyl 2-(4-but-2-ynoxyphenyl)sulfanyloctanoate Chemical compound CCCCCCC(C(=O)OCC)SC1=CC=C(OCC#CC)C=C1 HAXCQSPZTUOZKN-UHFFFAOYSA-N 0.000 description 4
- PNQCIFJSRPWXHI-UHFFFAOYSA-N ethyl 2-(4-thiophen-2-ylphenyl)acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1C1=CC=CS1 PNQCIFJSRPWXHI-UHFFFAOYSA-N 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- XAAKCCMYRKZRAK-UHFFFAOYSA-N isoquinoline-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NC=CC2=C1 XAAKCCMYRKZRAK-UHFFFAOYSA-N 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 230000003287 optical Effects 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- 230000001131 transforming Effects 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 200000000019 wound Diseases 0.000 description 4
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- HHAMMCRMHQCXQK-UHFFFAOYSA-N 2-(2-bromocyclohexyl)acetic acid Chemical compound OC(=O)CC1CCCCC1Br HHAMMCRMHQCXQK-UHFFFAOYSA-N 0.000 description 3
- LBTGIGNBWBTOSY-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-2-(4-chlorophenyl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1=CC=C(Cl)C=C1 LBTGIGNBWBTOSY-UHFFFAOYSA-N 0.000 description 3
- XWXCBWLMWWUCBX-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-naphthalen-2-ylacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1=CC=C(C=CC=C2)C2=C1 XWXCBWLMWWUCBX-UHFFFAOYSA-N 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 229910017912 NH2OH Inorganic materials 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N Sulfuryl chloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000004946 alkenylalkyl group Chemical group 0.000 description 3
- 125000005038 alkynylalkyl group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 description 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N benzohydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001808 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 230000005595 deprotonation Effects 0.000 description 3
- 238000010537 deprotonation reaction Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000011368 organic material Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 201000008838 periodontal disease Diseases 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N β-Propiolactone Chemical class O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- AWEQHTSYCDFTQK-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-(3-chlorophenyl)acetic acid Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(O)=O)C1=CC=CC(Cl)=C1 AWEQHTSYCDFTQK-UHFFFAOYSA-N 0.000 description 2
- LMYDPXBSGBAOLI-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyloctanoic acid Chemical compound CCCCCCC(C(O)=O)SC1=CC=C(OCC#CC)C=C1 LMYDPXBSGBAOLI-UHFFFAOYSA-N 0.000 description 2
- YAOLTEPPKVIFGN-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-2-cyclohexyl-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)C1CCCCC1 YAOLTEPPKVIFGN-UHFFFAOYSA-N 0.000 description 2
- SJMXURWLATULOM-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-N-hydroxy-2-naphthalen-2-ylacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)C1=CC=C(C=CC=C2)C2=C1 SJMXURWLATULOM-UHFFFAOYSA-N 0.000 description 2
- AXLWGQROAABRNC-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-7-cyano-N-hydroxyheptanamide Chemical compound CC#CCOC1=CC=C(S(=O)(=O)C(CCCCCC#N)C(=O)NO)C=C1 AXLWGQROAABRNC-UHFFFAOYSA-N 0.000 description 2
- DXGSCTMFTRQSJU-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-7-cyanoheptanoic acid Chemical compound CC#CCOC1=CC=C(S(=O)(=O)C(CCCCCC#N)C(O)=O)C=C1 DXGSCTMFTRQSJU-UHFFFAOYSA-N 0.000 description 2
- PSKIOMJBUJPQBG-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-(thian-4-yl)acetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1CCSCC1 PSKIOMJBUJPQBG-UHFFFAOYSA-N 0.000 description 2
- NAMYGCWUFQUUPD-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyloctanoic acid Chemical compound CCCCCCC(C(O)=O)S(=O)(=O)C1=CC=C(OCC#CC)C=C1 NAMYGCWUFQUUPD-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- SCAQBOUTEGYULE-UHFFFAOYSA-N 4-(4-but-2-ynoxyphenoxy)-N-hydroxybutanamide Chemical compound CC#CCOC1=CC=C(OCCCC(=O)NO)C=C1 SCAQBOUTEGYULE-UHFFFAOYSA-N 0.000 description 2
- KBZYZKZDZYVXNW-UHFFFAOYSA-N 4-(4-but-2-ynoxyphenoxy)butanoic acid Chemical compound CC#CCOC1=CC=C(OCCCC(O)=O)C=C1 KBZYZKZDZYVXNW-UHFFFAOYSA-N 0.000 description 2
- WTDBNDAYNLGKGW-UHFFFAOYSA-N 4-(4-hydroxyphenyl)butanoic acid Chemical compound OC(=O)CCCC1=CC=C(O)C=C1 WTDBNDAYNLGKGW-UHFFFAOYSA-N 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- BQMVVYNDHYSKRF-UHFFFAOYSA-N C(C#CC)OC1=CC=C(C=C1)S(=O)(=O)CC(=O)O Chemical compound C(C#CC)OC1=CC=C(C=C1)S(=O)(=O)CC(=O)O BQMVVYNDHYSKRF-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 102000020504 Collagenase family Human genes 0.000 description 2
- 108060005980 Collagenase family Proteins 0.000 description 2
- 210000004087 Cornea Anatomy 0.000 description 2
- 208000004275 Demyelinating Disease Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N Diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 208000009721 Leukemia, Monocytic, Acute Diseases 0.000 description 2
- 210000002540 Macrophages Anatomy 0.000 description 2
- 208000002780 Macular Degeneration Diseases 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 208000001491 Myopia Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N Ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N Propargyl bromide Chemical class BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 206010040767 Sjogren's syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RMVRSNDYEFQCLF-UHFFFAOYSA-N Thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N Trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000003143 atherosclerotic Effects 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UAEXCEVJEZHPEO-UHFFFAOYSA-N ethyl 2-(4-hydroxyphenyl)sulfanyloctanoate Chemical compound CCCCCCC(C(=O)OCC)SC1=CC=C(O)C=C1 UAEXCEVJEZHPEO-UHFFFAOYSA-N 0.000 description 2
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 2
- VMOXWFSCEDQLQF-UHFFFAOYSA-N ethyl 4-(4-but-2-ynoxyphenoxy)butanoate Chemical compound CCOC(=O)CCCOC1=CC=C(OCC#CC)C=C1 VMOXWFSCEDQLQF-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000003617 indole-3-acetic acid Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000002287 keratoconus Diseases 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 201000004044 liver cirrhosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 230000000873 masking Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- UZHISWLCHOMTIO-UHFFFAOYSA-N methyl 4-(4-hydroxyphenyl)butanoate Chemical compound COC(=O)CCCC1=CC=C(O)C=C1 UZHISWLCHOMTIO-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative Effects 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 239000001184 potassium carbonate Substances 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 200000000008 restenosis Diseases 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 150000003463 sulfur Chemical class 0.000 description 2
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000000472 traumatic Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- WNRWEBKEQARBKV-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine Chemical compound ClCCN1CCCCC1 WNRWEBKEQARBKV-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- HLQZCRVEEQKNMS-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylbenzene Chemical compound C1=CC(CCl)=CC=C1C1=CC=CC=C1 HLQZCRVEEQKNMS-UHFFFAOYSA-N 0.000 description 1
- ZQGMEPBICQEXCJ-UHFFFAOYSA-N 1-[2-[4-(2-chloroethyl)phenoxy]ethyl]piperidine Chemical compound C1=CC(CCCl)=CC=C1OCCN1CCCCC1 ZQGMEPBICQEXCJ-UHFFFAOYSA-N 0.000 description 1
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 1
- PVSPTVQNQJFQMP-UHFFFAOYSA-N 1-but-1-ynoxybut-1-yne Chemical compound CCC#COC#CCC PVSPTVQNQJFQMP-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-Crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- GHVBLQWTDJFLTE-UHFFFAOYSA-N 2-(1-acetylpiperidin-4-yl)-2-(4-but-2-ynoxyphenyl)sulfonylacetic acid Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(O)=O)C1CCN(C(C)=O)CC1 GHVBLQWTDJFLTE-UHFFFAOYSA-N 0.000 description 1
- DWXSYDKEWORWBT-UHFFFAOYSA-M 2-(2-bromophenyl)acetate Chemical compound [O-]C(=O)CC1=CC=CC=C1Br DWXSYDKEWORWBT-UHFFFAOYSA-M 0.000 description 1
- ZFKRMQURYQDVLG-UHFFFAOYSA-N 2-(2-but-2-ynoxyphenyl)sulfonyloctanoic acid Chemical compound CCCCCCC(C(O)=O)S(=O)(=O)C1=CC=CC=C1OCC#CC ZFKRMQURYQDVLG-UHFFFAOYSA-N 0.000 description 1
- JBZIAYIOAWKJLG-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(4-but-2-ynoxyphenyl)sulfanylacetic acid Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(O)=O)C1=CC=CC(Br)=C1 JBZIAYIOAWKJLG-UHFFFAOYSA-N 0.000 description 1
- YIFLAUJBDUSBJQ-UHFFFAOYSA-N 2-(3-bromophenyl)-2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1=CC=CC(Br)=C1 YIFLAUJBDUSBJQ-UHFFFAOYSA-N 0.000 description 1
- XNPFVORXOVPQKQ-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenoxy)acetic acid Chemical compound CC#CCOC1=CC=C(OCC(O)=O)C=C1 XNPFVORXOVPQKQ-UHFFFAOYSA-N 0.000 description 1
- CQGVLCSKLFGYPB-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-(2-methoxyphenyl)acetic acid Chemical compound COC1=CC=CC=C1C(C(O)=O)SC1=CC=C(OCC#CC)C=C1 CQGVLCSKLFGYPB-UHFFFAOYSA-N 0.000 description 1
- YYFIMVMQZXVKTA-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-(3-chlorophenyl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(=O)NO)C1=CC=CC(Cl)=C1 YYFIMVMQZXVKTA-UHFFFAOYSA-N 0.000 description 1
- YUZYHGVJRYGNGS-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-(4-chlorophenyl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(=O)NO)C1=CC=C(Cl)C=C1 YUZYHGVJRYGNGS-UHFFFAOYSA-N 0.000 description 1
- HXGRNLPCSXDUGM-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-(4-ethoxyphenyl)acetic acid Chemical compound C1=CC(OCC)=CC=C1C(C(O)=O)SC1=CC=C(OCC#CC)C=C1 HXGRNLPCSXDUGM-UHFFFAOYSA-N 0.000 description 1
- HMTBBIQJGPWWIH-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-(4-fluorophenyl)butanoic acid Chemical compound C=1C=C(F)C=CC=1C(CC)(C(O)=O)SC1=CC=C(OCC#CC)C=C1 HMTBBIQJGPWWIH-UHFFFAOYSA-N 0.000 description 1
- RWQSUCDFUCUAOI-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-(4-methoxyphenyl)acetic acid Chemical compound C1=CC(OC)=CC=C1C(C(O)=O)SC1=CC=C(OCC#CC)C=C1 RWQSUCDFUCUAOI-UHFFFAOYSA-N 0.000 description 1
- PFOXOEJBRQHGAI-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-naphthalen-2-ylacetic acid Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(O)=O)C1=CC=C(C=CC=C2)C2=C1 PFOXOEJBRQHGAI-UHFFFAOYSA-N 0.000 description 1
- IIGRQTZDHBBJDQ-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-2-phenylacetic acid Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(O)=O)C1=CC=CC=C1 IIGRQTZDHBBJDQ-UHFFFAOYSA-N 0.000 description 1
- UCIRESZFNLTXNE-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-6-[[2-(1,3-dioxoisoindol-2-yl)acetyl]amino]hexanoic acid Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(O)=O)CCCCNC(=O)CN1C(=O)C2=CC=CC=C2C1=O UCIRESZFNLTXNE-UHFFFAOYSA-N 0.000 description 1
- PTQUWUSJQFSCFV-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-N-hydroxy-2-(2-methoxyphenyl)acetamide Chemical compound COC1=CC=CC=C1C(C(=O)NO)SC1=CC=C(OCC#CC)C=C1 PTQUWUSJQFSCFV-UHFFFAOYSA-N 0.000 description 1
- CDIBBFPULKXHGN-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfanyl-N-hydroxy-2-phenylacetamide Chemical compound C1=CC(OCC#CC)=CC=C1SC(C(=O)NO)C1=CC=CC=C1 CDIBBFPULKXHGN-UHFFFAOYSA-N 0.000 description 1
- LMVMXGLSCFFZIQ-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfinyl-2-(4-chlorophenyl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)C(C(=O)NO)C1=CC=C(Cl)C=C1 LMVMXGLSCFFZIQ-UHFFFAOYSA-N 0.000 description 1
- ZCOPBLLSJUICJP-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-2-(1,1-dioxothian-4-yl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1CCS(=O)(=O)CC1 ZCOPBLLSJUICJP-UHFFFAOYSA-N 0.000 description 1
- IDBZYPQZVZIRQG-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-2-(3-chlorophenyl)-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1=CC=CC(Cl)=C1 IDBZYPQZVZIRQG-UHFFFAOYSA-N 0.000 description 1
- LLGAZCDSMNQXHE-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-2-(oxan-4-yl)acetic acid Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(O)=O)C1CCOCC1 LLGAZCDSMNQXHE-UHFFFAOYSA-N 0.000 description 1
- GBSRLNJGOSPGLS-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-2-(thian-4-yl)acetic acid Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(O)=O)C1CCSCC1 GBSRLNJGOSPGLS-UHFFFAOYSA-N 0.000 description 1
- MKEVHBFZBURDHJ-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-2-cyclohexyl-N-hydroxyacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1CCCCC1 MKEVHBFZBURDHJ-UHFFFAOYSA-N 0.000 description 1
- JNPUYKMOUHYTKS-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-methyl-3-[4-(2-piperidin-1-ylethoxy)phenyl]propanamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C)(C(=O)NO)CC(C=C1)=CC=C1OCCN1CCCCC1 JNPUYKMOUHYTKS-UHFFFAOYSA-N 0.000 description 1
- FYQNXQRUDZMSAX-UHFFFAOYSA-N 2-(4-but-2-ynoxyphenyl)sulfonyl-N-hydroxy-2-naphthalen-1-ylacetamide Chemical compound C1=CC(OCC#CC)=CC=C1S(=O)(=O)C(C(=O)NO)C1=CC=CC2=CC=CC=C12 FYQNXQRUDZMSAX-UHFFFAOYSA-N 0.000 description 1
- VEHXUZFCBGMKGF-UHFFFAOYSA-N 2-(4-thiophen-2-ylphenyl)acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CS1 VEHXUZFCBGMKGF-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical group O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- WIMQMZDLEQWZBO-UHFFFAOYSA-N 2-(oxan-4-ylidene)ethyl acetate Chemical compound CC(=O)OCC=C1CCOCC1 WIMQMZDLEQWZBO-UHFFFAOYSA-N 0.000 description 1
- LOQVGWPYKDTRNW-UHFFFAOYSA-N 2-[4-(2-piperidin-1-ylethoxy)phenyl]ethanol Chemical compound C1=CC(CCO)=CC=C1OCCN1CCCCC1 LOQVGWPYKDTRNW-UHFFFAOYSA-N 0.000 description 1
- OKYMLPQEWYUPFT-UHFFFAOYSA-N 2-bromoethyl octanoate Chemical compound CCCCCCCC(=O)OCCBr OKYMLPQEWYUPFT-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- SXNFGDHVYPZYFH-UHFFFAOYSA-N 3-(4-but-2-ynoxyphenoxy)propanoic acid Chemical compound CC#CCOC1=CC=C(OCCC(O)=O)C=C1 SXNFGDHVYPZYFH-UHFFFAOYSA-N 0.000 description 1
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- LCZDCKMQSBGXAH-AWEZNQCLSA-N 3-[[3-[(2S)-2-amino-2-carboxyethyl]-5-methyl-2,6-dioxopyrimidin-1-yl]methyl]-5-phenylthiophene-2-carboxylic acid Chemical compound O=C1C(C)=CN(C[C@H](N)C(O)=O)C(=O)N1CC1=C(C(O)=O)SC(C=2C=CC=CC=2)=C1 LCZDCKMQSBGXAH-AWEZNQCLSA-N 0.000 description 1
- PYJVGTWBTIEAMV-UHFFFAOYSA-N 3-bromobut-1-yne Chemical compound CC(Br)C#C PYJVGTWBTIEAMV-UHFFFAOYSA-N 0.000 description 1
- HRDCVMSNCBAMAM-UHFFFAOYSA-N 3-prop-2-ynoxyprop-1-yne Chemical class C#CCOCC#C HRDCVMSNCBAMAM-UHFFFAOYSA-N 0.000 description 1
- DEOJMVLFGSPFIZ-UHFFFAOYSA-N 4-(2-methoxyphenyl)butanoic acid Chemical compound COC1=CC=CC=C1CCCC(O)=O DEOJMVLFGSPFIZ-UHFFFAOYSA-N 0.000 description 1
- QTZIZRWTHCAMHN-UHFFFAOYSA-N 4-(4-but-2-ynoxyphenyl)butanoic acid;4-(4-but-2-ynoxyphenyl)-N-hydroxybutanamide Chemical compound CC#CCOC1=CC=C(CCCC(O)=O)C=C1.CC#CCOC1=CC=C(CCCC(=O)NO)C=C1 QTZIZRWTHCAMHN-UHFFFAOYSA-N 0.000 description 1
- RHQCJYNIFSOIGA-UHFFFAOYSA-N 4-but-2-ynoxybenzenesulfonyl fluoride Chemical compound CC#CCOC1=CC=C(S(F)(=O)=O)C=C1 RHQCJYNIFSOIGA-UHFFFAOYSA-N 0.000 description 1
- KEXIKJSIMOKDKK-UHFFFAOYSA-N 4-but-2-ynoxyphenol Chemical compound CC#CCOC1=CC=C(O)C=C1 KEXIKJSIMOKDKK-UHFFFAOYSA-N 0.000 description 1
- FBHLNVZIWOYHIZ-UHFFFAOYSA-N 4-ethoxycyclohexa-1,5-diene-1,4-diol Chemical compound CCOC1(O)CC=C(O)C=C1 FBHLNVZIWOYHIZ-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 206010064930 Age-related macular degeneration Diseases 0.000 description 1
- 208000009400 Aortic Disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 210000002469 Basement Membrane Anatomy 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N Benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- FDYKKSCTWFIWEE-UHFFFAOYSA-N C(C#CC)OC1=C(C=CC=C1)CCCC(=O)O Chemical compound C(C#CC)OC1=C(C=CC=C1)CCCC(=O)O FDYKKSCTWFIWEE-UHFFFAOYSA-N 0.000 description 1
- BVMZNJYWIUWLIY-UHFFFAOYSA-N C(C#CC)OC1=CC=C(C=C1)S(=O)(=O)C(CCCC[NH-])C(NO)=O Chemical compound C(C#CC)OC1=CC=C(C=C1)S(=O)(=O)C(CCCC[NH-])C(NO)=O BVMZNJYWIUWLIY-UHFFFAOYSA-N 0.000 description 1
- ICUQVZDGQREWLQ-UHFFFAOYSA-N CCC1=CC(OC)=CC=C1OC(C)=O Chemical compound CCC1=CC(OC)=CC=C1OC(C)=O ICUQVZDGQREWLQ-UHFFFAOYSA-N 0.000 description 1
- UGBDHDICCJIJPI-UHFFFAOYSA-N COC(C(C1=CC=C(C=C1)OCC)SC1=CC=C(C=C1)O)=O Chemical compound COC(C(C1=CC=C(C=C1)OCC)SC1=CC=C(C=C1)O)=O UGBDHDICCJIJPI-UHFFFAOYSA-N 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 206010011017 Corneal graft rejection Diseases 0.000 description 1
- 208000002528 Coronary Thrombosis Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 238000005361 D2 NMR spectroscopy Methods 0.000 description 1
- 238000003476 Darzens condensation reaction Methods 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N Ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 210000002219 Extraembryonic Membranes Anatomy 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000012571 GlutaMAX medium Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Incidol Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N N,N'-Diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- OQJBFFCUFALWQL-UHFFFAOYSA-N N-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
- ZKYTXSSQYOZXDK-UHFFFAOYSA-N NN(CCCCC(C(=O)O)S(=O)C1=CC=C(C=C1)OCC#CC)C(C)=O Chemical compound NN(CCCCC(C(=O)O)S(=O)C1=CC=C(C=C1)OCC#CC)C(C)=O ZKYTXSSQYOZXDK-UHFFFAOYSA-N 0.000 description 1
- MKFBGRYQIODKRA-UHFFFAOYSA-N OCCc1ccc(OCCN2CCCCC2)cc1.ClCCc1ccc(OCCN2CCCCC2)cc1 Chemical compound OCCc1ccc(OCCN2CCCCC2)cc1.ClCCc1ccc(OCCN2CCCCC2)cc1 MKFBGRYQIODKRA-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 208000003107 Premature Rupture Fetal Membranes Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 229960000380 Propiolactone Drugs 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 206010038932 Retinopathy Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 229940083599 Sodium Iodide Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N Sulfuryl fluoride Chemical class FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N Tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000003298 Tumor Necrosis Factor Receptors Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000000475 acetylene derivatives Chemical class 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- GGMLTGPNQUTCPG-UHFFFAOYSA-N but-2-ynoxybenzene Chemical compound CC#CCOC1=CC=CC=C1 GGMLTGPNQUTCPG-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LKYXEULZVGJVTG-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH] LKYXEULZVGJVTG-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000010635 coffee oil Substances 0.000 description 1
- 108010048697 collagenase 1 Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002380 cytological Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000000925 erythroid Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RNMNNDYQXQUQMH-UHFFFAOYSA-N ethyl 2-(4-but-2-ynoxyphenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(OCC#CC)C=C1 RNMNNDYQXQUQMH-UHFFFAOYSA-N 0.000 description 1
- UYZPLUBAZCNLGX-UHFFFAOYSA-N ethyl 2-(4-but-2-ynoxyphenyl)sulfonylacetate Chemical compound CCOC(=O)CS(=O)(=O)C1=CC=C(OCC#CC)C=C1 UYZPLUBAZCNLGX-UHFFFAOYSA-N 0.000 description 1
- YLCFXBRZHALYDL-UHFFFAOYSA-N ethyl 2-(4-but-2-ynoxyphenyl)sulfonyloctanoate Chemical compound CCCCCCC(C(=O)OCC)S(=O)(=O)C1=CC=C(OCC#CC)C=C1 YLCFXBRZHALYDL-UHFFFAOYSA-N 0.000 description 1
- MBJJVXODYFHLGZ-UHFFFAOYSA-N ethyl 2-(4-hydroxyphenyl)sulfanylpropanoate Chemical compound CCOC(=O)C(C)SC1=CC=C(O)C=C1 MBJJVXODYFHLGZ-UHFFFAOYSA-N 0.000 description 1
- JLMMMEDWRUVCEW-UHFFFAOYSA-N ethyl 2-(oxan-4-yl)acetate Chemical compound CCOC(=O)CC1CCOCC1 JLMMMEDWRUVCEW-UHFFFAOYSA-N 0.000 description 1
- HMRYLZJIPRVVCW-UHFFFAOYSA-N ethyl 2-(oxan-4-ylidene)acetate Chemical compound CCOC(=O)C=C1CCOCC1 HMRYLZJIPRVVCW-UHFFFAOYSA-N 0.000 description 1
- WGKQUBVOAJZQCS-UHFFFAOYSA-N ethyl 2-(thian-4-yl)acetate Chemical compound CCOC(=O)CC1CCSCC1 WGKQUBVOAJZQCS-UHFFFAOYSA-N 0.000 description 1
- DULCUDSUACXJJC-UHFFFAOYSA-N ethyl 2-phenylacetate Chemical compound CCOC(=O)CC1=CC=CC=C1 DULCUDSUACXJJC-UHFFFAOYSA-N 0.000 description 1
- HBZGVMJZSWZNPE-UHFFFAOYSA-N ethyl 4-(4-hydroxyphenoxy)butanoate Chemical compound CCOC(=O)CCCOC1=CC=C(O)C=C1 HBZGVMJZSWZNPE-UHFFFAOYSA-N 0.000 description 1
- CFQOANXDICIVGF-UHFFFAOYSA-N ethyl 4-(4-phenylmethoxyphenoxy)butanoate Chemical compound C1=CC(OCCCC(=O)OCC)=CC=C1OCC1=CC=CC=C1 CFQOANXDICIVGF-UHFFFAOYSA-N 0.000 description 1
- PPXUHEORWJQRHJ-UHFFFAOYSA-N ethyl isovalerate Chemical compound CCOC(=O)CC(C)C PPXUHEORWJQRHJ-UHFFFAOYSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 125000004407 fluoroaryl group Chemical group 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000000855 fungicidal Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 101700011691 nhr-7 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N o-Nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000003239 periodontal Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- PQEXLIRUMIRSAL-UHFFFAOYSA-N tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate Chemical compound CCOC(=O)CC1CCN(C(=O)OC(C)(C)C)CC1 PQEXLIRUMIRSAL-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- UKTDFYOZPFNQOQ-UHFFFAOYSA-N tributyl(thiophen-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CC=CS1 UKTDFYOZPFNQOQ-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Abstract
The invention concerns compounds of formula (I) which are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
Description
ALQUINIL CONTAINING HYDROXAMIC ACID COMPOUNDS AS TACE INHIBITORS
FIELD OF THE INVENTION This invention relates to acetylenic hydroxamic acids that act as inhibitors of the enzyme (TACE) that converts to TNF-a. The compounds of the present invention are useful under conditions of diseases mediated by TNF-a, such as arthritis. rheumatoid, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative loss of cartilage.
BACKGROUND OF THE INVENTION Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basal membranes. These endopeptidas containing zinc consist of several subgroups of enzymes that include collagenases, is tromelisinas and gelatinasas. Of these classes, gelatinases have been shown to be the MMPs most intimately involved with the growth and spread of tumors. It is known that the level of expression of gelatinase is high in malignancies, and that gelatinase can degrade
REF: 131086 the basement membrane that leads to tumor metastasis. Angiogenesis, required for the growth of solid tumors, has recently also been shown to have a gelatinase component for its pathology. In addition, there is
• evidence to suggest that gelatinase is involved in the rupture of plaques associated with atherosclerosis. Other conditions mediated by
'"MMPs are restenosis, osteopenias mediated with MMP, inflammatory diseases of the central nervous system, skin aging, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, ulceration of the cornea, scarring of abnormal wounds, bone disease, proteinuria , aortic aneurysmal disease, degenerative loss of cartilage followed by traumatic joint damage, demyelinating diseases of the central nervous system, liver cirrhosis, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowel disease, periodontal disease, macular degeneration age-related diabetic retinopathy, vi treorret proliferative inopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, eye tumors, ocular angiogenesis / neovascularization and corneal graft rejection For recent examinations, see: 1) Recent Advances in Matrix Mecalloproteinase Inhibitor Research, R. P. Beckett, A. H. Davidson, A. H. Drummond, P. Huxley and M. Whittaker, Research Focus, Vol. 1, 16-26, (1996), (2) Curr. Opin. Ther. Patents (1994) 4 (1): 7-16, (3) Curr. Medicinal Chem. (1995) 2: 743-762, (4) Exp. Opin. Ther. Patents (1995) 5 (2): 1087-110, (5) Exp. Opin. "Ther. Patents (1995) 5 (12): 1287-1196: (6) Exp. Opin. Ther.Patents (1998) 8 (3): 281-259.The enzyme (TACE) which converts to TNF-a catalyzes the formation of TNF-a from the TNF-a precursor protein bound to the membrane TNF-a is a pro-inflammatory cytokine that is believed to have a role in rheumatoid arthritis [Shire, MG; Muller, GW Exp. Opin. Ther, Patents 1998, 8 (5), 531; Grossman, JM; Brahn, EJ Women's Health 1997, 6 (6), 627; Isomaki, P.; Punnonen, J. Ann. Med. 1997, 29, 499, Camussi, G., Lupia, E ". Drugs, 1998, 55 (5), 613.] Septic shock [Mathison, et al. , J. Clin. Invest. 1988, 81, 1925; Miethke, et al. , J. Exp. Med. 1992, 175, 91.], rejection of the graft [Piguet, P. F., Grau, G. E .; et al. J. Exp. Med. 1987, 166, 1280.], cachexia [Beutler, B .; Cerami, A. Ann. Rev. Biochem. 1988, 51, 505.], anorexia, inflammation [Ksontini, R .; MacKay, S. L. D .; Molda er, L. L., Arch. Surg. 1998, 133, 558.], congestive heart failure [Packer, M. Circ? Lation, 1995, 92 (6), 1379; Ferrari, R .; Bachetti, T .; et al., Circulation, 1995, 92 (6), 1479.], injury of post-ischemic reperfusion, inflammatory disease of the central nervous system, bowel disease, inflammatory, resistance to insulin. [1] [Hotamisligil, GS; Shargill, N. S .; Spiegelman, B. M .; et al. Science, 1993, 259, 87.] and HIV infection [Peterson, P. K.; Gekker, G .; et al. J. Clin. Invest. 1992, 89, 574; Pallars-Truj i 1 lo, J .; Lopez-Soriano, F. J. Argües, J.M. Med. Res. Reviews, 1995, 15 (6), 533.]], in addition to its well-documented antitumor properties [Oíd, L. Science, 1985, 230, 630.]. For example, the search with anti-TNF-α antibodies and transgenic animals have been shown to block the formation of TNF-α which inhibits the progression of arthritis [Rankin, E.C .; Choy, E.H .; Kassimos, D; Kingsley, G.H .; Sopwith, A.M .; Isenberg, D.A .; Panayi, G.S. Br. J. Rhematol. 1995, 34, 334; Pha rmaproj ects, 1996; Therapeutic Updates 17 (Oct.), aul97-M2Z.]. This observation has recently spread in humans as well as was described in "TNF-a in Human Diseases", Current Pha rma ce uti ca l Des i gn, 1996, 2, 662. It is expected that small molecular inhibitors of TACE will have the potential to treat a variety of disease states. Although a variety of TACE inhibitors are known, many of these molecules are peptides and peptides that suffer from problems of bioavailability and pharmacokinetics. In addition, many of these molecules are non-selective, being potent inhibitors of the matrix metalloproteinases and, in particular, MMP-1. Inhibition of MMP-1 (collagenase 1) has been postulated to cause joint pain in clinical trials of MMP inhibitors [Scrip, 1998, 2349, 20]. Non-peptidic, bioavailable, selective TACE inhibitors that act for a long time in this manner would be highly desirable for the treatment of the disease states discussed above. The hydroxamic acid inhibitors with sulfon of MMPs, of the general structure I have been described [Burgess, L.E .; Rizzi, J.P .; Rawson, D.J. European Patent Application 818442. Groneberg, R.D Neuenschwander, K.W .; Djuric, S.W .; McGeehan, G.M Burns, C.J .; Condom, S.M .; Morrissette, M.M Salvino, J.M .; Scotese, A.C .; Ullrich, J.W. PCT International Application WO 97/24117. Bender, S.L .; Broka, C.A .; Campbell, J.A .; Castelhano, A.L .; Fisher, L.E .; Hendricks, R.T .; Sarma, K. European Patent Application 780386. Venkatesan, A.M .; Grosu, G. T .; Davis, J.M .; Hu, B .; O'Dell, M. J. PCT International Application WO 98/38163.] An exemplification of this class of the MMP inhibitor is RS-130830, "shown below.
RS-130830
Within the sulfone hydroxamic acid class of the MMP inhibitor, the linker between the sulfone and hydroxamic acid portions have been extended to three carbons (I, n = 2) without significant loss in potency [Barta, T. E .; Becker, D. P .; Villamil, C. I .; Freskos, J. N .; Mischke, B.
V .; Mullins, P. B .; Heintz, R. M .; Getman, D. P .; McDonald, J. J. PCT International Application WO 98/39316. McDonald, J. J.: Barta. TEA.; Becker, D. P .; Bedell, L. J.; Rao, S. N.; Freskos, J. N .; Mischke, B. V. PCT International Application WO 98/38859.]. Hydroxamic acids with piperidinsulphone, II (n = 1) have been reported [Becker, D. P .; Villamil, C. I .; Boehm, T. L .; Getman, D. P .; -'McDonald, J. J .; DeCrescenzo, G. A. PCT International Application WO 98/39315.]. Similar piperidine derivatives wherein the methylene linking the piperidine ring to the sulfone have been deleted (II, n = 0) have been reported [Venkatesan, A. M.; Grosu, G. T .; Davis, J. M .; Baker, J. L. PCT International Application WO 98/37877.].
Hydroxamic acids with sulfone III, wherein an hydroxyl group alpha has been placed on hydroxamic acid, have been described [Freskos, J. N .; Boehm, T. L .; Mischke, B. V .; Heintz, R. M.;
McDonald, J. J .; DeCrescenzo, G. A .; Howard, S. C International PCT Application WO 98/39326. Robinson, R P. PCT International Application WO 98/34915.].
lll
The sulfone-based MMP inhibitors of general structure IV, which utilize a thiol as the zinc chelator, have been reported [Freskos, J.N .; Abbas, Z.S .; DeCrescenzo, G. A .; Getman, D.P .; Heintz, R.M .; Mischke, B.V .; McDonald, J.J. PCT International Application WO 98/03164].
IV
The inhibitors of es t romellsina with the general structure V have been described [Shuker, S.B .; P.J .; Hajduk, P.J .; Meadows, R.P .; Fesik, S.W. Sci en ce, 1996, 2 74, 1531-1534. Hajduk, P.J .;
Sheppard, G .; Nettesheim, D.G .; Olejniczak, E.T .; Shuker, S.B .; Meadows, R.P .; Steinman, D.H .; Carrera, Jr., G.M .; Marcotte, P.A .; Severin, J .; Walter, K .; Smith, H .; Gubbins, E .; Simmer, R .; Holzman, T.F .; Morgan, D.W .; Davidsen, S.K .; Summers, J.B .; Fesik, S.W. J. Am. Chem. Soc. 1997, 1 1 9, 5818-5827. Olejniczak, E.T .; Hajduk, P.J; Marcotte, P.A .; Nettesheim, D.G .; Meadows, R.P .; Edalji, R .; Holzman, T.F .; Fesik, S.W. J. Am. Ch em. So c. 1997, 1 1 9, 5828- 5 32. Fesik, S. W .; Summers, J. B .; Davidsen, S. K .; • 'Sheppard, G. S .; Steinman, D. H .; Carrera, G. M .; Florjancic, A .; Holms, J. H. PCT International Application WO 97/18188.].
Salah et al., Liebigs Ann. Chem. 195, (1973) discloses some thio-substituted acetohydroxamic acid derivatives with aryl and aryl-substituted sulfonyl of the general formula 1_. These compounds were prepared to study the Mannich reaction. Subsequently, they were tested for their fungicidal activity.
Some carboxylic acids with sulfone are described in U.S. Patent 4,933,367. These compounds were shown to exhibit hypoglycemic activity.
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to inhibitors of the non-peptide, low molecular weight, novel metalloproteinase (MMPs) matrix and the enzyme (TACE) that converts TNF-a to the treatment of arthritis, tumor metastasis, tissue ulceration, scarring of abnormal wounds, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection. In accordance with this invention there is provided a group of compounds of the general formula I:
wherein: Ri is hydrogen, aryl, heteroaryl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms or cycloheteroalkyl with 5-carbon atoms. to 8 carbon atoms having 1 to 2 heteroatoms selected from N, NR7, S and 0; '"R2 and R3 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH;
R5 is hydrogen, alkyl of 1-8 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, heteroaryl, or cycloheteroalkyl with 4 to 8 carbon atoms; R-7 is hydrogen, aryl, aralkyl, alkyl of 1-6 carbon atoms, or cycloalkyl of 3-6 carbon atoms, oxy, alkanoyl with 1 to 8 carbon atoms, C00R5, C0R5, -S02-alkyl with 1 to 8 carbon atoms, -S02-aryl, -S02-heteroaryl, -CO-NHRi; Rs, R9, Rio and R11 are each, independently, hydrogen, aryl, aralkyl, 5-10 heteroaryl members having 1-3 heteroatoms selected from N, NR7, O and S, heteroalkyl having from 1-3 selected heteroatoms of N, NR7, O and S, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl with 4 to 8 carbon atoms having 1-3 heteroatoms selected from N, NR7, 0 and S, alkyl of 1-18 carbon atoms. carbon, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; R12 is hydrogen, aryl or 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, NR7, S and O, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl having 5 to 8 carbon atoms having 1 to 2 heteroatoms selected from N, NR7, S and O, or alkyl of 1-6 carbon atoms; A is O, S, SO, S02, NR, or CH2; X is O, S, SO, S02, NR7, or CH2; And it is aryl or heteroaryl, with the proviso that A and
X are not attached to adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof. In some preferred embodiments of the present invention Y is phenyl, pyridyl, thienyl, furanyl, imidazolyl, triazolyl and thiadiazolyl. Still more preferred compounds of the present invention are compounds of Formula I, wherein R and R3 are each, independently, hydrogen or alkyl of 1-6 carbon atoms; R? _ Is hydrogen; and Y is phenyl. The compounds that inhibit the most preferred metalloproteinase and TACE matrix of this invention are: 2- (4-But-2-ynyloxy-benzenesulfonyl) -N-hydroxy-2-methyl-3-pyridin-3-yl-propionamide; 2- (4 -But -2-in i loxi-benzenesulfonyl) -N-hydroxy-2-methyl-3- [4- (2-pyridin-1-yl-ethoxy) -phenyl] -propionamide; 3-Biphenyl-4-yl-2- (4-but-2-ynyloxy-benzenesulfonyl) -N-hydroxy-2-methyl-propionamide; 2- (4-But-2-ynyloxy-phenyl-sulfanyl) -octanoic acid hydroxyamide; 2- (But-2-ynyloxy-benzenesulfonyl) -octanoic acid hydroxyamide; 2- [(R) - (4-Butyl-2-ynyloxy) -sulfinyl-N-hydroxy-octanamide; 2 - [(S) - (4-Butyl-2-ynyloxy) -sulfinyl-N-hydroxy-octanamide; 3- (4 -But-2-inyloxy-phenoxy) -N-hydroxy-propionamide; 4- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-but-iramide; 2- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-acetamide; 4- (4-But-2-ynyloxy-phenyl) -N-hydroxy-but-iramid; [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxy-ca rbamoi-pentyl] -amide of quinoline-2-carboxylic acid;
Hydroxyamide of 2- (4-but-2-ynyloxy-phenylisulfanyl) -6- [2- (1,3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid; N- [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentyl] -2-phenethyl-benzamide; 2- (4-But-2-ynyloxy-phenylsulfanyl) -6- [2- (3, 4-dichloro-phenyl) -acetylamino] -hexanoic acid hydroxyamide; '"[5- (4 -But -2-ynyloxy-phenylsulfanyl) -5-hydroxy-ca rbamoi-pentyl] -amide of quinoline-3-carboxylic acid;
2- (4-But-2-ynyloxy-phenylsulfanyl) -6- (4-t-iofen-2-yl-butylamino) -hexanoic acid hydroxyamide; [5- (4 -But-2-ynyloxy-phenylsulfanyl) -5-hydroxy-ca rbamoi-pentyl] -amide of 9H-Xanthen-9-carboxylic acid;
2- (4-But-2-ynyloxy-phenylsulfanyl) -6-diphenylacetylaminohexanoic acid hydroxyamide; [5- (4 -But-2-aminoloxy-phenylsulfanyl) -5-hydroxy-carbamoyl-1-pentyl] -amide of isoquinoline-1-carboxylic acid; Hydroxyamide 6- (2-benzo [b] thiophen-3-yl-acetylamino) -2- (4-bt-2-ynyloxy-phenyl-sulfanyl) -hexanoic acid hydroxyamide; [5- (4 -But -2-linoxy-benzenesulfinyl) -5-hydroxy-carbamoyl-pentyl] -amide of quinoline-2-carboxylic acid;
2- (4-But-2-ynyloxy-benzenesulfinyl) -6- [2- (1, 3-dioxo-1,3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid hydroxyamide; N- [5- (4-But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentyl] -2-phenethyl-benzamide; Hydroxyamide 2- (butyl-2-ynyloxy-benzenesulfinyl) -6- [2- (3,4-dichloro-phenyl) -acetyl-amino] -hexanoic acid hydroxyamide; '"[5.- (4 -But-2-yl loxi-benzenesulfinyl) -5-hydroxy-ca rbamoi-pentyl] -amide of quinoline-3-carboxylic acid;
2 - (4-But-2-ynyloxy-benzenesulfinyl) -6- (4-thiophen-2-yl-butylamino) -hexanoic acid hydroxyamide; [5- (4 -But-2-yl loxi-benzenesulfinyl) -5-hydroxy-ca rbamoi-pentyl] -amide of 9H-Xanthen-9-carboxylic acid; Hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfinyl) -6-diphenylacetyl-0-hexanoic acid [5- (4 -But -2-linoxy-benzenesulfinyl) -5-hydroxy-carbamoyl-pentyl] - isoquinoline-1-carboxylic acid amide; Hydroxyamide 6- (2-benzo [b] t -pheno-3-yl-acetylamino) -2- (4-but-2-linoxy-benzenesulfinyl) -hexanoic acid hydroxyamide; Hydroxyamide 2- (4 -But-2-ynyloxy-benzenesulfinyl) -6- (2-lH-indol-3-yl-acetylamino) -hexanoic acid hydroxyamide;
[5- (4 -But-2-yl loxi-benzenesulfinyl) -5-hydroxy-carbamoyl-1-pentyl] -amide of quinoline-2-carboxylic acid; Hydroxyamide 2 - (4-but-2-ynyloxy-benzenesulfonyl) -6-- [2- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) -acetylamino] - hexanoic; N- [5- (-But-2-ynyloxy-benzenesulfonyl) -5-hydroxy-carbamoyl-pentyl] -2-phenethi-1-benzamide; 2- (4-But-2-ynyloxy-benzenesulfonyl) -6- [2- (3, -dichloro-phenyl) -acetyl-amino] -hexanoic acid hydroxyamide; [5- (4 -But -2-ynyloxy-benzenesulfonyl) -5,5-hydroxy-carbamoyl-pentyl] -amide of quinoline-3-carboxylic acid; [5- (4 -But-2-yl loxi-benzenesulfonyl) -5-hydroxy-carbamoyl-1-pentyl] -amide of 9H-Xanthen-9-carboxylic acid;
Hydroxyamide 2- (4-but-2-ynyloxy-benzenesulfonyl) -6-di-phenylacetylaminohexanoic acid hydroxyamide; [5- (4 -But-2-aminoloxy-benzenesulfonyl) -5-hydroxycarbamoyl-1-pentyl] -aminoquinoline-1-carboxylic acid amide; Hydroxyamide 6- (2-benzo [b] thiophen-3-yl-acetylamino) -2- (4-but-2-inyloxy-benzenesul-fonyl) -hexanoic acid hydroxyamide; . { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} -quinoline-2-carboxylic acid amide;
Hydroxyamide of 2- (-but-2-ynyloxy-phenylsulfanyl) -6- acid. { 2- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] acetylamino} hexanoic;
N-. { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pent i 1 -carbamoi 1] -methyl} -2-phenethyl-benzamide; Hydroxyamide of 2- (4-but-2-loxy-phenylsulfanyl) -6- acid. { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acetylamino} -hexanoic; . { [5- (4-But-2-ynyloxy-phenylsul-phenyl) -5-hydroxy-carbamoyl-pentylcarbamoyl] -methyl} quinoline-3-carboxylic acid amide; . { [5- (4 -But -2-linoxyphenylsulfanyl) -5-hydroxycarbamoyl-1-pentylcarbamoyl-1] -met-il} 9H-Xanten-9-carboxylic acid amide; Hydroxyamide 2- (4-but-2-ynyloxy-phenylsulphyl) -6- (2-di-phenylacetylamino-acetylamino) -hexanoic acid hydroxyamide; . { [5- (-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -met-yl} isoquinoline-1-carboxylic acid amide; . { [5- (-But-2- ini loxyphenyl sulphonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} 1-methyl-1H-pyrrole-2-carboxylic acid amide;
Hydroxyamide 6- [2- (2-benzo [b] thiophen-3-yl-acetylamino) -acetylamino] -2- (4-but-2-ynyloxy-phenylsulfanylhexanoic acid; { [5- (4- But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -met-yl.} - quinoline-2-carboxylic acid amide; 2- (4-but-2-ynyloxy) -hydroxyamide; benzenesulfinyl) -6-. {2- [2- (1, 3-dioxo-1,3-dihydro-isoindol-2-yl) -acetylamino] -acetylamino} -hexanoic acid; N- { [5- (-But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentyl-carbamoyl] -methyl} -2-phenethyl-benzamide; 2- (4-but-2-ynyl) -hydroxyamide; -benzene-sulfinyl) -6- { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acet-ylamino} -hexanoic; {. [5- (4-But-2- inyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pent i lcarbamoi 1] -met i 1.} quinolic acid amide 3-carboxylic acid hydroxyamide 2- (4-but-2-ynyloxy-benzene) sulfinyl) -6- [2- (4-thiophen-2-yl-butyrylamino) -acetylamino] -hexanoic; {. [5- (4-But-2-inil oxy-benzenesulfinyl) -5-hydroxy-carbamoyl-1-pentylcarbamoyl] -met-il} 9H-Xanten-9-carboxylic acid amide;
2- (4-But-2-ynyloxy-benzenesulfinyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic acid hydroxyamide; . { [5- (4-But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} l-methyl-lH-pyrrole-2-carboxylic acid amide; Hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfonyl) -6- acid. { 2- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -acetylamino} -hexanoic; N-. { [5- (-but-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} -2-phenethylbenzamide; Hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfonyl) -6- acid. { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acetylamino} -hexanoic; . { [5- (4-but-2-inkyloxy-benzenesul fonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -met-il} quinoline-3-carboxylic acid amide; . { [5- (4 -But-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -met-il} -amide of acid
9H-Xanten-9-carboxylic acid; 2- (4-But-2-ynyloxy-benzenesulfonyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic acid hydroxyamide;
. { [5- (4-But-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} isoquinol in-1-carboxylic acid amide; Hydroxyamide 6- [2 - (2-benzo [b] t iofen-3-i-acetylamino) -acetylamino] -2- (4-but-2-ynyloxybenzenesulfonylhexanoic acid; 2- (4- Hydroxyamide but-2-ynyloxy-benzenesulfonyl) -6- [2- (2-1H-indol-3-yl-acetylamino) -acetylamino] -hexanoic acid; 2- { [4- (2-butynyloxy) phenyl] sulfonyl.} - N-hydroxy-4 -. {4- [2- (1-piperidinyl) -ethoxy phenyl Jbutanamide; 2- {[4- (2-butynyloxy) phenyl] sulfonyl}. -7-cyano-N-hydroxy-heptanamide; 2- {[[4- (2-butynyloxy) phenyl] sulfanyl} -2-cyclohexyl-N-hydroxyacet amide; 2-. {[4- ( 2-butynyloxy) phenyl] sulfinyl} -2-cyclohexyl-N-hydroxyacetamide; 2- {[[4- (2-butynyloxy) phenyl] sulfonyl} -2-cyclohexyl-N-hydroxyacetamide; {. [4- (2-Butynyloxy) phenyl] sulfanyl} - N-hydroxy-2- (4-methoxyphenyl) acetamide; (2R) -2- { [4- (2-Butynyloxy) phenyl] sulfanil .} - N-hydroxy-2- (4-methoxyphenyl) ethanamide; (2S) -2- { [4- (2-but in i lox i) phenyl] sulfanyl.} - N-hydroxy-2- (4-methoxy phenyl) Ethanamide;
2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (4-methoxyphenyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (4-chlorophenyl)
N-hydroxyacetamine; 2- . { [4- (2-Butynyloxy) phenyl] sulfinyl} -2- (4-chlorophenyl)
N-hydroxyacetamide; 2- . { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (4-chloro phenyl)
N-hydroxyacetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (3-chlorophenyl) N-hydroxyacetamide; 2- . { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (3-chlorophenyl)
N-hydroxyacetamide; 2- (4-bromo-phenyl) -2-. { [4- (2-Butynyloxy) phenyl] sulfanil}
N-hydroxyacetamide; (2S) -2- (4-bromo-phenyl) -2-. { [4- (2-Butynyloxy) phenyl] -sulfinyl} -N-hydroxyacetamide; (2R) -2- (4-bromophenyl) -2-. { [4- (2-Butynyloxy) phenyl] -sulfinyl} -N-hydroxyacetamide; 2- (4-bromo phenyl) -2-. { [4- (2-Butynyloxy) phenyl] -sulfonyl} -N-hydroxyacetamide; 2-. { [4- (2-butynyl oxy) phenyl] sul fanil} -N-hydroxy-2- [4- (2-thienyl) phenyl] -acetamide; (2R) -2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- [4- (2-thienyl) -phenyl] ethanamide;
2- . { [4- (2-butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- [4- (2-thienyl) phenyl] -acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (1-naphthyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy -2 - (1-naphthyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1-naphthyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (4-fluorophenyl) -N-hydroxy-2- (1 -naphthyl) acetamide; 2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -2- (4- fluorophenyl) -N-hydroxy acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -2- (4- fluorophenyl) -N-hydroxyacetamide; 2- (2-methoxyphenyl) -2-. { [- (2-Butyloxy) phenyl] -sulfanyl} -N-hydroxyacetamide; 2- (2-methoxyphenyl) -2-. { [4- (2-Butynyloxy) phenyl] -sulfinyl} -N-hydroxyacetamide; 2-. { [4- (2-butynyloxy) phenyl] sulfanyl-N-hydroxy-2- (4-ethoxyphenyl) acet amide; 2-. { [4- (2-Butynyloxy) phenyl] sulfinyl-N-hydroxy-2- (4-ethoxyphenyl) acetamide; 2- . { [4- (2-butynyloxy) phenyl] sulfonyl-2- (4-chlorophenyl) N-hydroxyacetamide;
2-. { [4- (2-Butynyloxy) phenyl] sulfanyl-N-hydroxy-2- (3-bromophenyl) acetamide; . (2R) -2-. { [4- (2-butynyloxy) phenyl] sulfinyl-N-hydroxy-2- (3-bromophenyl) acetamide; (2S) -2-. { [4- (2-butynyloxy) phenyl] sulfinyl-N-hydroxy-2- (3-bromophenyl) acetamide; 2- . { [4- (2-Butynyloxy) phenyl] sulfonyl} -2- (3-bromo phenyl) -N-hydroxyacetamide; 2- . { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-acetamide; R-2-Í [4- (2-Butynyloxy) phenyl] sulfinyl} -2-isopropyl-N-hydroxyacetamide; S-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-isopropyl-N-hydroxyacetamide; 2- . { [4- (2-butynyloxy) phenyl] sulfonyl} -2-isopropyl-N-hydroxyacetamide; 2- . { [4- (2-Butynyloxy) phenyl] sulfanil} -2-phenyl-N-hydroxyacetamide; R-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-phenyl-N-hydroxyaceta ida; S-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-phenyl-N-hydroxyacetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (2-naphthyl) -N-hydroxyacetamide;
2- . { [4- (2-Butynyloxy) phenyl] sulfinyl} -2- (2-naphthyl) -N-hydroxyacetamide; 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (2-naphthyl) -N-hydroxyacetamide; 4- [l-. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (hydroxy-amino) -2-sxoethyl] -1-piperidinecarboxylate tert-butyl; 2-. { [4- (2-Butynyloxy) phenyl] sulphonyl} -N-hydroxy -2- (4-piperidinyl) acetamide; 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- [1- (4-methoxybenzyl) -piperidinyl] acetamide; 2- (l-benzoyl-4-piperidinyl) -2-. { [4 - (2-Butyloxy) -phenyl] sulfonyl} -N-hydroxy-acetamide; 2- (l-acetyl-4-piperidinyl) -2-. { [4- (2-Butynyloxy) -phi] 1] sulphonyl} -N-hydroxy-acetamide; 2- . { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2-tetrahydro-2H-pyran-4-yl-acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} - -hydroxy-2-tetrahydro-2H-thiopyran-4-yl-acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1-oxidotetrahydro-2H-t-pyroran-4-yl) -acetamide; and 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1, 1-dioxidotetrahydro-2H-thiopyran-4-yl) -acetamide.
Heteroaryl, as used throughout the disclosure, is a 5-10 membered mono- or bicyclic aromatic ring having 1-3 heteroatoms selected from N, NR7, S and O. Heteroaryl is preferred:
where K is defined as 0, S or -NR7, and R7 is as defined above. Preferred heteroaryl rings include pyrrole, furan, thiophene, pyridine, pyrimidine, pyridazine, pyrazine, triazole, pyrazole, imidazole, isothiazole, thiazole, isoxazole, oxazole, indole, isoindol, benzofuran, benzothiophene, quinoline, isoquinoline, quinoxaline, quinazoline, benzotriazole , indazole, benzimidazole, benzothiazole, benzisoxazole, and benzoxazole. The heteroaryl groups of the present invention may be mono or disubstituted.
Cycloheteroalkyl with 4 carbon atoms is defined as
where K is O, S or NR7 and R7 is as defined above. Preferred heterocycloalkyl rings include piperidine, piperazine, morpholine, tetrahydropyran, tetrahydrofuran or pyrrolidine. The heterocycloalkyl groups of the present invention can optionally be mono- or di-substituted. Aryl, as used herein, refers to phenyl or naphthyl aromatic rings which may optionally be mono- or di-substituted. Alkyl, alkenyl, alkynyl and perfluoroalkyl include both a straight chain as well as branched portions. The alkyl, alkenyl, alkynyl, and cycloalkyl groups can be unsubstituted (carbons, bonded to hydrogen, or other carbons in the chain or ring) or can be mono- or poly-substituted. Lower alkyl is alkyl with 1 to 6 carbon atoms. Aralkyl as used herein refers to a substituted alkyl, -alkyl-aryl group, wherein alkyl is lower alkyl and preferably from 1 to 3 carbon atoms, and aryl is as previously defined. Heteroaralkyl as used herein refers to a substituted alkyl, alkyl-heteroaryl group wherein alkyl is lower alkyl and preferably from 1 to 3 carbon atoms, and heteroaryl is as previously defined. Halogen means bromine, chlorine, fluorine and iodine.
Suitable substituents of aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl, alkenyl, alkynyl and cycloalkyl include, but are not limited to, halogen, alkyl of 1-6 carbon atoms; 'alkenyl of 2-6 carbon atoms; alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -0R5, -CN, -C0R5, perfluoroalkyl of 1-4 carbon atoms, -0- perfluoroalkyl of 1-4 carbon atoms, -C0NR5R6 , -S (0) nR5, -OPO (OR5) 0R6, -PO (OR5) R6, -0C (0) 0R5, -OR5NR5R6, -OC (0) NR5R6, -C (0) NR50R6, -C00R5, - S03H, -NR5R6, -N [(CH2) 2] 2NR5, -NR5COR6, -NR5COOR6, -S02NR5R6, -N02, -N (R5) S02R6, -NR5CONR5R6, -NR5C (= NR6) NR5R6, -NR5C (= NR6 ) N (S02) R5R6, -NR5C (= NR6) N (C = OR5) R6, -tetrazol-5-yl, -S02NHCN, -S02NHCONR5R6, phenyl, heteroaryl or cycloheteroalkyl of 5 to 8 carbon atoms; wherein -NR5Re can form a pyrrolidine, piperidine, morpholine, thiomorpholine, oxazolidine, thiazolidine, pyrazolidine, piperazine or azetidine ring; R5 and R1 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, heteroaryl or cycloheteroalkyl of 5 to 8 carbon atoms; R7 is hydrogen, aryl, heteroaryl, alkyl of 1-6 carbon atoms or cycloalkyl of 3-6 carbon atoms, and n is 0-2. When a portion contains more than one substituent with the same designation, each of these substituents may be the same or different. The pharmaceutically acceptable salts can be formed of organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrochemical, phosphoric, nitric acids, sulfuric, methanesulfonic, naphthalenesulonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic portion. The salts may also be formed of organic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium or potassium, when a compound of this invention contains an acidic portion. The compounds of this invention may contain an asymmetric carbon atom and any of the compounds of this invention may contain one or more asymmetric centers and may in this way give rise to optical isomers and diastereomers. While shown to be without respect to stereochemistry, the present invention includes such optical isomers - and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the stereoisomers -R and S and pharmaceutically acceptable salts thereof. It is recognized that an optical isomer, including the diastereomer and enantiomer, or stereoisomer may have favorable properties over the other. Thus, when describing and claiming the invention, when a racemic mixture is described, it is clearly contemplated that both optical isomers, including the diastereomers and enantiomers, or stereoisomers substantially free of the other, are also described and claimed. The compounds of this invention are shown to inhibit the enzymes MMP-1, MMP-9, MMP-13 and the enzyme (TACE) which converts to TNF-a and are therefore useful in the treatment of arthritis, tumor metastasis, tissue ulceration, healing
• of abnormal wounds, periodontal disease, graft rejection, insulin resistance, bone disease, and HIV infection. In particular, the compounds of the invention provide improved levels of inhibition of TACE i n vi tro activity and in cell assay and / or improved selectivity on MMP-1 and are thus particularly useful in the treatment of diseases mediated by TNF. Also according to the present invention, there are provided processes for producing the compounds of the present invention, which processes comprise one of the following: a) reacting a compound of the formula
wherein n, X, Y, A, Ri, R2, R3, R8, Rg, Rio, and Rii are as defined above or a reactive derivative thereof, with a compound of the formula
R12NHOH
wherein Ri2 is as defined above, to give a compound of formula I; or b) deprotect a compound of the formula:
wherein n, X, Y, A, Ri, R 2, R 3, R 8, R 9, R o, R n and R 12 are as defined above, and R 30 is a suitable protecting group such as t-butyl, benzyl, and trialkyl ilo, to give a corresponding compound of the formula I
c) separating a supported hydroxamate derivative with resin containing the group
wherein n, X, Y, A, R, R2, R3, Rs, Rg, Rio, and Rn are as defined above to give a compound of the formula I; or d) dissolving a mixture (e.g. racemate) of optically active isomers of a compound of formula I to isolate an enantiomer or diastereomer substantially free of the other enantiomer or diastereomers; or e) acidifying a basic compound of formula I with a pharmaceutically acceptable acid to give a pharmaceutically acceptable salt; or f) converting a compound of the formula I having a reactive substituent group or site to a compound of the formula I having a different substituent group or site. With respect to process a) the reaction can be carried out by processes known in the art, for example by the reaction of an acid chloride or an anhydride reactive derivative mixed with the compound of the formula R? 2NHOH. The removal of the protecting groups, as illustrated by process b) can be carried out by processes known in the art to provide the hydroxamic acid. Process c) can be carried out as described herein with reference to the Reaction Scheme 11 for example using a strong acid such as TFA to separate the hydroxamate from the resin. standard separation techniques for the isolation of particular enantiomeric or diastereomeric forms For example, a racemic mixture can be converted to a mixture of optically active diastereoisomers by reaction with a simple enantiomer of a "resolving agent" (for example by of the diastereomeric salt or formation of a covalent bond.) The resulting mixture of optically active diastereomers can be separated by standard techniques (e.g., crystallization or chromatography) and the individual optically active diastereoisomers then treated to remove the resolution "thereby liberating the simple enantiomer of the compound of the invention You can also use chiral chromatography (using a chiral support, eluent or ion pair-forming agent) to directly separate the enantiomeric mixtures. The compounds of the formula I can be isolated in the form of a salt of a pharmaceutically acceptable acid, for example an organic or inorganic acid by treatment with an acid as described above. With respect to process e) compounds of the formula I having a reactive substituent group such as hydroxy or amino or a site such as -S- can be converted to other compounds of the formula I in known manner, for example alcohol a ester or ether. Reactive sites such as a sulfur atom can be oxidized to SO or S02, (for example as shown in the Schemes, Reaction 2 and 8 below). If necessary, the reactive substituent groups can be protected during the synthesis of compounds of the formula I and eliminated as a last step. The compounds of the present invention, wherein n = 0, X = 0, S or NHR7 and A = S, SO or S02 can be conveniently prepared according to one of the general processes described below. As described in Reaction Scheme 1, the appropriately substituted mercaptan derivative is alkylated using a derivative of a-bromoacetic acid ester in chloroform which is brought to reflux using N, N-di isopropylethylamine as a base. The sulfide derivative obtained in this way is reacted with an appropriately substituted propargyl bromide derivative in acetone which is brought to reflux using K2CO3 as the base. In the case of X = -N-R7, N-'alkylation in DMF / NaH can be carried out at room temperature. The sulfide derivative obtained in this way is oxidized using m-chloroperbenzoic acid in CH2C12 or using Oxone in methanol / water. The sulfone obtained from the aforementioned process can be either alkylated further using a variety of alkyl halides to obtain the disubstituted derivatives or it can be hydrolyzed using NaOH / MeOH at room temperature. However, instead of using the ethyl ester, if the tertiary butyl ester is present, the hydrolysis can be carried out with TFA / CH2C12 at room temperature. Subsequently, the carboxylic acid obtained is converted to the hydroxamic acid derivative by the reaction with oxalyl chloride / DMF (catalytic) and hydroxylamine / triethylamine.
REACTION SCHEME 1
a: Et 3 N / CHCl 3 / TA; b: Derivative of propargyl bromide / K2C03 / Acetone / Reflux; c: 'Oxona / TH: MeOH / TA; d: R9Br / K2C03 / 18-Corona-6 / Acetone / Ref luxury; e: NaOH / THF: MeOH / TA; f: (COCÍ) 2 / DMF / NH2OH. HCl / Et3N. According to Reaction Scheme 2, the sulfur derivative can be hydrolyzed to carboxylic acid using NaOH / MeOH at room temperature and subsequently converted to the hydroxamic acid derivative described in Reaction Scheme 1. Monosulfurized sulfide derivatives can to be further alkylated using potassium bis (trimethylsilyl) -amide and the alkyl halides appropriately substituted to form the disubstituted sulfide derivatives. These may be subsequently hydrolyzed and converted to the hydroxamic acid derivative described in Reaction Scheme 1. The sulfinyl derivatives were prepared by oxidizing the hydroxamic acid derivatives of sulfur with 30% H202 in methanol at room temperature.
Reaction Scheme 2:
a: NaOH / THF: MeOH / TA; b: (COCÍ) 2 / NH2OH. HCl / Et3N; c: H202 / MeOH / TA; d: KN [Si (CH3) 3] 2 / THF / R9Br The thiols used as intermediates for the synthesis of compounds of the invention can be made according to Reaction Scheme 3. In this way, the salts of sulphonic acid 1 , wherein XRso is a hydroxy, thiol or substituted amino propion, can be alkylated with acetylenes 2, where J is a suitable leaving group such as mesylate, tosylate or halogen triflate to give 3.
Acetylenes 2 are commercially available or known compounds, or can be synthesized by methods known to those skilled in the art. The sulfonic acid salts 3 can be converted to the corresponding sulfonyl chloride or other sulfonylating agent 4 by known methods, such as the reaction with oxalyl chloride, phosphorus oxychloride or another reagent compatible with the substituents Rx, R2 and R3 and acetylene The sulfonyl chloride 4 can then be reduced to the corresponding thiol by using triphenylphosphine in a suitable solvent mixture such as dichloromethane / DMF at a temperature between -20 ° C and 30 ° C. Alternatively, the disulfide 6 can be converted to di-acetylene 7 by reaction with compounds 2, followed by reduction of the disulfide bond to provide the desired thiols 5. The bisacetylenes 7 can also be converted to thiols via the sulfonyl chlorides 4. The alkylation of the phenol, thiophenol, aniline or protected aniline 8 with 2 to give 9, followed by the reaction with chlorosulfonic acid provides sulphonic acids 10 which are easily converted to 4 with oxalyl chloride or similar reagents and subsequently reduced to thiols 5. The thiophenols 11 are also precursors for 5 via thiol protection with a triphenylmethyl or other suitable protecting groups, XH alkylation, where X is O, N or S, and the deprotection of sulfur.
Reaction Scheme 3:
RaX jL + R, x x SOjNa Ri
soX - O-O X »
The compounds of the invention wherein X is N, O, S, SO or S02, can be synthesized according to Reaction Scheme 4 and Reaction Scheme 5.
Alkylation of para-disusyl aryl 14, or its protected equivalent, with acetylene 2 in the presence of a base such as potassium carbonate in a polar aprotic solvent such as acetone or DMF at a temperature between 20 ° C and 120 ° C provides the propargyl mono-ether 15. Those skilled in the art will recognize that protecting groups may be required to avoid undesirable side reactions and increase the yield of the reaction. The need and choice of the protecting group for a particular reaction is known to those skilled in the art. The reaction of this compound with "-propiolactone, or a substituted propiolactone derivative (wherein the substituents have been omitted from the Reaction Scheme for clarity), in the presence of a base such as potassium t-butoxide in a solvent polar, or solvent mixture, such as THF or DMF produces the carboxylic acid 16. The conversion of the carboxylic acid 16 to the corresponding hydroxamic acid, 17, is carried out via the formation of an activated ester derivative such as an acid chloride or an acid anhydride followed by the reaction with hydroxylamine. It is understood by those skilled in the art that when A is sulfur, in Reaction Scheme 4 and all subsequent relevant Reaction Schemes, the sulfur can be oxidized to the corresponding sulfoxide or sulfone at any stage after the formation of the thioether, using a suitable oxidant such as oxone, air, m-chloroperbenzoic acid or hydrogen peroxide. Compounds 17 are also accessible from the Michael addition of compound 15 to an acrylate ester, or substituted acrylate ester (substituents have been omitted from the Reaction Scheme for clarity), to provide 18, wherein R3o is hydrogen or a suitable carboxylic acid protecting group. The deprotection of the ester portion then provides carboxylic acid 16 which can be converted into the analogous hydroxamic acid, 17. Similarly, the Michael addition of mono-protected mono-protected 1, 4-aryl, wherein ZR2s is hydroxy or protected hydroxy, thiol or amine, gives the compound 20. The non-masking of the protecting group gave the thiol, aniline or phenol 21 which can be alkylated with the propargyl derivative 2 to provide 18. The mono-protected compound 19 can also be reacted with b-propiolactone to provide 22.
The esterification of 22 gave 20, which can then be converted into compounds 17 of the invention. Alternatively, 22 can be deprotected followed by alkylation to give 16 or 18.
Reaction Scheme 4:
The synthesis of the compounds of the invention wherein X is N, O, S, SO or S02, and the linker between the proximal heteroatom and the hydroxamic acid is a one or three carbon chain that can be synthesized according to the Scheme Reaction 5. Compound 19, wherein XR25 is hydroxy or protected hydroxy, thiol or amine, can react with ester 24 or lactone 24a, wherein R3o is -hydrogen or a suitable carboxylic acid protecting group, with a group appropriately substituted projection such as halogen, tosylate, mesylate, or triflate, to provide 25. The non-masking of the heteroatoms X of compound 25 then provides 26, which can then be alkylated with the propargyl derivative 2 to give the acet i leno-és ter 27. The ester 27 can be converted to the corresponding hydroxamic acid 28 through conversion of the ester to the carboxylic acid by hydrolysis of acid or base, followed by conversion to the hydroxamic acid as described in Reaction Scheme 4. Alternatively, compound 15, prepared as shown in Reaction Scheme 2, can be directly alkylated with ester 24 or lactone 24a to give 27 and then 28. Substituents on alpha carbon to the hydroxamic, although omitted from the Reaction Scheme for clarity, may be added through the deprotonation and rapid cooling of compounds 25 or 27 with a suitable electrophile.
Reaction Scheme 5:
The compounds of the invention wherein A is a methylene or substituted methylene group, and X is oxygen, can be obtained according to Reaction Scheme 6. Esters or carboxylic acids 29, commercially available or known in the literature, are they can convert to the corresponding phenols, 30. Alkylation of the phenol with acetylene 2 gave the propargyl ethers, 31, which can be converted to the corresponding carboxy acids and then to the hydroxamic acids, 33, as described in the Scheme. Reaction 4. The substituents on the alpha to the hydroxamic carbon, although omitted from the Reaction Scheme for clarity, can be added through the deprotonation and rapid cooling of the compounds 29 or 31 with an appropriate electrophile.
Reaction Scheme 6:
The compounds of the invention wherein A is -S02-, and R8 and R9 are not hydrogen, are initially available from the -fluorobenzyl iol 34 as shown in Reaction Scheme 7. The deprotonation of the thiol followed by the reaction with β-propiolactone, or an acrylate ester, or an ester derivative 24, and subsequent oxidation of the resulting thioether provides the sulfone-acid 35. The displacement of the 4-fluoro substituent of 35, or its corresponding ester, with the propargyl derivative 36 , wherein X is N, O or S, then provides sulfone 16. Compound 16 can be converted to the compounds of the invention according to Reaction Scheme 4. Fluoroaryl 35 can also react with a hydroxyl group, thio or masked amino (HXR, where R or is a suitable protecting group) in the presence of a base such as sodium hydride in a polar aprotic solvent such as DMF to provide 36. Deprotection of 36 followed by alkylation c on the acetylene derivative 2 then gives 16.
Reaction Scheme 7:
Compounds of the invention wherein X is NH are also available starting from the commercially available, appropriate nitro aryl compound 38. In this way, the anion of the compound 38 can be used to alkylate the -propiolactone, or a substituted derivative, or an acrylate ester to provide 39. The reduction of the nitro group followed by the alkylation of the resulting aniline then gives 16. The compound 38 can also be alkylated with the ester derivative 24 to produce the nitro-ester 40, followed by the reduction to give the corresponding aniline, analogous to the compound 26 of the Reaction Scheme 5.
Reaction Scheme 8:
40 26
The compounds of the invention wherein Rn, alpha for the hydroxamic acid, is a hydroxy group, can be obtained via the epoxides 41, as shown in Reaction Scheme 9. These epoxides are available through the oxidation of the esters of corresponding acrylate or by the Darzens reaction of an alpha-haloester with an aldehyde or ketone. Reaction of the epoxide with thiol phenol or aniline 19 in the presence of a base provides the alpha hydroxy ester 42. Deprotection of 42 followed by alkylation with the propargyl derivative 2 gives 44. The conversion of the ester of 44 to the analogous hydroxamic acid as described in Reaction Scheme 4 then provides 45. Compounds 45, wherein A is sulfur, can be converted to the analogous sulfoxides or sulfones through oxidation with hydrogen peroxide, air, Oxone or other suitable reagent at this point . Similarly, the thiol, phenol or aniline can be reacted with 41 to give 44. The hydroxyl group of compound 43 can also be manipulated through conversion into a suitable leaving group, such as halide or sulphonate tea. , followed by displacement with several nucleophiles including amines to provide 44.
Reaction Scheme 9:
Another route for the alpha-hydroxy hydroxamic acids of the invention is shown in Reaction Scheme 10. Compound 15 can be alkylated with alcohol 46 to give 47. Oxidation of the alcohol, with or without concomitant thioether oxidation (for A = S), gave the aldehyde 48. The reaction of the aldehyde 48 with trimethylsilyl cyanide or another suitable reagent then provides the cyanohydrin 49. The hydrolysis of the nitrile from 49 to the corresponding carboxylic acid followed by the conversion to the hydroxamic acid as described in the Scheme of Reaction 4 gave 50.
Reaction Scheme 10
TMSCN Reaction Scheme 11 shows alternative methods for the preparation of the hydroxamic acid compounds using a solid phase support.
Reaction Scheme 11
Reagents and Conditions: a) 2-bromo-6-f taloyl-caproic acid, DIC, HOBt, DMF; b) p-hydroxybenzothiol, DBU, Nal, THF; c) 2-bromobutine, NaH, THF; d) 70% t-butyl hydroperoxide, benzenesulfonic acid, DCM; e) mCPBA, DCM; f) Hydrazine, THF, EtOH; g) N-phthaloyl glycine, DIC, HOBt, DMF; h) RCOOH, DIC, HOBt, DMF; i) TFA, DCM. 4-O-methylhydroxylamine-phenoxymethyl-copoly (styrene-1% -divinyl-benzene) -resin (hydroxylamine resin) can be coupled with 2-bromo-6-f-taloylcaproic acid to give the hydroxyamide resin. The coupling reaction can be carried out in the presence of carbodiimide, such as DIC, in an inert solvent such as DMF at room temperature. The bromide group can be displaced with hydroxybenzene in the presence of a base, such as DBU, in an inert solvent such as THF at room temperature. The sulfide can be oxidized to the sulfoxide by reaction with an oxidizing agent such as tert-butyl hydroperoxide in the presence of an acid catalyst such as benzenesulfonic acid, in an inert solvent such as DCM at room temperature. Alternatively, the sulfide can be oxidized to the sulfone by reaction with an oxidizing agent such as meta-chloroperoxy-benzoic acid, in an inert solvent such as DCM at room temperature. The phthaloyl protecting group can be removed by reaction with hydrazine in a solvent such as ethanol or THF. The free amine may then be extended by a glycine spacer by reaction with N-phthaloyl glycine in the presence of carbodiimide, such as DIC, in an inert solvent such as DMF at room temperature. Again the phthaloyl protecting group can be removed by reaction with hydrazine in a solvent such as ethanol or THF. The free amine can be acylated by reaction with an acid in the presence of carbodiimide, such as DIC, in an inert solvent such as DMF at room temperature. The sulfide, sulfoxide, or sulfone can be treated with acid, such as trifluoroacetic acid, in an inert solvent such as DCM to liberate the free hydroxamic acid.
REACTION SCHEME 12
Reaction Scheme 12 illustrates an alternative route for hydroxamic acid derivatives, alpha-substituted, (where A = S02 and n = 0). The reaction 51 with substituted sulfonyl fluorides can give derivatives of α-sulfoners ter 52 and subsequently can be converted to their respective hydroxamic acid derivatives. The following examples are presented to illustrate rather than to limit the scope of the invention.
Example 1 Preparation of 2- (4-but-2-ynyloxy-benzenesulfonyl) -N-hydroxy-2-methyl-3- [4- (2-piperidin-1-yl-ethoxy) -phenyl] -propionamide Step 1: To a stirred solution of 4-mercaptophenol (12.6 g, 100 mmol) and diisopropylethylamine (13.0 g, 101 mmol) in chloroform (200 ml) was slowly added ethyl-2-bromopropionate (18.2 g, 100 mmol) in a solution of chloroform (50 ml). The reaction mixture was refluxed slightly during the addiction. After the addition of ethyl 2-bromo propionate, the reaction mixture was refluxed for two hours and cooled to room temperature. The reaction mixture was washed with water and extracted with chloroform. It was dried over Na2SO4; it was filtered and concentrated. The product of 2- (4-hydroxy-phenylsulphylene 1) -propionic acid ethyl ester was taken for the next step without purification. Colorless oil; Yield 22.0 g (97%); MS: 227 (M + H) +.
Step 2: A mixture of 2- (4-hydroxy-phenylsulfanyl) -propionic acid ethyl ester (22.6 g, 100 mmol), l-bromo-2-butyne (13.2 g, 100 mmol) and anhydrous K2C03 (50 g, excess) was brought to reflux in acetone (300 ml) for 8 hours. After the reaction was completed, it was cooled to room temperature and filtered. The acetone layer was removed by distillation and the residue was extracted with chloroform, washed well with water; dried and concentrated. 2- (4-Buty-2-ynyloxy-phenylsulphyl) -propionic acid ethyl ester was isolated as "colorless oil; Yield 26.0 g 93%; MS: 279 (M + H) +.
Step 3: To a stirred solution of 2- (4-buty-2-ynyloxy-phenylsulfanyl) -propionic acid ethyl ester (2.78 g, 10 mmol) in methanol: THF (3: 1) (100 ml) oxone (10 g) , excess) was added in water (25 ml) at room temperature. The reaction mixture was stirred at room temperature for 8 hours and filtered. The organic layer was removed under reduced pressure and 2- (4-but i-2-yn-loxyphenylsulfonyl) -propionic acid ethyl ester was isolated as a colorless oil. Yield 3.0 g (96%); MS: 311 (M + H) +.
Step 4: A mixture of 2- (4-buty-2-ynyloxy-phenylsulfonyl) -propionic acid ethyl ester (3.1 g, 10 mmol), 4- (2-pyridin-1-yl-ethoxy) chloride hydrochloride -benzyl (2.9 g, 10 mmol), 18-crown-6 (500 mg), tetrabutylammonium bromide (500 mg) and K2C03 (10 g, excess) was brought to reflux in acetone (200 ml) for 8 hours. At the end, the reaction mixture was cooled to room temperature, filtered and concentrated. The residue was extracted with chloroform, washed well with water; dried and concentrated. The crude product was purified by column chromatography eluting with 70% ethyl acetate; Hexane 2- (4-But i-2-ynyloxy-phenylsulfonyl) -2-met il-3- [4- (2-piperidin-1-yl-ethoxy) -phenyl] propionic acid ethyl ester was isolated as a red oil. Yield 3.2 g, (60%); MS: 528 (M + H) +.
Step 5: To a stirred solution of 2- (4-buty-2-ynyloxy-phenylsulfonyl) -2-methyl-3- [4- (2-piperidin-1-yl-ethoxy) -phenyl] propionic acid ethyl ester ( 3.0 g, 5.4 mmol) in THF: MeOH (1: 1) (100 mL), 10 N NaOH (10 mL) was added at room temperature. The reaction mixture was heated at 60 ° C for 24 hours. The reaction mixture was concentrated and carefully neutralized with 5N HCl and extracted with chloroform. The product was washed well with water and dried over anhydrous Na 2 SO and concentrated. 2- (-but i-2-ynyloxy-phenylsulfonyl) -2-methyl-3- [4- (2-piperidin-1-yl-ethoxy) -phenyl] propionic acid was isolated as a yellow solid. P.f. 84 ° C; Yield 2.0 g (74%); MS: 500 (M + H).
Step 6: To a stirred solution of 2- (4-buty-2-ynyloxy-phenylsulfonyl) -2-methyl-3- [4- (2-piperidin-1-yl-ethoxy) -phenyl] propionic acid (4.99 g), 10 mmol) and DMF (4 mL) in methylene chloride (100 mL), oxalyl chloride (6.3 g, 50 mmol) was added slowly at 0 ° C in a methylene chloride solution. After the addition was complete, the reaction mixture was stirred at room temperature for 1 hour. In a separate flask, NH20H.HC1 (3.5 g, 50 mmol) was dissolved in DMF (20 ml) and Et3N (10 g, 100 mmol) was added. The reaction mixture was diluted with acetonitrile (25 ml) and cooled to 0 ° C. The acid chloride prepared in the separate flask was concentrated to remove excess oxalyl chloride and redissolved in 100 ml of methylene chloride added slowly to NH2OH. The reaction mixture was stirred at room temperature for 24 hours and concentrated under reduced pressure. The residue obtained was extracted with chloroform; washed well with water; dried over anhydrous Na2SO4. The chloroform layer was filtered and concentrated. The obtained product was purified by silica gel column chromatography eluting with 10% methanol; chloroform. Isolated in this way 2- (4-buty-2- ini loxyphenylsulfonyl) -N-hydroxy-2-methyl-3- [4- (2-piperidin-1-yl-ethoxy) phenyl] propionamide was converted to its hydrochloride salt by reacting it with methanolic acid chloride. Colorless solid, P.f. 114-116 ° C; Performance 4.5 (87%); MS: 515 (M + H).
Example 2 3-Biphenyl-4-yl-2- (4-Buty-2-ynyloxy-phenylsulfonyl) -N-hydroxy-2-methyl-propionamide The ethyl ester of 3-biphenyl-4-yl-2- ( 4-Buty-2-ynyloxy-phenylsulfonyl) -2-methyl-propionic following the procedure of Example 1
(Stage 4) Starting from the acid ethyl ester
2- (4-But i-2-ynyloxy-phenylsulfonyl) -propionic acid (3.1 g, 10 mmol) and 4-phenylbenzyl chloride (20.2 g, 10 mmol), 4.2 g of the product was isolated as a yellow oil. Performance (88%); MS: 477 (M + H) +. 3-Biphenyl-4 -yl-2- (-But i-2-ynyloxy-phenylsulfonyl) -2-methyl-1-propionic acid was prepared starting from the ethyl ester of 3-biphenyl-4-yl-2- (4-biphenyl) acid. -Buti-2-ynyloxy-phenylsulfonyl) -2-methyl-propionic acid (4.0 g, 8.4 mmol) dissolved in MeOH (100 ml) and 10 N NaOH (20 ml). The resulting reaction mixture was worked up as described in Example 1 (Step 5). Yield 3.2 g (85%); MS: 449 (M + H) +. Starting from 3-biphenyl-4-yl-2- (4-Buty-2-ynyloxy-phenylsulfonyl) -2-methyl-propionic acid. { 3.0 g, 6.7 mmol) and following the procedure described in Example 1 (Step 6) was isolated 2.8 g of 3-biphenyl-4-yl-2- (4 -Buti-2-ini loxyphenyl sulphonyl) - N-hydroxy-2-met il-propionamide as a colorless solid. P.f. 92-4 ° C; Yield 90%; MS: 464 (M-f H) +.
Example 3 2- (4-Buty-2-ynyloxy-phenylsulfonyl) -N-hydroxy-2-methyl-3-pyridin-3-ylpropionamide The ethyl ester of 2- (4-Buty-2-ynyloxy) acid was prepared. phenylsulfonyl) -2-met il-3-pyridin-3-ylpropionic following the procedure of Example 1 (Step 4). Starting from 2- (4-buty-2-ynyloxy-phenylsulfonyl) -propionic acid ethyl ester (7.0 22.5 mmoles) and 3-picolyl chloride hydrochloride (4.5 g, 27.4 mmoles), 9.0 g of the product was isolated as a yellow oil Performance (98%); MS: 402 (M + H) +.
2- (4-But-i-2-ynyloxy-phenylsulfonyl) -2-methyl-3-pyridin-3-yl-propionic acid was prepared starting from the ethyl ester of 2- (4-Butyl-2-ynyloxy) acid phenylsulfonyl) -2-methyl-3-pyridin-3-ylpropionic acid (8.0 g, 19.9 mmol) dissolved in MeOH (100 ml) and 10 N NaOH (20 ml). The resulting reaction mixture was worked up as described in Example 1 (Step 5). Yield 5.1 g (69%); MS: 374 (M + H) +. Starting from 2- (4-buty-2-ynyloxy-phenylsulfonyl) -2-methyl-3-pyridin-3-ylpropionic acid (6.0 g, 16 mmol) and following the procedure described in Example 1 (Step 6) , 4.8 g of 2- (4-Buty-2-ynyloxy-phenylsulfonyl) -N-hydroxy-2-methyl-3-pyridin-3-ylprcpionamide was isolated as a colorless solid. The hydrochloride salt was prepared as described in example 1. P.f. 154-56 ° C; Performance 89%; MS: 389 (M + H) +.
EXAMPLE 4 2- (4-Buty-2-ynyloxy-phenylsulfanyl) -N-hydroxy-propionamide The 2- (4 -But i-2-ynyloxy-phenylsulfanyl) -propionic acid was prepared starting from the ethyl ester of acid 2- (4-buty-2-ynyloxy-phenyl-sullyl) -propionic acid (5.56 g, 20 mmol) dissolved in MeOH (100 ml) and 10 N NaOH. The resulting reaction mixture was worked up as described in Example 1 (Step 5). Yield 4.8 g (96%); MS: 249 (MH). "Starting from 2- (4-buty-2-ynyloxy-phenylsulphyl) -propionic acid (6.0 g, 24 mmol) and following the procedure described in Example 1 (Step 6), 500 mg of 2- (4 -But i-2-ini loxyphenylsulfonyl) -N-hydroxy-propionamide was isolated as a colorless solid, mp 102-4 ° C, yield 8%, MS: 266 (M + H) +.
Example 5 2- (4-But-2-ynyloxybenzenesulonyl) -octanoic acid hydroxyamide 2- (Hydroxy-phenylsulfanyl) -octanoic acid ethyl ester was prepared according to the general method described in Example 1 (Step 1) . Starting from 4-mercapto phenol (12.6 g, 100 mmol) and 2-bromoethyl octanoate (25.2 g, 100 mmol), 25 g of 2- (4-hydroxy-phenyl-sulfanyl) -octanoic acid ethyl ester was isolated. as a colorless liquid. Performance 84%; MS: 297 (M + H) +. 2- (4-But-2-ynyloxy-phenylsulfanyl) -octanoic acid ethyl ester was prepared according to the general method described in Example 1 (Step 2).
Starting from the 2- (4-hydroxy-phenylsulfanyl) -octanoic acid ethyl ester 13.6 g, 46 mmoles) and l-bromo-2-but-ina (6.23 g, 47 mmoles). Yield 13.78 g (86%); amber oil; MS: 349.0 (M + H) +. 2- (4-But-2-ynyloxy-phenylsul-phenyl) -octanoic acid was prepared according to the general method described in Example 1 (Step 5). Starting from the 2- (4-but-2-ynyloxy-phenylsulfanyl) -octanoic acid ethyl ester 4.77 g, 13.7 mmol), 4.16 g of the product was isolated. Yield 96%; MS: 321.0 (M + H) +. 2- (4-But-2-ynyloxy-benzenesulfonyl) -octanoic acid ethyl ester was prepared according to the general method described in Example 1 (Step 3). Starting from the 2- (4-but-2-ynyloxy-phenylsulfanyl) -octanoic acid ethyl ester (7.26 g, 21 mmol), 6.78 g of the product was isolated. Performance (85%); yellow oil; MS: 381.2 (M + H) +. 2- (-but-2-ynyloxy-benzenesulfonyl) -octanoic acid was prepared starting from the ethyl ester of 2- (4-but-2-ynyloxy-benzenesulfonyl) -octanoic acid (6.52 g, 17 mmol) dissolved in THF: Methanol (100: 50 ml) and NaOH ION (10 ml). The resulting reaction mixture was worked up as described in Example 1 (Step 5). Yield 2.42 g (42%); colorless gum; MS: 352.9 (M + H) +. Starting from 2- (4-but-2-ynyloxy-benzenesulfonyl) -octanoic acid (2.21 g, 6 mmol) and following the procedure described in Example 1 (Step 6), 270 mg of 2-hydroxyamide was isolated. - (4-But-2-ynyloxy-benzenesulfonyl) -octanoic acid as an amber colored gum. Yield 42%; MS: 369.7 (M + H) +; 'XH NMR (300 MHz, DMSO-d6): d 0.826 (m, 3H), 1.33 (m, 9H), 1.77 (s, 3H), 1.89 (d, J = 2.2, 1H), 3.03 (d, J = 4 Hz, 1H), 4.73 (m, 2H), 5.78 (s, 1H), 6.56 (s, 1H), 7.1 (d, 2H), 7.92 (m, 2H).
EXAMPLE 6 2- (4-But-2-ynyloxy-phenylsulfanyl) -octanoic acid hydroxyamide 2- (-but-2-ynyloxy-phenylsulfanyl) -octanoic acid was prepared according to the general method described in Example 1 (Stage 5) Starting from the 2- (4-but-2-ynyloxyphenylsulfanyl) -octanoic acid ethyl ester (4.77 g, 13.7 mmol), 4.16 g of product was isolated. Yield 96%; MS: 321.0 (M + H) +. Starting from 2- (4-but-2-ynyloxy-phenylsulfanyl) -octanoic acid (4.12 g, 12.9 mmol) and following the procedure described in Example 1 (Step 6), 2.23 g of 2-hydroxyamide was isolated. - (4-But-2-ynyloxy-phenylsulfanyl) -octanoic acid as a white solid, mp. 125 ° C; Performance 73%; MS: 335.9 (M + H) +; AH NMR (300 MHz, DMSO-d6): d 0.856 (m, 3H), 1.24 (m, 6H), 1.57 (m, 2H), 1.71 (m, 2H), 1.83 (t, 3H), 2.55 (m , 2H), 4.78 (d, 2H), 6.95 (d, 2H), 7.36 (d, 2H), 8.96 (s, 1H), 10.62 (s, 1H).
Example 7 (S) -2- [(R) - [4- (2-Butynyloxy) phenylsulfinyl)] - N -hydroxy-octanamide & Example 8 (S) -2- [(S) - [4- (2-Butynyloxy) phenylsulfinyl)] -N-hydroxy-octanamide The hydroxyamide of 2- (-but-2-ynyloxy-phenylsulfanyl) -octanoic acid (prepared in Example 6)
(1.78 g, 5 mmol) was dissolved in methanol (50 ml) and H202 (30%, 10 ml) was added. The reaction mixture was stirred at room temperature for 96 hours and cooled rapidly with ice-cooled solution of NaHS03 solution. The reaction mixture was concentrated under reduced pressure and the residue was extracted with chloroform. Examination of the reaction mixture showed the formation of two diastereomers and were separated by column chromatography on silica gel eluting with 50% ethyl acetate; Hexane 411 g of (S) -2- [(R) -4-but-2-ynyloxy-phenylsulfinyl) -octanoic acid hydroxamide was isolated as a white solid, m.p. 132.3 ° C; Performance 24%; MS: 352.0 (M + H) +; 1R NMR (300 MHz, DMS0-d6): d 0.834 (m, 3H), 1.19 (m, 9H), 1.76 (m, 1H), 1.84 (t, 3H), 3.11-3.17 (dd, 2H), 3.33 (t, 3H), 4.81 (d, 2H), 7.15 (d, J = 2.8, 2H), 7.36 (d, J = 2.3, 2H), 9.00 (s, 1H), 10.56 (s, 1H). Starting from the hydroxyamide of 2- (4-but-2-ynyloxy-phenylsulfanyl) -octanoic acid (1.78 g, 5.0 mmol) and following the procedure described in Example 7, 0.411 g of acid hydroxamide (S) was isolated. ) -2 - [(S) - -but-2-ynyloxy-phenylsulfinyl) -octanoic acid as a white solid, mp 112.2 ° C; Yield 12%; MS: 352.0 (M + H) +; 1 H NMR (300 MHz, DMSO-d 6): d 0.804 (m, 3 H), 1.01 (m, 9 H), 1.59 (m, 1 H), 1.84 (t, 3 H), 3.33 (s, 3 H), 4.84 (d , 2H), 7.16 (d, J = 2.5, 2H), 7.61 (d, J = 2.7, 2H), 9.21 (s, 1H), 10.82 (s, 1H).
E n p lo 9 3- (4-But-2-ynyloxy-f-enoxy) -N-hydroxy-propionamide Stage 1: 4-But-2-ynyloxy-phenol To a solution of 4.13 g, (0.038 mole) of hydroquinone in 80 ml of acetone was added 5.19 g (0.375 moles) of potassium carbonate and 5.0 g (0.038 moles) of l-bromo-2-but-ina. The resulting mixture was heated to 55-60 ° C for 8 hours and then stirred overnight at room temperature. The reaction mixture was then poured into ice and extracted with ether. The combined organic materials were washed with IN sodium hydroxide solution. The combined aqueous layers were acidified with IN HCl solution and extracted with dichloromethane. The dichloromethane layers were washed with water and brine, dried over Na 2 SO 4, filtered through Magnesol® and concentrated in vacuo to provide 2.0 g of the phenol as a brown oil.
Step 2: 3- (4-But-2-ynyloxy-phenoxy) -propionic acid To a 0 ° C solution of 1015 g (8.60 mmoles) of potassium t-butoxide suspended in 10 ml of dry THF was added a solution of 1.40 • (8.60 mmoles) of -but-2-ynyloxy-phenol, dissolved in 30 ml of THF / DMF (5: 1). The reaction was stirred at room temperature for 10 minutes and then re-cooled to 0 ° C followed by the addition of 0.66 ml (9.46 mmol) of the pure -propiolactone. The resulting mixture was stirred overnight at room temperature and then concentrated in vacuo. The residue was diluted with ethyl acetate and extracted with saturated sodium bicarbonate solution. The alkaline aqueous extracts were acidified to pH2 with concentrated HCl solution and the solid precipitate was collected by filtration, washed with water and dried to give 0.089 g of the carboxylic acid as a black solid; p.f. 88-92 ° C. Electrospray Mass Spectrum 232.9 (M-H) ".
Step 3: 3- (4-But-2-ynyloxy-enoxy) -N-hydroxy-propionamide To a solution of 0 ° C of 0.089 g, (0.379 mmole) of 3- (4-but-2-ynyloxy) acid phenoxy) propionic, dissolved in 1 ml of dichloromethane and 0.059 ml of DMF was added 0.379 ml (0.758 mmoles) of a 2M solution of oxalyl chloride. The reaction was warmed to room temperature and stirred for 2 hours and then re-cooled to 0 ° C. A mixture of 0.139 ml (2.27 mmol) of a 50% hydroxylamine solution, 0.73 ml of THF and 0.21 ml of triethylamine was then added to the reaction. The reaction was stirred at room temperature for 12 hours and then concentrated in vacuo. The residue was extracted with dichloromethane and the combined organic materials were washed with water, 2N citric acid solution and brine, dried over Na 2 SO 4, filtered and concentrated in vacuo. The residue was triturated with ethyl acetate / hexanes to give the hydroxamic acid as a white solid; p.f. 116-118 ° C. Electrospray Mass Spectrum: 249.9 (M + H) +.
Example 10 4- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-butyramide Step 1: 4- (4-Benzyloxy-phenoxy) -butyric acid ethyl ester To a suspension of 1.2 g (0.030 mole) of hydride of sodium at 60% in 100 ml of toluene was added 6.12 g (0.030 mole) of 4- (benzyloxy) phenol and the reaction was stirred at room temperature for 30 minutes followed by the addition of 5.85 g (0.030 mole) of 3- bromobut ethyl ethyl. The resulting mixture was heated to reflux overnight and then filtered. The filtrate was washed with 0.5 N sodium hydroxide solution, 3% sodium carbonate solution, water and brine, dried over Na 2 SO 4, filtered and concentrated in vacuo to provide 5.45 g of the bis-ether as a white solid. . Mass Spectrum Electrospray: 314.8 (M + H) +.
Stage 2: 4- (4-hydroxy-phenoxy) -butyric acid ethyl ester To a solution of 3.58 g (0.011 mole) of 4- (4-benzyloxy-phenoxy) -butyral ethylester in 200 ml of ethanol was added. added 0.81 g of 5% palladium on charcoal and the resulting mixture was stirred under 2.46 kg / cm2 (35 psi) of hydrogen for 4 hours. The resulting mixture was filtered through Magnesol® and concentrated in vacuo to provide 1.97 g of the phenol as a gray solid. Electrospray Mass Spectrum: 225 (M + H) +.
Step 3: 4- (4-But-2-ynyloxy-phenoxy) -butyric acid ethyl ester To a solution of 524 mg (2 mmol) of triphenylphosphine dissolved in 20 ml of benzene and 50 ml of THF was added 0.175 ml (2.3 mmoles) of 2-butin-1-ol. After five minutes, 0.39 g (21.28 mmol) of the 4- (4-hydroxy-phenoxy) butyl ether ethyl ester, dissolved in 10 ml of THF, was added to the reaction followed by 0.369 ml (2.34 mmol) of diethyl azodicarboxylate. The resulting reaction mixture was stirred for 18 hours at room temperature and then concentrated in vacuo. The residue was chromatographed on silica gel eluting with ethyl ilohexanes (1:10) to provide 0.28 g (58%) of 4- (4-but-2-ynyloxy-phenoxy) -butyl ethyl ester. irico desired as a clear liquid. Mass Spectrum: 276.9 M +.
Step 4: 4- (4-But-2-ynyloxy-phenoxy) -butyric acid To a solution of 0.37 g, (1.34 mmol) of 4 - (4 -But-2-ynyloxy-phenoxy) -butyric acid ethyl ester in 6 ml of THF / methanol (5: 1) was added 1.6 ml of a solution of sodium hydroxide IN and the resulting mixture was stirred for 1.5 hours at 70 ° C. The reaction mixture was then concentrated, triturated with ether, filtered and dried to give 0.36 g of the carboxylate salt as a white solid. Electrospray Mass Spectrum:
247 (M-H) ".
Step 5: 4- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-butyramide. According to the procedure of Example 9 (step 3) 0.36 g (1.33 mmoles) of 4- (4-But-2-ynyloxy-phenoxy) butyric acid provides 0.237 g (68%) of the hydroxamic acid as a white solid; p.f. 123-125 ° C. Electrospray Mass Spectrum: 263.9 (M-H) ".
Example 11 2- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-acetamide
Ethyl ester (4-But-2-ynyloxy-phenoxy) -acetic acid To a suspension of 600 mg (0.015 mole) of 60% sodium hydride in 100 ml of toluene was added 3.0 g (0.015 mole) of 4-benzyloxy ) phenol and the reaction was stirred at room temperature for 30 minutes followed by the addition of 1.61 ml (0.015 mole) of ethyl chloroacetate. The resulting mixture was heated to reflux overnight and then filtered. The filtrate was washed with 0.5N sodium hydroxide solution, 3% sodium carbonate solution, water and brine, dried over Na 2 SO 4, filtered and concentrated in vacuo to provide 2.62 g of the bis-ether as a solid. White. P.f. 65-67 ° C. To a solution of 2.58 g (8.74 mmol) of the product mentioned in the above in 200 ml of ethanol, 0.81 g of palladium on carbon at 5% was added and the resulting mixture was stirred under 2.46 kg / cm2 (35 psi) of hydrogen for 4 hours. The resulting mixture was filtered through Magnesol® and concentrated in vacuo to provide 1.7 g of the phenol as a gray solid. P.f. 100-105 ° C. According to the procedure of Example 10 (Step 3), 1.65 g (8.41 mmol) of the phenol and 0.63 ml of 2-butyn-1-ol provide 1.2 g (60%) of the butynyl ether as a yellow oil.
Electrospray: 248.8 (M + H) +.
(4-But-2-ynyloxy-phenoxy) -acetic acid According to the procedure of Example 10 (Step 4), 1.0 g, 4.00 mmol) of (4-but-2-ynyloxy-phenoxy) -acetic acid ethyl ester provides 0.47 g of the carboxylic acid as a white solid; p.f. 114-116 ° C. Electrospray Mass Spectrum: 218.9 (M-H) ".
2- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-acetamide In accordance with the procedure of Example 9 (Step 3), 0.40 g, (1.82 mmol) of (4-But-2-ynyloxy) acid phenoxy) -acetic affords 0.20 g of the hydroxamic acid as a white solid; p.f. 130-132 ° C.
Electrospray Mass Spectrum: 235.9 (M + H) +.
Example 12 4- (4-But-2-ynyloxy-phenyl) -N-hydroxy-butyramide
4- (4-But-2-ynyloxy-phenyl) -butyric acid To a solution of 1.00 g (5.15 mmoles) of 4 - (-methoxyphenyl) butyric acid in 100 ml of dichloromethane at 0 ° C was added 15.5 ml (15.5 mmoles) of boron tribromide and the reaction was then allowed to warm to room temperature and stirred for 2 hours. The reaction mixture was then poured into 200 ml of saturated sodium bicarbonate solution and the organic layer was separated. The aqueous layer was acidified with concentrated HCl solution and then extracted with dichloromethane. The combined organic materials were dried over MgSO4were filtered and concentrated in vacuo to give 0.696 g of impure 4- (4-hydroxyphenyl) buty ric acid. To a solution of 0.69 g of 4- (4-hydroxyphenyl) butyric acid in 10 ml of DMF was added 0.956 g of sodium bicarbonate followed by 0.36 ml of iodomethane and the resulting mixture was stirred at room temperature for 5 hours. The reaction was diluted with water, extracted with ether, dried over MgSO4, filtered and concentrated in vacuo to give 0.553 g of methyl 4- (4-hydroxy phenyl) butyrate.
According to the procedure of Example 10 (step 3), 0.553 g (2.851 mmol) of methyl 4- (4-hydroxy phenyl) butyrate and 0.256 ml of 2-butyn-1-ol provide 0.294 g of the butynyl ether-methyl ester. after chromatography on silica gel eluting with ethyl acetate / hexanes (1:10). To a solution of 0.294 g (1195 mmol) of the butynyl ether methyl ester in 12 ml of THF / methanol (1: 1) was added 6.0 ml of 1N sodium hydroxide solution and the resulting mixture was stirred at room temperature for 6 hours. The reaction mixture was then acidified with 5% HCl solution, extracted with ethyl acetate, dried over MgSO4 and concentrated in vacuo to provide 0.223 g of the carboxylic acid as a brown solid. Electrospray Mass Spectrum: 231 (M-H) ".
4- (4-But-2-ynyloxy-phenyl) -N-hydroxy-butyramide To a solution of 0.189 g (0.815 mmoles) of 4 - (-but-2-ynyloxy-phenyl) -butyric acid in 4.3 ml of DMF 0.132 g (0.978 mmol) of 1-hydroxy-benzotriazole was added followed by 0.208 g (1.083 mmol) of 1- [3- (dimethylamino) propyl] -3-ethyl-carbodiimide hydrochloride and the resulting mixture was stirred at room temperature for 1 hour. To the reaction mixture was then added 0.23 ml of 50% aqueous hydroxylamine solution and the reaction was stirred overnight at room temperature. The reaction was then diluted with water and extracted with ethyl acetate. The combined organics were washed with water and saturated sodium bicarbonate, dried over Na 2 SO, filtered and concentrated in vacuo to give 0.156 g of the hydroxamic acid as a brown solid. Electrospray Mass Spectrum: 248.0 (M + H) +.
Example 13 2- (4-But-2-ynyloxy-phenylsulfanyl) -6- [2- (1, 3-dioxo-1,3-dihydro-iso-indol-2-yl) -acetylamino] -hexanoic acid hydroxyamide
Step: Coupling of 2-bromo-6-phthaloyl-caproic acid to the hydroxylamine resin. 4-O-Methylhydroxylamine-phenoxymethyl-copoly (styrene-1% -divinylbenzene) -resin1 (20 g, 1.1 meq / g) was placed in a peptide synthesis vessel (Chemglass Inc. Part Number CG-1866) and it was suspended in DMF (60 ml). 2-Bromo-N-phthaloyl-caproic acid (15 g, 2.0 eq.), 1-hydroxybenzotriazole hydrate (HOBt, 18 g, 6.0 eq.) And 1,3-diisopropyl-carbodiimide (DIC, 14 ml. 4.0 eq.). The reaction was stirred on an orbital shaker at room temperature for 2-16 hours. The reaction was filtered and washed with DMF (3 x 50 ml). A sample of resin was removed and subjected to the Kaiser test. If the test showed the presence of the free amine
(resin turned blue), the coupling described above was repeated, otherwise the resin was washed with DCM (3 x 50 ml), MeOH (2 x 50 ml), and DCM
(2 x 50 ml). (One wash consisted of the addition of the solvent and stirring either by bubbling nitrogen or stirring on the orbital stirrer for 1-5 minutes, then filtration under vacuum). The resin was dried in vacuo at room temperature.
Stage B: Displacement of the bromide with 4-hydroxybenthiol. The hydroxyamide resin of 2-bromo-6-ft aloyl-hexanoic acid prepared in Step A (20 g, 1.1 meq./g) was suspended in THF (50 ml). They added -hydroxybenzene iol (12 g, 5.0 eq.), Sodium iodide (13 g, 5.0 eq.) And 1, 8 -dia zabi cycle [5.4.0] undec-7-ene (DBU, 8.9 ml, 3.0 eq.). The reaction was stirred at room temperature for 12-16 hours. The mixture of 11
The reaction was filtered and washed with DMF (2 x 20 ml), DMF: water 9: 1) (2 x 20 ml), DMF (20 ml), MeOH (2 x -20 ml), and DCM (2 x 20 ml) ). The resin was dried at room temperature.
Stage C: Alkylation with 2-bromobutin The hydroxyamide resin of 2- (4-hydroxy-phenylsulphyl) -6-phthaloyl-hexanoic acid prepared
'' in Step B (20 g, 1.1 meq / g) was suspended in THF (50 ml) and cooled to 0 ° C. 2-Bromobutyne (8.0 ml, 2.0 eq.) And sodium hydride (2.4 g, 3.0 eq.) Were added and the mixture was stirred at room temperature overnight. The reaction mixture was filtered and washed with DMF (2 x 20 ml), MeOH (2 x 20 ml), and DCM (2 x 20 ml). The resin was dried at room temperature.
Step D: Removal of the phthaloyl group The hydroxyamide resin of 2- (4-but-2-inoxyphenyl sulphyl) -6-phthaloyl-hexanoic acid prepared in Step C (3.4 g, 1.1 meq / g) was suspended in THF
(150 ml) and ethanol (150 ml) and hydrazine was added
(30 ml). The reaction mixture was stirred on an orbital shaker at room temperature for 12-24 hours. The reaction was filtered and washed with DCM (2 x 50 ml), DMF (2 x 50 ml), MeOH (2 x 50 ml), and DCM (2 x 50 ml). The resin was dried at room temperature.
Step E: Acylation of the primary amine The hydroxyamide resin of 6-amino-2- (4-but-2-inoxi-phenyl sulphyl) -hexanoic acid prepared in Step D (0.33 g, 1.1 meq / g) it was suspended in DMF (60 ml). N-phthaloylglycine (1.5 g, 4.0 'eq.) 1-hydroxybenzot-riazole hydrate (HOBt, 1.43 g, 6.0 eq.) And 1,3-diisopropyl-1-carbodiimide (DIC, 0.18 ml, 4.0 eq.) Were added. . The reaction was stirred on an orbital shaker at room temperature for 2-16 hours. The reaction was filtered and washed with DMF (3 x 5 mL). A sample of resin was removed and subjected to the Kaiser test. If the test showed the presence of the free amine (resin turned blue), the coupling described above was repeated, otherwise the resin was washed with DCM (3 x 5 ml). MeOH 2 x 5 ml), and DCM (2 x 5 ml). The resin was dried at room temperature.
Stage F: Separation of the hydroxyamide of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- [2- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) -acet-ylamino acid ] -hexanoic of the resin The hydroxyamide resin of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- [2- (1, 3-dioxo-l, 3-dihydro-iso-indole-2) -yl) -acetylamino] -hexanoic prepared in step E (0.33 g, 1.1 meq / g) was suspended in DCM (1.0 ml) and TFA (1.0 ml) was added. The reaction was stirred for 1 hour at room temperature. The reaction was filtered and the resin was washed with DCM (2 x 1 ml). The filtrate and the washing were combined and concentrated to dryness in a Savant SpeedVac Plus apparatus. Methanol (1 ml) was added and the mixture was concentrated. The crude product was purified by reverse phase CLAP under the following conditions: Column: OdS-AM, 20 mm x 50 mm, size 5 particulate (YMC, Inc. Wilmington, North Carolina) Solvent Gradient Time Water Acetonitrile 0.0 95 5 16 min. 5 95 Flow Rate: 22.5 ml / min.
Example 13 The hydroxyamide of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- [2- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid had a retention time of 4.5 min of CLAP and EM "of 510 (M + H).
The following compounds of hydroxamic acids were synthesized following the steps in Example 13, and using quinaldic acid, 2-bibenylcarboxylic acid, 3,4-dichlorophenylacetic acid, 3-quinolinecarboxylic acid, 4 - (2-t) acid ienyl) -butyric acid, xanthen-9-carboxylic acid, diphenylacetic acid, 1-isoquinolinecarboxylic acid, N-met ilpyrrole-2-carboxylic acid, t-phthalen-3-acetic acid, or indole- 3-acetic
Use 23 [quinoline-2-carboxylic acid 5- (4-but-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentyl] -amide. Stage A: Oxidation of sulphide to sulfoxide. The hydroxyamide resin of 2 - (4-but-2-ynyloxy-phenylsulfanyl) -6-phthaloylhexanoic acid prepared in Example 13, Step C (6.7 g, 1.1 meq / g) was "suspended in DCM (200 ml). and 70% tert-butyl hydroperoxide (45 ml) and benzenesulfonic acid (2 g) were added.The reaction mixture was stirred on an orbital shaker at room temperature for 12-24 hours.The reaction was filtered and washed with DCM (2 x 50 ml), DMF (2 x 50 ml), MeOH (2 x 50 ml), and DCM (2 x 50 ml) The resin was dried in vacuo or at room temperature.
Step B: Removal of the phthaloyl group The hydroxyamide resin of 2- (4-but-2-inoxi-benzenesulfinyl) -6-phthaloyl-hexanoic acid prepared in Step A was deprotected to give the hydroxyamide resin of 6-amino acid -2- (4-But-2-inoxi-benzenesulfinyl) -hexanoic acid according to the procedure in Example 13, Step D.
Step C: Acylation of the primary amine The hydroxyamide resin of 6-amino-2- (4-but-2-inoxi-benzenesulfinyl) -hexanoic acid (0.33 g, 1.1 meq / g) prepared in step B was acylated with quinadic acid (1.2 g, 4.0 eq.) according to the procedure in Example 13, Step E to give the resin of [5- (4-but-2-ynyloxy-benzenesul fini 1) -5-hydroxycarbamoyl-pentyl ] -quinoline-2-carboxylic acid amide.
Step D: Separation of the [5- (-but-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentyl] -amide of quinoline-2-carboxylic acid from the resin The resin of [5- (4-buty -2-inyloxy-benzenesulfini 1) -5-hydroxy-carbamoyl-pentyl] -amide of quinol in-2-carboxylic acid prepared in Step C
(0.33 g, 1.1 meq / g) was separated according to the procedure in Example 13, Step F to give the
Example 23: [5- (4-But-2-ynyloxy-benzenesul-f-yl) -5-hydroxy-carbamoyl-pentyl] -amide of quinoline-2-carboxylic acid as a mixture of erythroid days which had a time2 of CLAP retention of 4.35 / 4.5 min. and EM3 of 494 (M + H). The following hydroxamic acid compounds were synthesized following the steps in Example 23, and using N-phthaloylglycine, 2-bibenylcarboxylic acid, 3,4-dichlorophenylacetic acid, 3-quinolinecarboxylic acid, 4- (2-thienyl) acid -butyric, xant-9-carboxylic acid, diphenyl-acetic acid, 1-isoquinolinecarboxylic acid, N-methylpyrrole-2-carboxylic acid, t-thaphthalene-3-acetic acid, or indole-3-acetic acid.
Example 34 N- [5- (4-B-2-ynyloxy-benzenes-l-phonyl) -5-hydroxycarbamoyl-pentyl] -2-phenethyl-benzamide. Step A: Oxidation of Sulfide to Sulfone The hydroxyamide resin of 2- (4-but-2-inoxi-phenylsulfanyl) -6-phthaloylhexanoic acid prepared in Example 13, Step C (6.7 g, 1.1 meq / g) was suspended in DCM (200 ml) and mCPBA (8 g) was added. The reaction mixture was stirred on an orbital shaker at room temperature for 12-24 hours. The reaction was filtered and washed with DCM (2 x 50 ml), DMF (2 x 50 ml), MeOH (2 x 50 ml), and DCM (2 x 50 ml). The resin was dried in vacuo at room temperature.
Step B: Removal of the phthaloyl group The hydroxyamide resin of 2- (4-but-2-inoxi-benzenesulfonyl) -6-phthaloyl-hexanoic acid prepared in Step A was deprotected to give the 6-amino acid hydroxyamide resin -2- (4-but-2 -inoxy-benzenesulfinyl) -hexanoic acid according to the procedure in Example 13, Step D.
Step C: Acylation of the primary amine The hydroxyamide resin of 6-amino-2- (4-but-2-inoxi-benzenesulfonyl) -hexanoic acid (0.33 g, 1.1 meq / g) prepared in step B was acylated with 2-bibenylcarboxylic acid (1.6 g, 4.0 eq.) according to the procedure in Example 13, Step E to give the N- [5- (4-but-2-ynyloxy-benzenesulfonyl) -5-hydroxy resin carbamoyl -pent il] -2-fenet i 1 -benzami da.
Step D: Separation of the N- [5- (4-but-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentyl] -2-phenethyl-benzamide from the resin. The N- [5- (4-but-2-ynyloxy-benzenesulfonyl) -5-hydroxy carbamoyl-pentyl] -2-phenethyl-benzamide resin prepared in Step C (0.33 g, 1.1 meq / g) was separated according to the procedure in Example 13, Step F to give Example 34: of N- [5- (4-but-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentyl] -2-fenethe -benzamide which had a CLAP retention time2 of 5.0 min. and EM3 of 541 (M + H). The following compounds of hydroxamic acids were synthesized following the steps in Ex. 34, and using quináldico acid, N-phthaloylglycine, 3,4-dichlorophenylacetic acid, 3-quinol incarboxylic acid, xanthen-9-carboxylic acid, acid di-phenylacetic acid, 1-isoquinol incarboxylic acid, or t-thaphthalene-3-acetic acid.
Example 43 Hydroxyamide of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- acid. { 2- [2- (3,4-dichloro-phenyl) -acetylamino] acetylamino} -hexanoic.
Stage A: Elimination of the phthaloyl group The hydroxyamide resin of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- [2- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) hydroxyamide. ) -acetylamino] -hexanoic prepared in Example 13, Step E was deprotected to give the hydroxyamide resin of 6- (amino-acetylamino) -2 - (4-but-2-inyloxy-benzenesulfinyl) -hexanoic acid according to the procedure in Example 13, Step D.
Stage B: Acylation of the primary amine The hydroxyamide resin of 6- (α-n-acetylamino) -2- (4-but-2-inoxi-benzenesulfinyl) -hexanoic acid (0.33 g, 1.1 meq / g) prepared in Step A was acylated with 3,4-dichlorophenylacetic acid (1.5 g, 4.0 eq.) according to the procedure in Example 13, Step E to give the hydroxyamide resin of 2- (4- but-2-) acid. inyloxy-phenylsulfanyl) -6- { 2- [2- (3, -dichloro-phenyl) -acetylamino] -acetylamino} -hexanoic acid.
Step C: Separation of the hydroxamide from 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- acid. { 2- [2- (3,4-Dichlorophenyl) -acetylamino] -acetylamino} -hexanoic of the resin The hydroxyamide resin of 2 - (.4-but-2-ynyloxy-phenylsulfanyl) -6-. { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acetylamino] -hexanoic prepared in Step B (0.33 g, 1.1 meq / g) was separated according to the procedure in Example 13, Step F to give Example 43: of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- hydroxyamide. { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acetylamino} -hexanoic that had a CLAP retention time2 of 4.94 min. and EM3 of 567 (M + H). The following hydroxamic acid compounds were synthesized following the steps in Example 43, and using quinaldic acid, N-phthaloylglycine, 2-bibenylcarboxylic acid, 3-quinolinecarboxylic acid, xanthen-9-carboxylic acid, diphenylacetic acid, acid 1 isoquinolinecarboxylic acid, N-met ilpyrrole-2-carboxylic acid or t-thaphthalen-3-acetic acid.
Use 53 [5- (4-But-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentyl] -aminoquin-3-carboxylic acid amide. Stage A: Oxidation of sulphide to sulfoxide. The hydroxyamide resin of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid prepared in Example 13, Step E was oxidized to the hydroxyamide resin of 2- (-but-2-linoxy-benzenesulfinyl) -6- [2- (1,3-dioxo-1,3-dihydroxy) acid hydroxyamide. isoindol-2-yl) -acetylamino] -hexanoic acid according to the procedure in Example 23, Step A.
Stage B: Elimination of the phthaloyl group The hydroxyamide resin of 2- (4-but-2-ynyloxy-benzenesulfinyl) -6- [2- (l, 3-dioxo-l, 3-dihydro-isoindol-2-yl) ) -acetylamino] -hexanoic prepared in Step A was deprotected to give the hydroxyamide resin of 6- (amino-acetylamino) -2- • (4-but-2-ynyloxy-benzenesul fini 1) -hexanoic acid of according to the procedure in Example 13, Step D.
Step C: Acylation of the primary amine The hydroxyamide resin of 6- (amino-acetylamino) -2- (4-but-2-inoxi-benzenesulfinyl) -hexanoic acid (0.33 g, 1.1 meq / g) prepared in the step B was acylated with 3-quinolinecarboxylic acid (1.2 g, 4.0 eq.) According to the procedure in Example 13, Step E to give the resin of [5- (4-but-2-ynyloxy-benzenesulfinyl) -5 -hydroxycarbamoyl-pentyl] -aminoquin-3-carboxylic acid amide.
Step D: Separation of the [5- (4-but-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentyl] -amide of quinoline-3-carboxylic acid from the resin The resin of [5- ( 4-but-2-ynyloxy-benzenesulfinyl) -5-hydroxy-carbamoyl-pentyl] -amide of quinoline in-3-carboxylic acid prepared in Step C (0.33 g, 1-1 meq / g) was separated according to the procedure in Example 13, Step F to give Example 53: of [5- (4-but-2-ynyloxy-benzenesul finyl) -5-hydroxy-carbamoyl-pentyl] -amide of quinolin-3 acid -carboxylic acid as a mixture of diastereomers that had a CLAP retention time2 of 3.49 min. and EM3 of 551 (M + H). The following hydroxamic acid compounds were synthesized following the steps in Example 53, and using quinaldic acid, N-phthaloylglycine, 2-bibenylcarboxylic acid, 3,4-dichlorophenylacetic acid, 4 - (2-thienyl) butyrate, acid xanthen-9-carboxylic acid, di-phenyl-acetic acid, or N-methylpyrrole-2-carboxylic acid.
Example 62 2- (4-But-2-ynyloxy-benzenesulfonyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic acid hydroxyamide Step A: Oxidation of sulphide to sulfoxide. The hydroxyamide resin of 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic prepared in Example 13, Step E was oxidized to the hydroxyamide resin of 2- (4-but-2-ynyloxy) acid. benzenesulfonyl) -6- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid according to the procedure in Example 34, Step A. Step B : Elimination of the phthaloyl group The hydroxyamide resin of 2- (4-but-2-ynyloxy-benzenesul fonyl) -6- [2- (l, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic prepared in Step A was deprotected to give the hydroxyamide resin of 6- (amino-acetylamino) -2- (4-but-2-ynyloxy-benzenesulfinyl) -hexanoic acid according to the procedure in Example 13, Step D.
Step C: Acylation of the primary amine The hydroxyamide resin of 6- (amino-acetylamino) -2- (4-but-2-inoxi-benzenesulfonyl) -hexanoic acid (0.33 g, 1.1 meq / g) prepared in the step B was acylated with diphenylacetic acid (1.5 g, 4.0 eq.) According to the procedure in Example 13, Step E to give the hydroxyamide resin of 2- (4-but-2-ynyloxy-benzenesulfonyl) -6- acid. (2-diphenylacetylaminoacetylamino) -hexanoic acid.
Stage D: Separation of 2- (4-but-2-ynyloxy-benzenesulfonyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic acid hydroxyamide from the resin The hydroxyamide resin of 2- (4-but -2-loxi-benzenesulfonyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic prepared in Step C
(0.33 g, 1.1 meq / g) was separated according to the procedure in Example 13, Step F to give the
Example 62: 2- (4-But-2-ynyloxy-benzenesulfonyl) -6- (2-di-phenylacetylamino-acetylamino) -hexanoic acid hydroxyamide which had a CLAP retention time of 4.90 min. and EM3 of 606 (M + H). The following hydroxamic acid compounds were synthesized following the steps in Example 62, and using N-phthaloylglycine, 2-bibenylcarboxylic acid, 3,4-dichlorophenylacetic acid, 3-quinolinecarboxylic acid, xanthen-9-parboxylic acid, -isoquinolinecarboxylic acid, t-phthalic acid-3-acetic acid, or indole-3-acetic acid.
References: 1"Ricter, LS; Desai, MC Te t rah edron Le tt ers, 1997, 38, 321-322 2. LC Conditions: Hewlett Packard 1100; YMC ODS-A 4.6 mm x 50 mm column 5 ua 23 ° C, 10 uL injection, Solvent A: TFA / 0.05% water, Solvent B: 0.05% TFA / acetonitrile, Gradient: Time "0: 98% A; 1 minute: 98% A; 7 minutes: 10% A; 8 minutes: 10% A; 8.9 minutes: 98% A; After 1 minute of time. Flow rate 2.5 ml / minute; Detection: DDA of 220 and 254 nm. 3. EM conditions: API -electropulveri zador
Example 71 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-4-. { 4- [2- (1-piperidinyl) ethoxyphenyl} butanamide Step 1: 2- [4 - (2-Piperidin-l-yl-ethoxy) -phenyl] -ethanol To a solution of 4-hydroxyphenetyl alcohol (5.02 g, 36.3 mmol) and chloroethyl-piperidine (7.36 g, 39.96 mmoles) in 30 ml of DMF, 5 g of K2C0 was added. The reaction was stirred at 80 ° C overnight. After cooling, the mixture was rapidly cooled with water, then extracted into CHC13. The organic layer was separated, dried over Na2SO4, filtered and concentrated. 2 - [- (2-Piperidin-1-yl-ethoxy) -phenyl] -ethanol (4.58 g, 18.4 mmol) was isolated as a brown oil; Yield 51%; MS: 250.3 (M + H) +.
Stage 2: 1-. { 2- [4 - (Chloro-ethyl) -phenoxy] -ethyl} -piperidine
2 - [4 - (2-Piperidin-1-yl-ethoxy) -phenyl] -ethanol (4.23 g, 16.98 mmol) was dissolved in 200 ml of THF. HCl gas was bubbled through the solution at 0 ° C for 5 minutes. Thionyl chloride (2.48 ml, 33.9 mmol) was added dropwise at 0 ° C. The reaction mixture was heated to reflux for 2 hours before it was concentrated. It was isolated 1-. { 2 - [4-chloroethyl] -phenoxy] -ethyl} -piperidine (4.74 g, 15.6 mmol) as a brown semi-solid; Yield 92%; E: 268.3 (M + H) +.
Stage 3: Prepared 2-. { [4 - (2-Butyloxy) phenyl] -sulfonyl} -4-. { Ethyl 4- [2- (1-piperidinyl) ethoxyphenyljbutanoate according to the general method described in Example 1 (Step 4) starting from l-. { 2- [4- (Chloro-ethyl) -phenoxy] -ethyl} -piperidine (4.74 g, 15.64 mmol) and (4-but-2-inyloxy-benzenesulfonyl) -acetic acid ethyl ester (3.56 g, 12 mmol); 1.21 g of the crude product. Performance 19%; coffee oil; MS: 528.1 (M + H) +.
Step 4: 2- acid was prepared. { [4 - (2-Butyloxy) phenyl] -sulfonyl} -4-. { 4- [2- (1-piperidinyl) ethoxy] phenyljbutanoic according to the general method described in Example 1 (Step 5). Starting from 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -4-. { 4- [2- (1-piperidinyl) -ethoxyphenyl} ethyl butanoate (1.21 g, 2.29 mmol), 750 mg of off-white solid was isolated. Performance 65%; MS: 500.3 (M + H) +.
Stage 5: Starting from acid 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -4-. { 4- [2- (1-piperidinyl) -ethoxy] phenyl} butanoic (660 mg, 1.32 mmol) and following the procedure described in Example 1 (Step 6), 50 mg of 2- was isolated. { [4 - (2-Butyloxy) -phenyl] sulfonyl} -N-hydroxy-4-. { 4- [2- (1-piperidinyl) -ethoxyphenyl} Butanamide as a pale yellow solid. P.f. 68 ° C; Yield 7%; MS: 515.2 (M + H) +; 1 R NMR (300 MHz, DMS0-d6): d 0.853 (m, 2H), 1.36 (s, 2H), 1.67-1.82 (band, 4H), 1.84 (s, 3H), 1.95 (q, 2H), 2.94 (m, 2H), 3.45 (m, 4H), 3.73 (t, 1H), 4.33 (t, J = 4.41 Hz, 2H), 4.88 (d, 2.25 Hz, 2H), 6.91 (m, 2H), 7.05 (d, 2H), 7.16 (m, 2H), 7.69 (m, 2H), 9.28 (s, 1H), 9.88 (s, 1H).
Example 72 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -7-cyano-N-hydroxy-heptanamide 2- was prepared. { [4 - (2-Butyloxy) phenyl] -sulfonyl} -7-ethyl cyanoheptanoate according to the general method described in example 1 (step 4), starting from (4-but-2-ynyloxy-benzenesul-fonyl) -acetic acid ethyl ester (10 g, 33.8 mmol ) and 6-bromohexanoni trilo (4.48 ml, 33.8 mmol); 7.9 g of white solid. P.f. 63 ° C; Yield 60%; MS (El): 391.4 (M + H) +. 2 - acid was prepared. { [4 - (2-Butynyloxy) phenyl] -sulfonyl} -7-cyanoheptanoic acid according to the general method described in example 1 (step 5), starting from 2-. { [- (2-Butynyloxy) phenyl] sulphonyl} Ethyl-7-cyanoheptanoate (300 mg, 0.77 mmol); 230 mg of yellow gel. Yield 82%; MS: 362.4 (M-H). "
Starting from acid 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -7-cyanoheptanoic acid (3.78 g, 10.4 mmol) and following the procedure described in Example 1 (step 6), 1.11 g of 2- was isolated. { [4- (2-butynyloxy) phenyl] sulfonyl} -7-cyano-N-hydroxy-heptanamide as a white powder. P.f .: 120 ° C; Yield: 28%; MS: 379.3 (M + H) +; 1 H-NMR (300 MHz, DMS0-d 6): d 1.16-1'.31 (band, 4H), 1.44 (m, 2H), 1.69 (m, 2H), 1.85 (s, 3H), 2.42 (t, J = 7 Hz, 2H), 3.71 (t, J = 7.3 Hz, 1H), 4.89 (d, 2.19 Hz, 2H), 7.18 (d, J = 8.9 Hz, 2H), 7.72 (d, J = 8.9 Hz, 2H), 9.24 (s, 1H), 10.88 (s, 1H).
Example 73 2-. { [4- (2-butynyloxy) phenyl [sulfanil} -2-cyclohexyl-N-hydroxyacetamide Step 1: 2-Bromocyclohexylacetic acid To a solution of cyclohexylacetic acid (10 g, 70 mmol) in 100 ml of CC1 was added red phosphorus (6.32 g, 204 mmol). The mixture was heated to reflux and bromine (70.7 ml, 1.38 mmol) was added dropwise over 3 hours through the condenser via an addition funnel. The reaction was heated to reflux for 5 hours before it was rapidly cooled with water, then washed with 10% Na 2 SO 4, water, then in NaHCO 3. The sodium bicarbonate solution was conducted to acidic pH using IN HCl. The solid was collected and the aqueous filtrate was extracted with CHC13, washed with saturated Na2HS04 solution, then with water. The organic layer was dried over Na 2 SO 4, filtered and concentrated and combined with solid harvested previously to provide 3.22 g of 2-bromocyclohexylacetic acid as a white solid. Performance 21%; MS: 219.1 (M-H) ~.
Step 2: Ethylcyclohexyl [4- (hydroxyphenyl) sulfanyl] -acetic acid was prepared according to the general method described in Example 1 (step 1), starting from 2-bromocyclohexylacetic acid (3.08 g, 13.9 mmoles) and 4-mercaptophenol (2 g, 14.2 mmol); 3.10 g of yellow oil. The product was quite pure and was taken for other transformations. Performance 84%; MS: 265 (M + H) +.
Step 3: Cyclohexy-1 [4- (hydroxy phenyl) sulphyl] ethyl acetate To a solution of et-cyclohexyl [4- (hydroxyphenyl) sulfanyl] -acetic acid (3.1 g, 11.65 mmol) in 100 ml of ethanol, was added 1 ml of sulfuric acid. The mixture was heated to reflux overnight then concentrated, extracted into methylene chloride, washed first with saturated NaHC03 solution then with water. The organic layer was dried over Na 2 SO 4, filtered over magnesol and concentrated to provide 1.22 g of ethyl cyclohexyl [4- (hydroxyphenyl) sulfanyl] ethyl acetate as a yellow oil. Yield 35%; MS: 295.4 (M + H) +.
Stage 4: Prepared. { [4 - (2-butyloxy) phenyl] sulfanil}
(cyclohexyl) ethyl acetate according to the general method described in example 1 (step 2), starting from cyclohexyl [4- (hydroxyphenyl) sulphyl] -acetic acid (1 g, 3.4 mmol) and -bromo -2-but ina
(0.32 ml, 3.7 mmol); .1.25 g of yellow oil.
100% performance; MS (EI): 346.1 (M + H) +.
Step 5: Acid was prepared. { [4 - (2-Butyloxy) phenyl] -sulfanyl} (cyclohexyl) acetic acid according to the general method described in example 1 (step 5), starting from. { [4- (2-Butynyloxy) phenyl] sulfanil} (cyclohexyl) -ethyl acetate (1.2 g, 3.47 mmol); 1.19 g of yellow oil. 100% performance; MS: 317.4 (M-H). "
Stage 6: Starting from acid. { [4- (2-Butynyloxy) phenyl] sulfanil} (cyclohexyl) acetic and following the procedure described in Example 1 (step 6), 672 mg of 2- was isolated. { [4 - (2-Butyloxy) -phenyl] sulfanil} -2-cyclohexyl-N-hydroxyacetamide as a white powder. P.f. 163 ° C; Yield 75%; MS: 334.1 (M + H) +; 1N NMR (300 MHz, DMSO-d6): d 0.86-1.12 (band, 5H), 1.62 (m, 5H), 1.83 (t, J = 2.25 Hz, 3H), 2.05 (d, J = 11.9 Hz, 1H ), 3.12 (d, J = 9.1 Hz, 1H), 4.73 (d, J = 2.34 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 7.36 (d, J = 8.7 Hz, 2H), 8.92 (s, 1H), 10.5 (s, 1H).
Example 74 2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -2-cyclohexyl-N-hydroxyacetamide Starting from 2 -. { [4 - (2-Butynyloxy) -phenyl] sulfanil} -2-cyclohexyl-N-hydroxyacetamide (580 mg, 1.74 mmol), and following the procedure described in Example 7, 230 mg of 2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-cyclohexyl-N-hydroxy-, acetamide as a white solid. P.f. 188 ° C; Yield: 38%; MS: 350.2 (M + H) +; 1 H NMR (300 MHz, DMSO-de): d 1.05 (m, 3H), 1.24 (, 2H), 1.41-1.72
(band, 5H), 1.84 (t, J = 2.22 Hz, 3H), 2.5 (m, 1H),
3. 14 (d, J = 7.23 Hz, 1H), 4.89 (m, 2H), 7.16 (d, J = 9)
Hz, 2H), 7.61 (d, J = 8.7 Hz, 2H), 9.0 (d, 1H), 10.4
(d, 1H).
Example 75 2-. { [4- (2-Butynyloxy) enyl] sulfonyl} -2-cyclohexyl-N-hydroxyacetamide To a solution of 2-. { [4- (2-butyloxy) phenyl] -sulfinyl} -2-cyclohexyl-N-hydroxy-acetamide (180 mg, 0.52 mmol) in MeOH / THF at room temperature, oxone (5.0 g, excess) in water (20 ml) was added. The reaction mixture was stirred at room temperature for 6 hours and filtered. The methanol / THF layer was concentrated and extracted with chloroform. The organic layer was washed well with water, dried, filtered and concentrated. The product was purified by silica gel column chromatography eluting with 4: 1 ethyl acetate: hexane and isolated 2-. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -2-cyclohexyl-N-hydroxy-acetamide as a white solid. P.f. 191 ° C; Yield: 45 mg
(24%); MS: 366.3 (M + H) +; H NMR (300 MHz, DMSO-d6): d
0. 95-1.12 (band, 5H), 1.58 (m, 5H), 1.85 (t, J = 2.22
Hz, 3H), 2.05 (m, 1H), 3.63 (d, J = 9.1 Hz, 1H), 4.87 (d, J = 2.34 Hz, 2H), 7.16 (d, J = 9 Hz, 2H), 7.76 ( d, J = 9 Hz, 2H), 9.01 (s, 1H), 10.7 (s, 1H).
Example 76 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (4-methoxyphenyl) acetamide Step 1: [(4-Hydroxyphenyl) sulfanyl] (4-methoxyphenyl) -acetic acid ethyl Bromine (4-methoxyphenyl) acetate (16.5 g, 60.4 mmol) ) to a stirred solution of triethylamine (10 ml), and 4-mercaptide ofenol (7.63 g, 60.4 mmol) in chloroform (200 ml). The mixture was refluxed overnight before it was concentrated and the residue was extracted into ethyl acetate and washed with water. The organic layer was dried over Na 2 SO, filtered and concentrated. The compound was isolated using silica gel column chromatography eluting with 20% ethyl acetate: hexane solution. [(4-Hydroxyphenyl) sul fani 1] (ethyl 4-methoxyphenyl) acetate was isolated as a yellow oil (15.82 g). Yield 82%; MS: 317.2 (M-H). "Was prepared { [4 - (2-Butynyloxy) phenyl] sullyl.
(4-methoxyphenyl) ethyl acetate according to the general method described in example 1 (step 1), starting from [(4-hydroxyphenyl) sulphyl] (4-methoxyphenyl) ethyl acetate (15.82 g, 49.7 mmoles) and 4-bromo-2-butine (4.79 ml, 54.7 mmoles); 17.66 g of yellow oil. Yield 96%; MS (EI): 370.1 (M + H) +. Acid was prepared. { [4 - (2-Butynyloxy) phenyl] -sulfanyl} (4-methoxyphenyl) acetic acid according to the general method described in example 1 (step 5),
(hydrolysis was carried out at room temperature for 24 hours) starting from. { [4- (2-Butynyloxy) phenyl] sulfanil} (4-methoxyphenyl) ethyl acetate (10 g, 27 mmol); 5.78 g of yellow oil. Performance 63%; MS: 341.2 (MH). "Starting from acid { [4- (2-Butynyloxy) phenyl] sulfanyl} - (-methoxy phenyl) acetic acid (5.59 g, 16.3 mmol) and following the procedure described in Example 1 (step 6), 450 mg of 2- {[4- (2-butynyloxy) phenyl] sulfanyl} -N-hydroxy-2- (4-methoxyphenyl) acetamide was isolated as a white solid. 156 ° C; Yield: 8%; MS: 358.3 (M + H) +; 1 H NMR (300 MHz, DMSO-d6): d 1.82 (t, J = 2.25 Hz, 3H), 3.72 (s, 3H) , 4.65 (s, 1H), 4.71 (q, J = 2.3 Hz, 2H), 6.89 (m, 4H), 7.26 (d, 2H), 7.53 (d, 2H), 9.0 (s, 1H), 10.8
(s, 1H).
Example 77 (2R) -2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (4-methoxyphenyl) ethanamide and (2S) -2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (4-methoxyphenyl) ethanamide Starting from 2-. { [4- (2-butyloxy) -phenyl] sulfanil} -N-hydroxy-2- (4-methoxy phenyl) acetamide (prepared in Example 76) (340 mg, 0.95 mmol), and following the procedure described in Example 7. The two diastereomers were separated by gel column chromatography of silica eluting with 50% ethyl acetate: hexane. The fastest moving isomer, namely, (2R) -2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (4-methoxy phenyl) ethanamide as a white powder. P.f .: 157 ° C; Yield: 49.0 mg (14%); MS: 374.3 (M + H) +; X H NMR (300 MHz, DMSO-d 6): d 1.83 (t, J = 2.25 Hz, 3 H), 3.70 (s, 3 H), 4.32 (s, 1 H), 4.76 (d, J = 2.37 Hz, 2 H), 6.8 (d, 2H), 6.99 (m, 4H), 7.13 (d, 2H), 9.2 (s, 1H), 11 (s, 1H). The slower moving isomer, namely (2S) -2- was isolated. { [4 - (2-Butyloxy) pheni 1] sul finyl} -N-Hydroxy-2- (4-methoxyphenyl) -etanamide as a white powder. P.f. 134 ° C; Yield: 39 mg (10%); MS: 374.2 (M + H) +; 1 H NMR (300 MHz, DMSO-d 6): d 1.85 (t, J = 2.25 Hz, 3 H), 3.77 (s, 3 H), 4.29 (s, 1 H), 4.81 (d, J = 2.4 Hz, 2 H), 6.93 (d, J = 8.76 Hz, 2H), 7.12 (d, J = 8.85 Hz, 2H), 7.32 (d, J = 8.76 Hz, 2H), 7.48 (d, J = 8.79 Hz, 2H), 8.95 ( s, 1H), 10.6 (s, 1H).
Example 79 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (4-methoxyphenyl) acetamide Starting from the 2-. { [4- (2-butyloxy) -phenyl] sulfanil} -N-hydroxy-2- (4-methoxy-phenyl) acetamide (290 mg, 0.8 mmol), and following the procedure described in Example 75, 120 mg of 2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (4-methoxy-phenyl) acet amide as a white powder. P.f. 190 ° C; Yield: 39%; MS: 390.2 (M + H) +; X H NMR (300 MHz, DMSO-de): d 1.85 (t, J = 2.22 Hz, 3 H), 3.74 (s, 3 H), 4.85 (d, J = 2.31 Hz, 2 H), 4.94 (s, 1 H), 6.86 (d, J = 9 Hz, 2H), 7.08 (d, J = 7.2 Hz, 2H), 7.26 (> d, J = 9 Hz, 2H), 7.45 (d, J = 9 Hz, 2H), 9.24 (d, J = 1. 5 Hz, 1H), 10.9 (s, 1H).
Example 80 2-. { [4- (2-Butynyloxy) phenyl] sul anil} -2- (4-chlorophenyl) -N-hydroxyacetamide. Ethyl (4-chlorophenyl) [(4-hydroxyphenyl) -sulfanyl] acetate was prepared according to the general method described in example 1 (step 1), starting from of bromine (4-chlorophenyl) ethyl acetate
(16.5 g, 59.6 mmoles) and 4-mercaptophenol (7.5 g, 59.6 mmoles); 18.8 g of white solid. P.f. 63 ° C; Yield 97%; EM 321.3 (M-H) ".
It was prepared. { [4 - (2-Butynyloxy) phenyl] sulfanyl} (4-chlorophenyl) ethyl acetate according to the general method described in example 1 (step 2), starting from (4-chlorophenyl) [(4-hydroxyphenyl) -sulfanyl] ethyl acetate (15.37 g, 47.7 mmoles) and 4-bromo-2-butine (4.26 ml, 48.7 mmoles); 12.57 g of yellow oil. Performance 69%; MS (EI): 374 (M + H) +. Acid was prepared. { [4 - (2-Butyloxy) phenyl] -sulfanyl} (4-chlorophenyl) acetic acid according to the general method described in example 1 (step 5), starting from. { [4- (2-butyloxy) phenyl] -sulfanyl} (4-chlorophenyl) ethyl acetate (3.91 g, 10.5 mmol); 2.63 g of yellow oil. Yield 72%; MS: 345.2 (MH). "Starting from acid { [4- (2-Butyloxy) -phenyl] sulfanyl} - (4-chlorophenyl) acetic (2.43 7.02 mmol), and following the procedure described in Example 1 (step 6), 65 mg of 2- {[4- (2-butynyloxy) phenyl] sulfanyl} -2- (4-chlorophenyl) -N-hydroxyacetamide was isolated as a white powder. 152 ° C; Yield: 3%; MS: 362.2 (M + H) +; 1 H NMR (300 MHz, DMSO-d6): 1.82 (t, J = 2.31 Hz, 3H), 4.72 (m, 3H), 6.89 (d, 2H), 7.26 (d, 2H), 7.4 (m, 4H), 9.1 (s, 1H), 10.9 (s, 1H).
Example 81 2-. { [4- (2-Butynyloxy) enyl] sulfinyl} -2- (4-chlorophenyl) - N-hydroxyacetamide Starting from 2-. { [4- (2-butyloxy) -phenyl] sulfanil} -2- (4-chlorophenyl) -N-hydroxy-acetamide (prepared from Example 80) (1.35 g, 3.74 mmol), and following the procedure described in Example 7, 70 mg of 2- was isolated. { [4- (2-Butynyloxy) -phenyl] sulfinyl} -2- (-chlorophenyl) -N-hydroxyacetamide as a white powder. This compound was tested as the mixture of diastereoisomers. P.f. 92 ° C; Yield: 5%; MS: 378 (M + H) +; 2 H NMR (300 MHz, DMSO-d 6): d 1.83 (t, J = 2.25 Hz, 3 H), 4.43 (s, 1 H), 4.77 (d, J = 2.37 Hz, 2 H), 6.98 (d, 2 H), 7.09 (d, 2H), 7.19 (d, 2H), 7.34 (d, 2H), 9.32 (s, 1H), 11 (s, 1H).
Example 82 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -2- (4-chlorophenyl) - N-hydroxyacetamide Starting from a mixture of 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (4-chlorophenyl) -N-hydroxyacetamide (from example 80) and 2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2- (4-chlorophenyl) -N-hydroxyacetamide (750 mg, 1.99 mmol), and following the procedure described in Example 75, 228 mg of 2- was isolated. { [4 - (2-Butyloxy) phenyl] sulfonyl} -2- (4-chlorophenyl) -N-hydroxyacetamide as a white solid. P.f. 140 ° C; Yield: 29%; MS: 394.2 (M + H) +; NMR * H (300 MHz, DMSO-d6): d 1.85 (t, J2.19 Hz, 3H), 4.86 (d, J = 2.28 Hz, 2H), 5.05 (s, 1H), 7.1 (d, 2H) , 7.4 (m, 4H), 7.5 (d, 2H), 9.33 (s, 1H), 10.8 (s, 1H).
Example 83 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (3-chlorophenyl) -N-hydroxyacetamide Step 1: Ethyl (3-chlorophenyl) [(-hydroxyphenyl) -sulfanyl] acetate was prepared according to the general method described in example 1 (step 1), starting from bromine (3-chlorophenyl) ethyl acetate (6.16 g, 16.5 mmol) and 4-mercaptophenol (2.08 g, 16.5 mmol); 4.36 g of clear oil. Yield 82%; MS: 321 (M-H). "
Stage 2: . { [- (2-Butyloxy) phenyl] sulfanil} (3-Chlorophenyl) ethyl acetate [3-Chlorophenyl] [(-hydroxyphenyl) sulfanyl] -acetic acid ethyl ester (4.2 g, 13 mmol) was stirred with THF (100 ml) in a dry two-necked flask under inert. 2-Butyn-1-ol (0.97 ml, 13 mmol) and 1,1 '- (azodicarbonyl) dipiperidine (3.94 g, 15.6 mmol). Tributylphosphine (3.90 ml, 15.6 mmol) was added in drops at 0 ° C. The reaction mixture was allowed to stir at room temperature under nitrogen for 2 hours before it was concentrated. The residue was triturated with ether and the filtrate was concentrated. It was isolated. { [4- (2-Butynyloxy) phenyl] sulfanil} (3-chlorophenyl) -acetic acid ethyl ester as a yellow oil (4.08 g) after silica gel column chromatography, using methylene chloride as the mobile phase. Performance 84%; MS (EI): 375 (M + H) +. Acid was prepared. { [4 - (2-Butynyloxy) phenyl] -sulfanyl} (3-chlorophenyl) acetic acid according to the general method described in example 1 (step 5), starting from. { [4 - (2-butyloxy) phenyl] -sulfanyl} (3-chlorophenyl) ethyl acetate (4.08 g, 10.9 mmol); 2.04 g of whitish powder. P.f. 64 ° C; Yield: 54%; MS: 691.4 (2M-H) "Starting from the acid { [4- (2-Butynyloxy) phenyl] sulfanyl} - (3-chlorophenyl) acetic acid (1.86 g, 5.37 mmol), and following the procedure described in Example 1 (step 6), 130 mg of 2 - { [4- (2-Butynyloxy) phenyl] sulfanyl} -2- (3-chlorophenyl) -N-hydroxyacetamide was isolated as a white powder Mp: 127 ° C;
Yield: 7%; MS: 362.1 (M + H) +; 1 H NMR (300 MHz, DMSO-d 6): d 1.82 (t, J = 2.31 Hz, 3 H), 4.72 (m, 3 H), 6.91 (d, 2 H), 7.26 (d, 2 H), 7.34 (m, 3 H) ), 7.48 (s, 1H), 9.1 (s, 1H), 10.9 (s, 1H).
Example 84 2-. { [4- (2-Butynyloxy) enyl] sulfonyl} -2- (3-chlorophenyl) - N-hydroxyacetamide Starting from a mixture of 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (3-chlorophenyl) -N-hydroxyacetamide and 2-. { [4 - (2-Butyloxy) phenyl] sulfin 1} -2- (3-chiorophenyl) -N-hydroxyacetamide (210 mg, 0.56 mmol), and following the procedure described in Example 75, 60 mg of 2- was isolated. { [4- (2-Butynyloxy) phenyl] -sulfonyl} -2- (3-chloro-phenyl) -N-hydroxyacetamide as a white powder. P.f .: 50 ° C; Yield: 27%; MS: 394.1 (M + H) +; 1 H NMR (300 MHz, DMS0-d6): d 1.84 (t, J = 2.22 Hz, 3H), 4.86 (d, J = 2.31 Hz, 2H), 5.06 (s, 1H), 7.12 (d, J = 8.97) Hz, 2H), 7.19-7.39 (band, 2H), 7.48 (m, 4H), 9.33 (d, J = 1. 2 Hz, 1H), 10.9 (s, 1H).
Example 85 2- (4-bromo-phenyl) -2-. { [4- (2-Butynyloxy) phenyl] sulfanil} - N-hydroxyacetamide Ethyl (4-bromo-phenyl) [(4-hydroxyphenyl) -sulfanyl] acetate was prepared according to the general method described in Example 1 (step 1), starting from bromine (4-bromo-phenyl) -acetate of ethyl (15 g, 45.6 mmol.) and 4-mercaptophenol (5.75 g, 45.6 mmol); 15.39 g of white solid. P.f. 55.6 ° C; Yield 92%; MS: 365.1 (MH). "(Ethyl 4-bromo-phenyl) - {. [4 - (2-butynyloxy) -phenyl] sulfani-1-ethyl acetate was prepared according to the general method described in Example 83 ( Step 2), starting from ethyl (4-bromophenyl) [(4-hydroxy-phenyl) sulfanyl] acetate (13.57 g, 36.9 mmol) and 2-butyn-1-ol (2.77 ml, 36.9 mmol); g of clear oil, Yield 59%, MS (EI): 420.8 (M + H) +, Acid (4-bromo-phenyl) { [4- (2-butynyloxy) phenyl] sulphyl). acetic acid according to the general method described in example 1 (step 5), starting from (4-bromophenyl) { [4- (2-Butynyloxy) phenyl] sulfanyl} ethyl acetate (1.2) g, 2.86 mmoles), 860 mg of brown oil, yield 77%, MS: 389.2 (MH). Starting from the acid (4-bromophenyl) -. { [4- (2-Butynyloxy) phenyl] sulfanil} acetic acid (790 mg, 2.02 mmol), and following the procedure described in Example 1 (step 6), 61 mg of 2- (4-brornophenyl) -2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-Hydroxyacetamide as a white solid. P.f .: 153 ° C; Yield: 24%; MS: 408 (M + H) +; X H NMR (300 MHz, DMSO-de): d 1.82 (t, J = 2.28 Hz, 3 H), 4.68 (s, 1 H), 4.71 (q, 2 H), 6.89 (d, 2 H), 7.25 (d, 2 H) ), 7.36 (d, 2H), 7.51 (d, 2H), 9.07 (s, 1H), 10.8 (s, 1H).
Example 86 (2S) -2- (4-bromophenyl) -2-. { [4- (2 -buyloxy) phenyl] -sulfinyl} -N-hydroxyacetamide and (2R) -2- (4-bromophenyl) -2-. { [4- (2-Butynyloxy) phenyl] -sulfinyl} -N-hydroxyacetamide Starting from 2- (4-bromo-phenyl) -2-. { [4- (2-Butynyloxy) phenyl] sulfanil} N-hydroxy-acetamide (from Example 85) (1.54 g, 3.7 mmol), and following the procedure described in Example 7, the two diastereoisomers were isolated. The two diastereoisomers were separated by silica gel column chromatography eluting with 50% ethyl acetate: hexane. The fastest-moving isomer, namely, (2S) -2- (4-bromophenyl) -2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-N-hydroxy acetamimda as a white solid. P.f. 167 ° C; Yield: 170 mg (11%); E: 424 (M + H) +; X H NMR (300 MHz, DMSOde): d 1.85 (t, J = 2.22 Hz, 3H), 4.39 (s, 1H), 4.82 (d, J = 2.34 Hz, 2H), 7.1 (d, 2H), 7.3 ( d, 2H), 7.5 (d, 2H), 7.56 (d, 2H), 9.07 (s, 1H), 10.7 (s, 1H).
The slow-moving isomer, viz., Was isolated (2R) -2- (4-bromophenyl) -2-. { [4- (2-butyloxy) phenyl] -sulfinyl} -2-N-hydroxyacetamide as a whitish solid. P.f. 93 ° C; Yield: 20 mg, (1.3%); MS: 423.9 (M + H) +; 1K NMR (300 MHz, DMSO-d6): d 1.83 (t, J = 2.13 Hz, 3H), 4.42 (s, 1H), 4.77 (d, J = 2.28 Hz, 2H), 7.0 (m, 4H), 7.2 (d, 2H), 7.5 (d, 2H), 9.33 (s, 1H), 10.9 (s, 1H).
Example 88 2- (4-bromo-phenyl) -2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} - N-hydroxyacetamide Starting from a mixture of 2- (4-brornophenyl) -2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxyacetamide and 2- (4-bromophenyl) -2-. { [4- (2-Butynyloxy) -phenyl] sulfinyl} -2-N-hydroxyacetamide (1.42, 3.4 mmol), and following the procedure described in Example 75, 610 mg of 2- (4-bromo-phenyl) -2- was isolated. { [4- (2-butynyloxy) phenyl] sulfonyl} -N-Hydroxyacetamide as a white solid. P.f. 187 ° C; Yield: 41%; MS: 440 (M + H) +; 1 H NMR (300 MHz, DMSO-d 6): d 1.85 (t, J = 2.22 Hz, 3 H), 4.86 (d, J = 2.31 Hz, 2 H), 5.03 (s, 1 H), 7.11 (d, 2 H) , 7.31 (d, 2H), 7.47 (d, 2H), 7.55 (d, 2H), 9.32 (s, 1H), 10.9 (s, 1H).
Example 89 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- [4- (2-thienyl) phenyl] acetamide Step 1: ethyl [4 - (2-thienyl) phenyl] acetate Nitrogen was bubbled through a mixture of 2-tributylstannylthiophene (15.68 ml, 49.4 mmoles) and
(4-bromophenyl) ethyl acetate (6 g, 24.7 mmol) in toluene (250 ml) before adding 0.5 g of tetrakis (triphenylphosphine) palladium (0). The mixture was refluxed under nitrogen for 4 hours before it was filtered through magnesol and concentrated. The residue was purified using silica gel column chromatography eluting with 20% ethyl acetate: hexane solution. Ethyl [4 - (2-thienyl) phenyl] acetate was isolated as a yellow oil
(4.15 g). Yield 68%; MS: 247.5 (M + H) +.
Step 2: Bromo [4 - (2 -1 ieni 1) pheny1] acetat or ethyl To a solution of ethyl [4- (2-thienyl) phenyl] -acetate (4.1 g, 16.6 mmol) in carbon tetrachloride (150 ml) benzoyl peroxide was added
(0.5 g) and N-bromosuccinimide (3.26 g, 18.3 mmol).
The mixture was refluxed under nitrogen for 3 hours before it was filtered and concentrated. The residue was purified using silica gel column chromatography eluting with 15% ethyl acetate: hexane solution. Bromo [4 - (2-thienyl) phenyl] ethyl acetate was isolated as a white, low melting solid (2.19 g). Performance 40%; MS (EI): 325.2 (M + H) +. [(4-Hydroxyphenyl) sulphanyl] [4- (2-thienyl) phenyl] ethyl acetate was prepared according to the general method described in example 1 (step 1), starting from bromine [4 - (2 -thienyl) phenyl] -acetic acid ethyl ester (2 g, 6.15 mmol) and 4-mercaptophenol (0.82 g, 6.5 mmol); 1.68 g of white solid. P.f. 103 ° C; Performance 73%; MS: 369.1 (MH). "Ethyl. {- [4- (2-Butynyloxy) phenyl] sulfanyl} - - [4 - (2-thienyl) phenyl] acetate was prepared according to the general method described in Example 83 (step 2), starting from [(-hydroxyphenyl) sulphyl] [4- (2-thienyl) phenyl] ethyl acetate (1.6 g, 4.3 mmol) and 2-butyn-l-ol (0.33 ml 4.32 mmol), 1.34 g of yellow oil, Yield 74%, MS (El): 421.71 (M + H) +, acid was prepared, {. [4 - (2-butyloxy) phenyl] -sulfanyl. [4- (2-thienyl) phenyl] acetic acid according to the general method described in example 1 (step 5), starting from { [- (2-butynyloxy) phenyl] -sulfanyl. Ethyl [4- (2-thienyl) phenyl] acetate (1.34 g, 3.17 mmol), 1.07 g of white solid, mp 137 ° C, yield 85%, MS: 439.1 (M + FA-H). " Starting from acid. { [4- (2-Butynyloxy) phenyl] sulfanil} [4- (2-thienyl) -phenyl] acetic acid (840 mg, 2.13 mmol), and following the procedure described in Example 1 (step 6), 1052 g of 2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- [4 - (2-thienyl) -phenyl] acetamide as a white solid. P.f. 182 ° C; Yield: 99%; MS: 410 (M + H) +; X H NMR (300 MHz, DMS0-d 6): d 1.81 (t, J = 2.31 Hz, 3 H), 4.71 (m, 3 H), 6.9 (d, 2 H), 7.13 (m, 1 H), 7.28 (d, 2 H) ), 7.44-7.62 (band, 6H), 9.07 (s, 1H), 10.8 (s, 1H).
Example 90 (2R) -2-. { [4- (2-Butynyloxy) enyl] sulfinyl} -N-hydroxy-2- [4- (2-thienyl) phenyl] ethanamide Starting from 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- [4- (2-thienyl) -phenyl] acetamide (1 g, 2.13 mmol), and following the procedure described in Example 7, was isolated
160 mg of (2R) -2-. { [- (2-Butyloxy) phenyl] sulfinyl} -N-hydroxy-2- [4- (2-thienyl) phenyl] ethanamide as an off-white solid. P.f .: 158 ° C; Yield: 18%; EM: 425.9
(M + H) +; 1 R-NMR (300 MHz, DMSO-de): d 1.79 (t, J = 2.1 Hz, 3 H), 4.43 (s, 1 H), 4.75 (d, J = 2.31 Hz, 2 H), 6.98 (d, J = 8.85 Hz, 2H), 7.12 (m, 3H), 7.22 (d, J = 8.79 Hz, 2H), 7.54 (m, 4H), 9.31 (d, 1H), 11 (s, 1H).
Example 91 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- [4- (2-thienyl) phenyl] acetamide Starting from a mixture of 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- [4- (2-thienyl) -phenyl] acetamide and 2-. { [4- (2-butyloxy) phenyl] sulfinyl} -N-hydroxy-2- [4- (2-thienyl) phenyl] ethanamide (410 mg, 0.96 mmol), and following the procedure described in Example 75, 110 mg of 2- was isolated. { [4- (2-butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- [4- (2-thienyl) -phenyl] acetamide as a gray solid. P.f .: 175 ° C; Yield: 26%; MS: 442.2 (M + H) +; 1 H NMR (300 MHz, DMSO-de): d 1.83 (t, 3 H), 4.85 (d, J = 2.01 Hz, 2 H), 5.04 (s, 1 H), 7.11 (m, 4 H), 7.39 (d, 2 H) ), 7.49-7.63 (band, 5H), 9.30 (s, 1H), 10.9 (s, 1H).
Example 92 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (1-naphthyl) acetamide. [(4-Hydroxyphenyl) sulfanyl] (1-naphthyl) ethyl acetate was prepared according to the general method described in Example 1 (Step 1). Starting from bromine (1-naphthyl) ethyl acetate (11.0 g, 38 mmol) and 4-mercaptophenol (4.8 g, 38 mmol), 8.14 g of [(4-hydroxyphenyl) sulfanyl] (1-naphthyl) was isolated. -ethyl acetate. Performance (64%); amber oil; MS 337.1 (MH). "{. [4- (2-Butynyloxy) phenyl] sulfanyl} - (1-naphthyl) acetate was prepared according to the general method described in Example 1 (Step 2). from (4-hydroxyphenyl) sulfanyl] (1-naphthyl) ethyl acetate (7.74 g, 23 mmol) and l-bromo-2-but-ina (3.4 g, 25 mmol), 7.64 g of the product was isolated. (85%); amber oil; EM 390.5 (M + H) + { [- (2-Butyloxy) phenyl] -sulfanyl} - (1-naphthyl) acetic acid was prepared according to the method General description described in Example 1 (Step 5) Starting from { [4- (2-Butynyloxy) phenyl] sulfanyl} - (1-naphthyl) acetate (7.64 g, 19.6 mmol), 4.92 g was isolated. of the product Yield (69%), white solid, mp 98.7 ° C; MS 722.8 (2M-H) ". Starting from acid. { [4- (2-butyloxy) phenyl] sulfanil} (1-naphthyl) acetic (4.69 g, 12.95 mmoles) and following the procedure described in Example 1 (Step 6), 2.95 g of 2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (1-naphthyl) -acetamide as a white solid. P.f .: 139.6 ° C; MS 378.1 (M + H) +; X H NMR (300 MHz, DMSO-d 6): d 1.87 (t,
3H), 4.62 (m, 2H), (s, 1H), 6.87 (d, J = 10 Hz, 2H),
7. 37 (d, J = 8 Hz, 2H), 7.46 (broad m, 4H), 7.80 (d,
J = 3 Hz, 1H), (d, J = 4 Hz), 8.03 (d, J = 8 Hz, 2H), 9.2 (s, 1H).
E n 93 93 2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (1-naphthyl) acetamide Starting from the 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (1-naphthyl) -acetamide (1.95 g, 5.2 mmol), and following the procedure described in Example 7, 0.19 g of 2- was isolated. { [4 - (2-Butyloxy) phenyl] sulfinyl} -N-hydroxy-2- (1-naphthyl) acetamide as a white solid. P.f .: 159.4 ° C; MS 394.1 (M + H) +; 1N-NMR (300 MHz, DMSOde): d 1.55 (t, 3H), 4.60 (m, 2H), 5.51 (s, 1H), 6.72 (d, J = 11.7 Hz, 2H), 7.24 (2H), 7.37 ( m, 3H), 7.77 (m, 3H), 8.19 (s, 1H), 10.68 (s, 1H).
Example 94 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1-naphthyl) acetamide Starting from the 2-. { [4- (2-butyloxy) -phenyl] sulfanil} -N-Hydroxy-2- (1-naphthyl) -acetamide (6 g, 15.9 mmol), and following the procedure described in Example 75, 0.162 g of 2- was isolated. { [4- (2-butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1-naphthyl) -acetamide as a white solid. P.f .: 213.3 ° C; MS 410.0 (M + H) +; AH NMR (300 MHz, DMSO-d6): d 1.84 (t, 3H), 4.81 (d, J = 2.3 Hz, 1H), 6.00 (s, 1H), 7.0 (d, J = 9 Hz, 2H), 7.45 (d, J = ll Hz, 2H), 7.51 (m, 2H), 7.95 (m, 2H), 8.01 (d, J = 17 Hz, 2H), 9.28 (s, 1H), 11.0 (s,
1 HOUR)
Example 95 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (4- fluorophenyl) -N-hydroxy-2- (1-naphthyl) acetamide. [(4-fluorophenyl) [(-hydroxyphenyl) -sul-fanyl] ethyl acetate was prepared according to the general method described in Example 1 (Step 1). Starting from bromine (4-fluorophenyl) ethyl acetate
(7.2 g, 28 mmol) and 4-mercaptophenol (3.8 g, 30 mmol), 7.08 g of the product was isolated. performance
(82.6%); amber oil; EM 305.3 (MH). "Ethyl { [4- (2-Butynyloxy) phenyl] sulfanyl}. -. (- (fluorophenyl) -acetate) was prepared according to the general method described in Example 1 (Step 2). Starting from [(4-fluorophenyl) [(4-hydroxyphenyl) sulphyl] ethyl acetate (7.05 g, 23 mmol) and l-bromo-2-butine (4.02 g, 30 mmol), 6.82 g of Product Yield (83%), amber oil, EM 358.0 (MH) ". Et and il acid was prepared. { [4 - (2-Butyloxy) -phenyl] sulfanil} (4-fluorophenyl) acetic acid according to the general method described in Example 1 (Step 5). Starting from [(4-fluorophenyl) [(4-hydroxy-phenyl) sulfanyl] ethyl acetate (4.73 g, 13 mmol), 3.26 g of product was isolated. Performance (75%); amber rubber; MS 329.3 (MH). "Starting from ethyl { [4- (2-Butynyloxy) phenyl] sulfanyl} - (4-fluorophenyl) acetic acid 3.0 g, 9.1 mmol), and following the procedure described in Example 1 (Step 6), 0.295 g of 2- {[[4- (2-butynyloxy) phenyl] sulphonyl} -2- (4-fluorophenyl) -N-hydroxyacetamide was isolated from the mixture of reaction as a white solid Mp: 105.7 ° C; MS 346.1 (M + H) +; XH NMR (300 MHz, DMSO-de): d 1.82 (t, 3H), 4.70-4.72 (m, 3H), 6.00 (s, 1H), 6.19-6.91 (d, J = 6.9 Hz, 2H), 7.15-7.21 (d, J = 17 Hz, 2H), 7.24-7.27 (d, J = 8.7 Hz, 2H), 7.4 ( m, 2H), 9.08 (s, 1H), 10.78 (s, 1H) Starting from 2- { [4- (2-Butynyloxy) phenyl] sulfanyl.} -2- (4-fluorophenyl) ) -N-hydroxyacetamide (1.29 g, 3.3 mmol), and following the procedure described in Example 7, 0.086 g was isolated as a white solid, Mp: 91.1 ° C, the main diastereoisomer was isolated EM 362.3 (M + H ) +; 1K NMR (300 MHz, DMSO-de): d 1.83 (t, 3H), 4.41 (s, 1H), 4.76-4.77 (d, J = 3 Hz, 2H), 6.97-7.01 (d, J = 9.9 Hz, 2H), 7.07-7.10 (dd, J = 8.9 Hz, 4H), 7.16-7.19 (d, J = 8.8 Hz, 2H), 9.3 ( s, 1H), 10.98 (s, 1H).
Example 97 Preparation of the 2 -. { [4- (2-Butynyloxy) phenyl] -sulfonyl} -2- (4-fluorophenyl) -N-hydroxyacetamide Starting from 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (4-fluorophenyl) -N-hydroxyacetamide (1.29 g, 3.3 mmol), and following the procedure described in Example 75, 0.106 g was isolated as a white solid. P.f .: 160.1 ° C; MS 378.2 (M + H) +; X H NMR (300 MHz, DMSO-d 6): d 1.84 (t, 3 H), 4.85-4.86 (d, J = 2 Hz, 2 H), 5.04 (s, 1 H), 7.08-7.11 (d, J = 9.0 Hz, 2H), 7.16-7.19 (t, J = 9.0 Hz, 2H), 7.38-7.40 (d, J = 5.4 Hz, 2H), 7.45-7.47 (d, J = 6.9 Hz, 2H), 9.3 (s) , 1H), 10.90 (s, 1H).
EXAMPLE 98 2- (2-methoxyphenyl) -2-. { [4- (2-butynyloxy) phenyl] -sulfanyl} -N-Hydroxyacetamide Ethyl (2-methoxyphenyl) [(-hydroxyphenyl) -sulfanyl] acetate was prepared according to the general method described in example 1 (step 1), starting from bromine (2-methoxyphenyl) acetate of ethyl (24 g, 87.5 mmol) and 4-mercaptophenol (11.0 g, 87.5 mmol); 24.9 g of amber oil. Performance 89%; MS: 320 (M + H) +. Prepared (2-methoxyphenyl). { [4- (2-Butynyloxy) -phenyl] sulfanil} ethyl acetate according to the general method described in example 1 (step 2), starting from ethyl (2-methoxyphenyl) [(4-hydroxy-phenyl) sulfanyl] acetate (3.2 g, 10 mmol) and 1 -bromine -2 -but ina (1.5 g> 11.2 mmoles); 3.2 g of clear oil. Performance 87%; MS (EI): 371 (M + H) +. Acid (2-methoxyphenyl) was prepared. { [4- (2-Butynyloxy) phenyl] sulfanil} acetic acid according to the general method described in example 1 (step 5), starting from (2-methoxy phenyl). { [4 - (2-Butynyloxy) phenyl] sulfanyl} ethyl acetate (3.1 g, 8.3 mmol); 2.7 g of white solid was isolated. Yield 93%; MS: 341.4 (MH). "Starting from (2-methoxy-phenyl) {. [4- (2-butynyloxy) phenyl] sulfanyl} acetic acid (2.6 g, 7.6 mmol), and following the procedure described in Example 1 (step 6), 2.6 g of 2- (2-methoxyphenyl) -2 { [4- (2-butynyloxy) phenyl] sulfanyl} -N-hydroxyacetamide was isolated as a white solid. Mp: 172-173 ° C; Yield: 97%; MS: 358.4 (M + H) +; XH NMR (300 MHz, DMSO-de): d 1.85 (s, 3H), 3.80 (s, 3H), 4.72. (s, 2H), 5.12 (s, 1H), 6.62 (m, 4H), 7.3-7.5 (m, 4H), 9.3 (broad s, 1H).
Example 99 2- (2-methoxyphenyl) -2-. { [4- (2-butynyloxy) enyl] -sulfinyl} -N-hydroxyacetamide Starting from 2-. { [4- (2-butyloxy) -phenyl] sulfanil} -2- (2-methoxy phenyl) -N-hydroxy -acetamide (3.0 g, 8.37 mmol), and following the procedure described in Example 7, 2.75 g of 2- (2-methoxyphenyl) -2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-Hydroxyacetamide as a white solid. P.f. 167.8 ° C; (Only the principal diastereoisomer was isolated: EM 374 (M + H) +; 2H NMR (300 MHz, DMSO-d6): d 1.83 (s, 3H), 3.32 (s, 3H), 4.41 (s, 2H), 5.2 (s, 1H), 6.31 (d, 1H), 6.44 (m, 3H), 7.22-7.40 (m, 3H), 7.81 (d, 1H), 8.62 (s, 1H), 10.41 (s, 1H) ).
Example 100 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-Hydroxy-2- (4-ethoxyphenyl) acetamide [(4-Hydroxyphenyl) sulfanyl] (4-ethoxyphenyl) -acetic acid methyl Bromo (4-ethoxyphenyl) acet atoate (7.6 g, 27.8 mmol) was added to stirring solution of triethylamine (30 ml), sodium sulfite (3.0 g, 23.8 mmol), and 4-mercaptophenol (3.5 g, 27.8 mmol) in methanol (200 ml). The mixture was stirred overnight before it was concentrated and the residue was extracted into ethyl acetate and washed with water. The organic layer was dried over Na 2 SO 4, filtered and concentrated. The compound was isolated using silica gel column chromatography eluting with 20% ethyl acetate: hexane solution. [(4-hydroxyphenyl) sulfanyl] (4-ethoxyphenyl) -acetic acid methyl ester was isolated as a crude product (7.76 g, 24.4 mmol). 88% yield. MS: 317.1 (M-H). "Prepared { [" 4- (2-Butyloxy) phenyl] sulfanil} - Methyl (4-ethoxyphenyl) acetate according to the general method described in example 1 (step 2). Starting from [(4-hydroxyphenyl) sulfani] (4-methoxyphenyl) ethyl acetate (7.76 g, 24.4 mmol) and l-bromo-2-butine (3.26 g, 24.4 mmol), 8.65 g of. { [4- (2-butyloxy) phenyl] sulfanil} Methyl (4-ethoxyphenyl) -acetate. Yellow oil 95% yield; MS (El): 369.72 (M) +.
Acid was prepared. { [4 - (2-Butyloxy) phenyl] -sulfanyl} (4-ethoxyphenyl) acetic acid according to the general method described in example 1 (step 5), starting from. { [4- (2-butyloxy) phenyl] -sulfanyl} (4-ethoxyphenyl) ethyl acetate (8.55 g, 23 mmol); 7.86 g. Yield 96%; MS: 355.1 (MH). "Starting from the { [4- (2-Butynyloxy) phenyl] sulfanyl} - (4-ethoxyphenyl) acetic acid (7.61 g, 20.6 mmol), and following the procedure described in Example 1 (step 6), 2,904 g of 2 - { [4 - (2-Butynyloxy) phenyl] sulfanyl} - N-hydroxy-2- (-ethoxy phenyl) -acetamide was isolated. 38%; MS 372.2 (M + H) +; 1 H NMR (300 MHz, DMSO-de): d 1.25 (t, J = 2.22 Hz, 3H), 1.80 (s, 3H), 4.00 (q, J = 2.22 Hz, 3H), 4.60 (s, 1H), 4.65 (s, 2H), 6.80 (d, J = 9 Hz, 2H), 6.90 (d, J = 9 Hz, 2H), 7.20 (d, J = 9 Hz, 2H), 7.35 (d, J = 9 Hz, 2H), 9.00 (s, 1H), 10.8 (s, 1H).
Example 101 2 -. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (4-ethoxyphenyl) acetamide Starting from 2-. { [4 - (2-Butynyloxy) -phenyl] sulfanil} -N-hydroxy-2- (4-ethoxyphenyl) acetamide (808 mg, 2.27 mmol) and following the procedure described in Example 27, 640 mg of 2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (4-ethoxy-phenyl) acetamide as a brown powder. Performance: 73%; MS: 388.2 (M + H) +. P.f. 192-193.
Example 102 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (4-chlorophenyl) -N-hydroxyacetamide was prepared 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (-chlorophenyl) -N-hydroxyacetamide starting from 2-. { [4 - (2-Butyloxy) phenyl] -sulfanyl} -N-hydroxy-2- (4-ethoxyphenyl) acetamide (808 mg, 2.27 mmol), and following the procedure described in Example 75, 1.1 g of 2- was isolated. { [4 - (2-Butyloxy) -phenyl] sulfonyl} -2- (4-chlorophenyl) -N-hydroxyacetamide as a white solid. MS: 404.2 (M + H) +, P.p. 138-140.
Example 103 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (3-bromophenyl) acetamide [(4-Hydroxyphenyl) sulfanyl] (3-bromophenyl) -acetate methyl Bromine (3-bromophenyl) acetate (7.2 g, 23.3 mmol) was added to a solution with stirring triethylamine (30 ml), sodium sulfite
(3.0 g, 23.8 mmol), and 4-mercaptophenol (2.94 g, 23.3 mmol) in methanol (200 mL). The mixture was stirred overnight before it was concentrated and the residue was extracted into ethyl acetate and washed with water. The organic layer was dried over Na 2 SO, filtered and concentrated. The compound was isolated using silica gel column chromatography eluting with 20% ethyl acetate: hexane solution. Methyl [(4-hydroxyphenyl) sulfanyl] (3-bromophenyl) acetate was isolated as a crude product (8.64 g). MS: 353.0 (MH). "Starting from [(4-hydroxyphenyl) -sulfanyl] (-methoxyphenyl) ethyl acetate (8.0 g crude, 22.7 mmol) and 1-bromo-2-butyne (3.04 g, 22.7 mmoles) and following the procedure described in example 1 (step 2), 4.91 g of methyl {. [4- (2-butyloxy) phenyl) sulfanyl} - (3-bromophenyl) acetate was isolated as yellow oil Yield 52%; MS: 405.6 (M + H) + Starting from { [4 - (2-Butynyloxy) -phenyl] sulfanyl}. (3-bromophenyl) ethyl acetate (4.04 g, 10%). mmoles) and following the procedure described in Example 1 (step 5), 3.83 g of acid { [4- (2-Butynyloxy) phenyl] sulfanyl} - (3-bromophenyl) acetic acid was isolated as a semi-solid. 98%; MS: 389.0 (MH) ". Starting from acid 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} (3-bromophenyl) acetic acid (3.83 g, 9.8 mmol), and following the procedure described in Example 1 (step 6), 1,675 g of 2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (3-bromophenyl) -acetamide Yield: 42%; MS: 408.0 (M + H) +; X H NMR (300 MHz, DMSO-d 6): d 1.60 (m, 3H), 2.26 (s, 3H), 4.45 (s, 1H), 4.47 (m, 2H), 6.66 (d, J = 9 Hz, 2H ), 7.03 (d, J = 9 Hz, 2H), 7.06-7.38 (m, 5H), 8.87 (s, 1H), 10.41 (s, 1H).
Example 104 (2R) -2-[[4- (2-bunyloxy) phenyl] sulfinyl} -N-hydroxy-2- (3-bromophenyl) acetamide • and (2S) -2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (3-bromophenyl) acetamide Starting from 2-. { [4 - (2-Butyloxy) -phenyl] sulfanil} -N-hydroxy-2- (3-bromo-phenyl) -acetamide (470 mg, 1.2 mmol), and following the procedure described in Example 7, the sulfide was oxidized to sulfoxide. The mixture of two diastereoisomers was separated by silica gel column chromatography eluting with 50% ethyl acetate; Hexane The fastest moving isomer, namely, (2R) -2- was isolated. { [4- (2-butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (3-bromophenyl) acetamide as a brown powder. Yield: 230 mg, (47%); MS: 423.9 (M + H) +. The slower motion isomer, namely, was isolated (2S) -2-. { [4 - (2-Butyloxy) phenyl] sulfinyl} -N-hydroxy-2- (3-bromophenyl) acetamide as a brown powder. Yield: 100 mg (20%); MS: 423.9 (M + H) +.
Example 106 2-. { [4- (2 -Butynyloxy) enyl] sulfonyl} -2- (3-bromophenyl) - N-hydroxyacetamide Starting from 2-. { [4 - (2-Butyloxy) -phenyl] sulfanil} -N-hydroxy-2- (3-bromo-phenyl) -acetamide (480 mg, 1.2 mmol), and following the procedure described in Example 75, 270 mg of 2- was isolated. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (4-chlorophenyl) -N-hydroxyacetamide as a brown powder. Yield: 52%; MS: 440.1 (M + H) +. X H NMR (300 MHz, DMSO-d 6): d 1.60 (m, 3H), 2.26 (s, 3H), 4.45 (s, 1H), 4.47 (m, 2H), 6.66 (d, J = 9 Hz, 2H ), 7.03 (d, J = 9 Hz, 2H), 7.06-7.38 (m, 5H), 8.87 (s, 1H), 10.41 (s, 1H).
Example 107 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2-isopropy1-N-hydroxyace amide Step 1: [4 - (hydroxyphenyl) sulphyl] acetate of etisopropyl was prepared according to the general method described in example 1 (step 1), starting from 2-bromine ethyl isovalerate (2.09 g, 10 mmol) and 4-mercaptophenol (1.26 g, 10.0 mmol); 2.5 g of yellow oil. The product was quite pure and was taken for other transformations. Performance 99%; MS: 255 (M + H) +.
Stage 2: Prepared. { [4- (2-Butynyloxy) phenyl] sulfanil} - (isopropyl) ethyl acetate according to the general method described in example 1 (step 2), starting from [4 - (hydroxyphenyl) sulphyl] -acetoisopropyl acetate (2.54 g, 10 mmol) and 4 - Bromo-2-butine (1.34 g, 10 mmol); 3.0 g of yellow oil. Performance 99%; MS (EI): 307 (M + H) +.
Step 3: Acid was prepared. { [4 - (2-Butyloxy) phenyl] -sulfanyl} (isopropyl) acetic acid according to the general method described in example 1 (step 5), starting from. { [4 - (2-Butynyloxy) phenyl] sulfanyl} - (isopropyl) ethyl acetate (3.06 g, 10 mmol); 2.7 g of yellow oil. Performance 99%; MS: 277 (M-H). "
Starting from the acid. { [4- (2-Butynyloxy) phenyl] sulfanil} (isopropyl) acetic acid (1.39 g, 5 mmol) and following the procedure described in Example 1 (step 6), 800 mg of 2- was isolated. { [4- (2-Butynyloxy) phenyl] sulfanil} -2-i sopropi 1-N-hydroxy acetamide as a white powder. P.f. 128 ° C; Yield: 54%; MS: 294.1 (M + H) +; X H NMR (300 MHz, DMSO-d 6): d 0.9 (d, 3 H), 1.02 (d, 3 H), 1.89 (s, 3 H), 1.98 (m, 1 H), 3.0 (d, 1 H), 3.2 (s) , 1H), 4.8 (s, 2H), 6.8 (d, J = 9 Hz, 2H), 7.4 (d, J = 9 Hz, 2H), 9.0 (s, 1H), 10.81 (s, 1H).
Example 108 R-2-. { t 4- (2-butynyloxy) phenyl] sulfinyl} -2-isopropy1-N-hydroxyacetamide Example 109 S-2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -2-isopropyl-N-hydroxyacetamide Starting from 2-. { [4 - (2-Butyloxy) -phenyl] sulfanil} -2-isopropyl-N-hydroxyacetamide (1.45 g, 5 mmol), and following the procedure described in Example 7, 123 mg of R-2 was isolated. { [4- (2-Butynyloxy) -phenyl] sulfinyl} -2-Isopropyl-N-hydroxy-acetamide as a white solid. The two diastereoisomers were separated by silica gel column chromatography eluting with 50% ethyl acetate: hexane. P.f. 68 ° C; Yield: 15%; MS: 310 (M + H) +. The slow moving isomer, namely, was isolated S-2-. { [4- (2-butyloxy) phenyl] sulfinyl} -2-isopropyl-N-hydroxyacetamide as a white solid. P.f. 148 ° C; Yield: 135 mg (17%); MS: 310 (M + H) +.
Example 110 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -2-isopropyl-N-hydroxyacetamide Starting from 2-. { [4 - (2-Butyloxy) -phenyl] sulfanil} -N-hydroxy-2-isopropylacetamide (1.4 g, 5 mmol), and following the procedure described in Example 75, 800 mg of 2- was isolated. { [4- (2-butynyloxy) phenyl] sulfonyl} -2-isopropyl-N-hydroxy-acetamide as a white powder. Yield: 49%; MS: 326.1 (M + H) +. X H NMR (300 MHz, DMSO-d 6): d 0.8 (d, 3 H), 1.0 (d, 3 H), 2.0 (s, 3 H), 2.1 (m, 1 H), 3.51 (d, 1 H), 3.2 (s) , 1H), 5.01 (s, 2H), 7.0 (d, J = 9 Hz, 2H), 7.56 (d, J = 9 Hz, 2H), 9.5 (s, 1H), 11.41 (s, 1H).
Example 111 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2-phenyl-N-hydroxyacetamide Step 1: Ethylphenyl [4- (hydroxyphenyl) sulfanyl] acet ate was prepared according to the general method described in example 1 (step 1), starting from 2-bromo-phenylacetate of ethyl (2.42 g, 10 mmol) and 4-mercaptophenol (1.26 g, 10.0 mmol); 2.7 g, of yellow oil. The product was quite pure and was taken for other transformations. Yield 93%; MS: 289 (M + H) +.
Stage 2: Prepared. { [4- (2-butyloxy) phenyl] sulfanil} - (phenyl) ethyl acetate according to the general method described in example 1 (step 2), starting from [4 - (hydroxy phenyl) sulphyl] ethylphenyl acetate (2.88 g, 10 mmol) and 4 - Bromo-2-but ina (1.34 g, 10 mmol); 3.2 g of yellow oil. Yield 94%; MS (EI): 341 (M + H) +.
Step 3: Acid was prepared. { [- (2-Butynyloxy) phenyl] -sulfanyl} (phenyl) acetic acid according to the general method described in example 1 (step 5), starting from. { [4- (2-Butyloxy) phenyl] sullyl} (phenyl) -acetic acid ethyl ester (3.4 g, 10 mmol); 3.0 g of yellow oil. Yield 88%; MS: 311 (MH). "Starting from acid { [4- (2-Butynyloxy) phenyl] sulfanyl} - (phenyl) acetic acid (3.12 g, 10 mmol), and following the procedure described in Example 1 (step 6), 3.0 g of 2- {[4- (2-butynyloxy) phenyl] sulfanyl} -2-phenyl-N-hydroxyacetamide was isolated as a white powder, mp 151 ° C; 91%; MS: 328 (M + H) +. 1 H NMR (300 MHz, DMSO-d 6): d 1.8 (s, 3 H), 4.8 (s, 2 H), 4.9 (s, 1 H), 6.8-7.6 ( m, 9H), 9.2 (broad s, 1H), 11 (broad s, 1H).
Example 112 R-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-phenyl-N-hydroxyacetamide Example 113 S-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-phenyl-N-hydroxyacetamide Starting from 2-. { [4 - (2-Butynyloxy) -phenyl] sulfanil} -2-phenyl-N-hydroxyacetamide (1.5 g, 4.5 mmol), and following the procedure described in Example 7, 400 mg of R-2 was isolated. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-phenyl-N-hydroxyacetamide as a white solid. The two diastereoisomers were separated by silica gel column chromatography eluting with 50% ethyl acetate: hexane. P.f. 153 ° C; Yield: 51%; MS: 344 (M + H) +; X H NMR (300 MHz, DMSO-d 6): d 1.8 (s, 3 H), 4.5 (s, 1 H), 4.9 (s, 2 H), 6.9-7.6 (m, 9 H), 9.0 (broad s, 1 H), 10.8 (broad s, 1H). The slow moving isomer, namely, was isolated S-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-phenyl-N-hydroxyacetamide as a white solid. P.f. 55 ° C; Yield: 300 mg (38%); MS: 344 (M + H) +; X H NMR (300 MHz, DMSO-d 6): d 1.7 (s, 3 H), 4.4 (s, 1 H), 4.7 (s, 2 H), 7.0-7.6 (m, 9 H), 9.3 (s, 1 H), 11.0 (s, 1H).
Example 114 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (2-naphthyl) -N-hydroxyacetamide Step 1: Ethyl (2-naphthyl-2- [4- (hydroxyphenyl) -sulfanyl] acetate was prepared according to the general method described in example 1 (step 1), starting from ethyl ester of a-bromo-2-naphthyl-acetic acid (2.93 g, 10 mmol) and 4-mercaptophenol (1.26 g, 10.0 mmol), 3.3 yellow oil.The product was quite pure and took for other transformations, 99% yield, EM: 339 (M + H) +.
Stage 2: Prepared. { [4- (2-Butyloxy) phenyl] sullyl} -2- (2-naphthyl) ethyl acetate according to the general method described in example 1 (step 2), starting from (2-naphthyl) -2 - [4- (hydroxyphenyl) sulfani] -acetate of ethyl (2.54 g, 10 mmol) and 4-bromo-2-butine (1.34 g, 10 mmol); 3.7 g of yellow oil. Performance 99%; MS (EI): 377 (M + H) +.
Stage 3: Acid was prepared. { [4.- (2-Butyloxy) phenyl] -sulfanyl} -2- (2-naphthyl) acetic acid according to the general method described in example 1 (step 5), starting from. { [4 - (2-Butyloxy) phenyl] -sulfanyl} -2- (2-naphthyl) ethyl acetate (3.76 g, 10 mmol); 3.5 g of yellow oil. Yield 96%; MS: 361 (MH). "Starting from acid { [4- (2-Butynyloxy) phenyl] sulfanyl} -2- (2-naphthyl) acetic acid (3.6 g, 10 mmol), and following the procedure described in Example 1 (step 6), 3.2 g of 2-. {[[4- (2-butynyloxy) phenyl] sulfanyl} -2- (2-naphthyl) -N-hydroxy-acetamide was isolated as a white powder, mp 148 ° C, yield: 84%, MS: 378 (M + H) +. 1 H NMR (300 MHz, DMSO-d6): 1.8 (s, 3H), 4.7 (s, 2H), 4.95. (s, 1H), 6.8-8.0 (s, 11H), 9.0 (broad s, 1H), 11 (s broad, 1H).
Example 115 2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -2- (2-naphthyl) -N- hydroacetamide Starting from 2-. { [4 - (2-Butynyloxy) -phenyl] sulfanil} -2- (2-naphthyl) -N-hydroxyacetamide (1.88 g, 5 mmol), and following the procedure described in Example 7, 900 mg of 2- was isolated. { [4- (2-Butynyloxy) -phenyl] sulfinyl} -2- (2-naphthyl) -N-hydroxy-acetamide as a white solid. The two diastereoisomers did not separate. P.f 157 ° C; Yield: 46%; MS: 394 (M + H) +.
Example 116 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (2-naphthyl) -N-hydroxyacetamide Starting from 2-. { [4- (2-Butynyloxy) -phenyl] sulfanil} -N-hydroxy-2- (2-naphthyl) acetamide (1.81 g, 5 mmol), and following the procedure described in Example 75, 1.2 g of 2- was isolated. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -2- (2-naphthyl) -N-hydroxy-acetamide as a white powder. Yield: 61%; MS: 410 (M + H) +. 1 H-NMR (300 MHz, DMS0-d 6): d 2.5 (s, 3 H), 4.9 (s, 2 H), 5.2 (s, 1 H), 7.0-7.9 (m, 11 H), 9.3 (broad s, 1 H), 11 (s, 1H).
Example 117 4- [l-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -2- (Hydroxyamino) -2-oxoethyl] -1-piperidinecarboxylic acid tert -butyl 4- (2-ethoxy-2-oxoet yl) -1-piperidinecarboxylic acid tert -butyl ester was made according to the process of the literature of Ashwood, Michael S .; Gibson, Andrew,.; Houghton, Peter G .; Humphrey, Guy R .; Roberts, D. Craig; Wright, Stanley H. B .; J. Chem. Soc. Perkin Trans. 1; 6; nineteen ninety five; 641-643 in two stages starting from N-tert-butoxycarbonyl-4-piperidone; 4.69 g of clear oil. 95% yield (over two stages); MS: 272.2 (M + H) +.
Step 1: To a dry flask under nitrogen was added 4- (l- { [4- (2-Butynyloxy) phenyl] sulfonyl} -2-ethoxy-2-oxo-yl) -1-piperidinecarboxylate of tert-butyl, sodium bis- (rimethsilyl) amide (7.05 g, 38 mmol). THF (100 ml) was added slowly and the temperature was lowered to -15 ° C. 4 - (2-ethoxy-2-oxoethyl) -1-piperidine-carboxylic acid tert-butyl ester (4.6 g, 16.97 mmol) and 4-but-2-ynyloxy-benzenesulfonyl fluoride
(4.08 g, 17.9 mmol) were combined in THF (50 ml) and added dropwise to the mixture, keeping the reaction temperature below -15 ° C. The mixture was stirred at -10 ° C for 1.5 hours before it was rapidly quenched with water and extracted into ethyl acetate. The organic layer was washed with water, then dried over Na 2 SO 4, filtered and concentrated. 4- (L- { [4- (2-Butynyloxy) phenyl] sulfonyl} -2-ethoxy-2-oxo-ethyl) -1-piperidinecarboxylic acid tert-butyl ester was isolated using gel column chromatography of silica eluting with 20% ethyl acetate: hexane solution; 3.74 g of clear gel. Yield 46%; MS: 480.2 (M + H) +.
Step 2: [1- (tert-Butoxycarbonyl) -4-piperidinyl] acid was prepared. { [4- (2-butynyloxy) phenyl] sulfonyl} -acetic according to the general method described in example 1 (step 5), starting from 4- (1- { [4- (2-butynyloxy) phenyl] sulfonyl.} -2-ethoxy-2 -oxoethyl) -1-piperidinecarboxylic acid tert-butyl ester (2.5 g, 5.2 mmol); 1.85 g of low melting yellow solid. Performance 79%; MS: 450.3 (M-H). "
Step 3: Starting from [1- (tert-butoxycarbonyl) -4-piperidinyl] acid. { [4- (2-Butynyloxy) phenyl] -sulfonyl} -acetic (1.75 g, 3.88 mmol), and following the procedure described in Example 1 (step 6), 283 mg of 4 - [1-. { [4 - (2-Butyloxy) phenyl] -sulfonyl} -2- (hydroxyamino) -2-oxoethyl] -1-piperidine carboxylate of tert-butyl as a white solid. P.f. 80 ° C; Yield: 16%; MS: 467.1 (M + H) +; 1 H NMR (300 MHz, DMSO-de: d 1.08-1.25 (band, 3H), 1.37 (s, 9H), 1.53 (m, 1H), 1.85 (t, J = 2.22 Hz, 3H), 1.99-2.12 ( band, 2H), 2.70 (m, 1H), 3.67 (d, J = 19.8 Hz, 1H), 3.83 (m, 2H), 4.88 (d, J = 2.31 Hz, 2H), 7.17 (d, J = 9 Hz, 2H), 7.76 (d, J = 9 Hz, 2H), 9.1 (s, 1H), 10.65 (s, 1H).
Example 118 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (4-piperidinyl) acetamide Step 1: 4- [1-. { [4- (2-Butynyloxy) phenyl] -sulfonyl} -2- (hydroxyamino) -2-oxoethyl] -1-piperidine-carboxylate of tert-butyl of 2-. { [- (2-Butynyloxy) -phenyl] sulfonyl} -N-hydroxy -2- (4-piperidinyl) -acetamide
(160 mg, 0.34 mmol) in methanolic HCl (50 ml) and allowed to stir at room temperature for 1 hour. The mixture was concentrated. After drying overnight, 80 mg of 2- was isolated. { [4 - (2-Butyloxy) phenyl] -sulfonyl} -N-hydroxy-2- (4-piperidinyl) acetamide as a pink powder. P.f. 140 ° C; Yield: 59%; MS: 367.2 (M + H) +; XH NMR (300 MHz, DMSO-d6): d 1.46-1.70 (band, 3H), 1.85 (t, 3H), 2.16-2.30 (band, 2H), 2.87 (m, 2H), 3.21 (m, 2H) , 3.79 (d, J = 8.79 Hz, 1H), 4.88 (d, J = 2.28 Hz, 2H), 7.17 (d, J = 9 Hz, 2H), 7.77 (d, J = 9 Hz, 2H), 8.52 (m, 1H), 8.73 (m, 1H), 9.18 (s, 1H), 10.9 (s, 1H).
Example 119 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- [1- (4-methoxybenzyl) -4-piperidinyl] acetamide Prepared. { [4- (2-Butynyloxy) phenyl] sulphonyl} - (4-piperidinyl) ethyl acetate according to the general method described in example 113 (step 1), starting from 4 - (1- {[4 - (2-butyloxy) phenyl] -sulfonyl .} -2-ethoxy-2-oxoethyl) -1-piperidinecarboxylic acid tert-butyl ester (2.5 g, 5.2 mmol); 1.88 g of yellow solid. Performance 87%; MS: 380.2 (M + H) +. Stage 2: . { [4 - (2-Butyloxy) phenyl] sulfonyl} [1- (4-methoxybenzyl) -4-piperidinyl] ethyl acetate To a solution of. { [- (2-Butyloxy) phenyl] -sulfonyl} (4-piperidinyl) ethyl acetate (1.08 g, 2.86 mmol) in chloroform (150 ml), triethylamine (2 ml) and p-methoxybenzyl chloride (0.39 ml, 2.86 mmol) were added. The mixture was heated to reflux overnight. The mixture was extracted into chloroform and washed twice with water. The organic layer was dried over Na 2 SO 4, filtered and concentrated. The residue was purified using silica gel column chromatography eluting with 50% ethyl acetate: hexane solution. It was isolated. { [4- (2-Butynyloxy) phenyl] sulfonyl} [1- (-methoxybenzyl) -4-piperidinyl] ethyl acetate as a yellow oil (650 mg). Yield 46%; MS: 500.1 (M + H) +. Acid was prepared. { [4- (2-butyloxy) phenyl] -sulfonyl} [1- (4-methoxybenzyl) -4-piperidinyl] acetic acid according to the general method described in example 1 (step 5), starting from. { [4- (2-Butynyloxy) -phenyl] sulfonyl} [l- (-methoxybenzyl) -4-piperidinyl} ethyl acetate (650 mg, 1.3 mmol); 540 mg of white solid. Yield 88%; MS: 472.1 (M + H) +. Starting from the acid. { [4- (2-Butynyloxy) -phenyl] sulfonyl} [1- (4-methoxybenzyl) -4-piperidinyl] acetic
(430 mg, 0.913 mmol), and following the procedure described in Example 1 (step 6), 220 mg of 2- was isolated. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -N-hydroxy-2- [1- (4-methyl oxybenzyl) -4-piperidinyl] acet amide as a white solid. P.f. 138 ° C; Yield: 50%; MS: 487.1 (M + H) +. 1 H NMR (300 MHz, DMSO-d 6): d 1.67 (m, 3H), 1.85 (t, J = 2.04 Hz, 3H), 2.12.2.26 (band, 2H), 2.86 (m, 2H), 3.17 (s) , 1H), 3.27 (m, 2H), 3.77 (s,
3H), 4.12 (m, 2H), 4.88 (d, J = 2.22 Hz, 2H), 6.99 (d,
J = 8.4 Hz, 2H), 7.16 (d, J = 9 Hz, 2H), 7.46 (d, J = 8.7
Hz, 2H), 7.77 (d, J = 8.7 Hz, 2h), 10.32 (s, 1H), 10.87
(s, 1H).
EXAMPLE 120 2- (l-Benzoyl-4-piperidinyl) -2-. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -N-hydroxyacetamide Step 1: (l-benzoyl-4-piperidinyl). { [4 - (2-Butyloxy) -phenyl] sulfonyl} ethyl acetate To a solution of. { [4 - (2-Butyloxy) phenyl] -sulfonyl} Ethyl (4-piperidinyl) acet ato (2 g, 4.8 mmol) in methylene chloride (100 ml) in an ice water bath was added triethylamine (1.34 ml, 9.6 mmol). Benzoyl chloride (0.56 ml, 4.8 mmol) was added dropwise maintaining the temperature at 0 ° C. The mixture was warmed to room temperature and stirred overnight before it was concentrated. The residue was extracted into chloroform and washed twice with water. The organic layer was dried over Na 2 SO 4, filtered and concentrated. It was isolated (l-benzoyl-4-piperidinyl). { [4- (2-butynyloxy) phenyl] sulfonyl} ethyl acetate using silica gel column chromatography eluting with 50% ethyl acetate: hexane solution; yellow solid (1.8 g). P.f. 120 ° C; Yield 72%; MS: 484.1 (M + H) +. Acid (l-benzoyl-4-piperidinyl) was prepared. { [4- (2-butynyloxy) phenyl] sulfonyl} acetic acid according to the general method described in example 1 (step 5) starting from (l-benzoyl-4-piperidinyl). { [4- (2-butyloxy) phenyl] sulfonyl} ethyl acetate (1.39 g, 2.88 mmol); 1.3 g of white solid. P.f. 90 ° C; Performance 99%; MS: 456.1 (M + H) +. Starting from acid (l-benzoyl-4-piperidinyl). { [4- (2-butynyloxy) phenyl] sulfonyl} -acetic (1.22 g, 2.68 mmol), and following the procedure described in Example 1 (step 6), 860 mg of 2- (l-benzoyl-4-piperidinyl) -2- was isolated. { [4- (2-butyloxy) -phenyl] sulfonyl} -N-Hydroxyacetamide as a white powder. P.f. 224 ° C; Yield: 68%; MS: 470.9 (M + H) +; 1R-NMR (300 MHz, DMSO-d6): d 1.16-1.62 (band, 3H), 1.84 (t, J = 2.1 Hz, 3H), 2.06-2.24 (band, 2H), 2.73-2.99 (band, 2H) , 3.52 (m, 1H), 3.71 (d, J = 8.61, 1H), 4.37 (m, 1H), 4.88 (d, J = 2.28 Hz, 2H), 7.17 (d, J = 8.7 Hz, 2H), 7.34 (m, 2H), 7.44 (m, 3H), 7.77 (d, J = 8.7 Hz, 2H), 9.14 (s, 1H), 10.7 (s, 1H).
Example 121 2- (l-acetyl-4-piperidinyl) -2-. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -N-Hydroxyacetamide was prepared (1-acetyl-piperidinyl). { [4- (2-Butynyloxy) phenyl] sulfonyl} ethyl acetate according to the general method described in example 116 (step 1), starting from. { [4 - (2-Butyloxy) -phenyl] sulfonyl} (4-piperidinyl) ethyl acetate (1.5 g, 3.61 mmol) and acetyl chloride (0.26 mL, 3.61 mmol); yellow oil (1.35 g). Performance 89%; MS: 422 (M + H) +. Acid (1-acetyl-4-piperidinyl) was prepared. { [4- (2-Butynyloxy) phenyl] sulfonyl-acetic acid according to the general method described in example 1 (step 5), starting from (1-acetyl-4-piperidinyl). { [4- (2-Butynyloxy) phenyl] sulfonyl} ethyl acetate (1.23 g, 2.92 mmol); 400 mg of white gel. Yield 35%; MS: 391.9 (MH). "Starting from (l-acetyl-4-piperidinyl) { [4- (2-Butynyloxy) phenyl] sulfonyl} acetic acid (290 mg, 0.74 mmole), and following the procedure described in Example 1 (step 6), 60 mg of 2- (l-acetyl-4-piperidinyl) -2- { [4- (2-butynyloxy) phenyl] -sul-fonyl} was isolated. -N-hydroxyacetamide as a white powder, mp 103 ° C, yield: 20%, MS: 408.9 (M + H) +, 1R-NMR (300 MHz, DMSO-d6): d 1.07-1.55 (m, 3H), 1.85 (s, 3H), 1.95 (m, 3H), 2.18 (m, 2H), 3.02 (, 2H), 3.67-3.76 (band, 1H), 4.29 (m, 1H), 4.88 (d, 2H), 7.16 (t, 2H), 7.78 (t, 2H), 9.15 (d, 1H), 10.7 (s, 1H).
Example 122 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-Hydroxy-2-tetrahydro-2H-pyran-4-yl-acetamide Step 1: Tetrahydro-4H-pyran-4-ylidene-ethyl acetate was prepared from tetrahydropyran-4-one (9.0 g, 90 mmol) and Phosphonoethoxyethyl acetate (20.16 g, 90 mmol) in DMF / K2C03 at 80 ° C. Colorless oil, Yield. 16.3 g, (96%), MS: 171 (M + H) +.
Step 2: Ethyl tet rahydro-4Hpyran-4-ylacetate was prepared from ethyl tetrahydro-4H-pyran-4-ylidenacetate (16.0 g, 94 mmol) and Pd / NH 4 COOH at 80 ° C. Colorless oil, Yield: 16.3 g, (quantitative), MS: 173.2 (M + H) +.
Step 3: 2- acetate was prepared. { [- (2-Butyloxy) -phenyl] sulfonyl} (tetrahydro-2H-pyran-yl) -ethyl according to the general method described in Example 113 (step 1). Starting from ethyl tetrahydro-4H-pyran-4-ylacetate (4.0 g, 23.3 mmoles) and 4-but-2-inyloxy-benzenesulfonyl fluoride (7.1 g, 26.0 mmoles); It was isolated. 7.0 g of product as a yellow oil. The product was purified by silica gel column chromatography eluting with 50% ethyl acetate: hexane. Performance: 89%; MS: 381 (M + H) +.
Step 4: 2- acid was prepared. { [- (2-Butynyloxy) phenyl] -sulfonyl} (tetrahydro-2H-pyran-4-yl) -acetic according to the general method described in Example 1 (step 5). Starting from 2 - acetate. { [4- (2-butynyloxy) phenyl] sulfonyl} (tetrahydro-2H-pyran-4-yl) -ethyl (7.0 g, 18.4 mmol), 6.1 g of product was isolated. Performance: quantitative; EM 351.4 (M-H) ".
Step 5: Prepare 2-. { [4 - (2-Butyloxy) phenyl] -sulfonyl} -N-hydroxy-2-tetrahydro-2H-pyran-4-acetylamide according to the general method described in example 1 (step 6). Starting from acid 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} (tetrahydro-2H-pyran-4-yl) -acetic acid (4.0 g, 11.4 mmol), 3.4 g of the product was isolated. The product was purified by silica gel column chromatography eluting with 75% ethyl acetate: hexane. White solid, P.f. 208-211, Yield: 84%; MS: 368.4 (M-H) ~; X H NMR (300 MHz, DMSO-de): d 1.25 (m, 2H), 1.42-1.66 (m, 4H), 2.45 (m, 2H), 4.66 (s, 2H), 4.68 (d, 1H), 5.15 (m, 1H), 6.82 (d, 2H), 7.41 (d, 2H), 9.15 (broad s, 1H).
Example 123 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-Hydroxy-2-tetrahydro-2H-thiopyran-4-yl-acetamide Step 1: Ethyl rahydro-4H-thi-pyrn-4-ylidene-ethyl acetate was prepared from tet rahydropyran-4 -one (10.0 g, 86 mmol) and diethyl phosphonoethethylacetate (21.2 g, 95 mmol) in DMF / K2C03 at 80 ° C. Colorless oil, Yield. 15.4 g, (96%), MS: 187 (M + H) +.
Step 2: Ethyl tetrahydro-4-thiopyran-ylacetate was prepared from ethyl tetrahydro-4-thiopyran-4-ylidenacetate (8.0 g, 43 mmol), NaBH (8.2 g, 5 equivalents) and NiCl 2 (5.0 g) at 0 °. C for 1 hour. Colorless oil, Yield: 8.1 g, (quantitative), MS: 189 (M + H) +.
Step 3: 2- acetate was prepared. { [4 - (2-Butyloxy) -phenyl] sulfonyl} (tetrahydro-2H-t-thiopyran-4-yl) -ethyl according to the general method described in Example 113 (step 1). Starting from ethyl tetrahydro-4-thiopyran-4-ylacetate (5.0 g, 26.6 mmol) and -but-2-ynyloxy-benzenesulfonyl fluoride (5.5 g, 26.0 mmol); 9.3 g of product was isolated as a yellow oil. The product was purified by silica gel column chromatography eluting with 50% ethyl acetate: hexane. Yield: 88%; MS: 398 (M + H) +.
Step 4: 2- acid was prepared. { [4- (2-butyloxy) phenyl] -sulfonyl} (tetrahydro-2H-thiopyran-4-yl) acetic acid according to the general method described in Example 1 (step 5). Starting from 2- acetate. { [4- (2-butynyloxy) phenyl] sulfonyl} (tet rahydro-2H-t-thiopyran-4-yl) -ethyl (7.0 g, 17.7 mmol), 6.8 g of product was isolated as a white solid. P.f. 141-3, Performance: quantitative; MS: 370 (M-H). "
Stage 5:. It was prepared 2-. { [- (2-Butyloxy) phenyl] -sulfonyl} -N-hydroxy-2-tetrahydro-2H-thiopyran-4-yl-acetamide according to the general method described in example 1 (step 6). Starting from acid 2-. { [4- (2-Butynyloxy) phenyl] sulphonyl} (tetrahydro-2H-thiopyran-4-yl) -acetic acid (4.5 g, 12.2 mmol), 4.6 g of the product was isolated. The product was purified by silica gel column chromatography eluting with ethyl acetate: hexane 1: 1. White solid, P.f. 175-177, Yield: 98%; MS: 385 (MH) "; XH NMR (300 MHz, DMSO-de): d 1.52 (m, 2H), 1.81 (s, 3H), 2.1 (m, 1H), 2.22 (, 1H), 2.38 (m , 1H), 2.69 (m, 4H), 3.73 (d, 1H), 4.71 (s, 2H), 7.05 (d, 2H), 7.79 (d, 2H), 9.18 (s broad, 1H), 10.62 (s) , 1 HOUR) .
Example 124 2-. { [4- (2-Butynyloxy-phenyl] sulfonyl] -N-hydroxy-2- (1-oxidotetrahydro-2H-thiopyran-4-yl) acetamide. 2- {[4- (2-butynyloxy) phenyl]] sulfonyl.}. N-hydroxy-2- (1-oxydotetrahydro-2H-thiopyranyl) acetamide, starting from 2- { [4 - (2-butynyloxy) phenyl] -sulfonyl.}. -N- hydroxy-2-tetrahydro-2H-thiopyran-4-acetamide (0.6 g, 1.6 mmol), and following the procedure described in Example 7, 600 mg of the product was isolated as a white solid, mp 219-220 ° C; : Quantitative, E: 401 (M + H) +. AH NMR (300 MHz, DMSO-d6): d 1.82 (s, 3H), 1.83-1.85 (m, 1H), 2.02-2.08 (m, 1H), 2.18-2.33 (m, 1H), 2.61-2.68 (m, 2H), 2.72-2.76 (m, 1H), 3.15-3.22 (m, 1H), 3.31 (s, 2H), 3.72 (d, 1H), 4.91 (s, 2H), 7.18 (d, 2H), 7.75 (d, 2H), 9.21 (s broad, 1H), 10.78 (s, 1H).
Example 125 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1,1- dioxidotetrahydro-2H-thiopyran-4-yl) acetamide Starting from 2-. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -N-hydroxy-2-tetrahydro-2H-thiopyran-4-yl-acetamide (0.5 g, 1.3 mmol), and following the procedure described in Example 75, 0.45 g of 2- was isolated. { [4 - (2-Butyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1, l-dioxidotetrahydro-2H-thiopyran-4-yl) -acetamide as a white powder. Yield: 93%; MS: 417 (M + H) +; TR NMR (300 MHz, DMSO-d6): d 1.88 (s, 3H), 2.12 (m, 1H), 2.15-2.23 (m, 2H), 2.55 (m, 2H), 2.92-3.15 (m, 4H) , 3.87 (d, 1H), 4.72 (s, 2H), 7.02 (d, 2H), 7.82 (d, 2H), 9.2 (broad s, 1H).
Pharmacology Representative compounds of this invention were evaluated as inhibitors of the enzymes MMP-1, MMP-9, MMP-13 and the enzyme that converts TNF-a (TACE). The standard pharmacological test procedures used, and results obtained that establish this biological profile are shown below.
Test procedures to measure the inhibition of MMP-1, MMP-9, and MMP-13 These standard pharmacological test procedures are based on the separation of thiopeptide substrates such as Ac-Pro-Leu-Gly (2-mercapto-4 - met il-pentanoi 1) Leu-Gly-OEt by the matrix metalloproteinases MMP-1, MMP-13 (collagenases) or MMP-9
(gelatinase), which results in the release of a substrate product that reacts colorimetically with DTNB (5,5'-di-t-bis (2-nitro-benzoic acid)). The activity of the enzyme is measured by the speed of the color increase. The thiopeptide substrate becomes cooler as a 20 mM reservoir in 100% DMSO and the DTNB is dissolved in 100% DMSO as a 100 mM reservoir and stored in the dark at room temperature. Both the substrate and the DTNB are diluted together at 1 mM with substrate buffer
(50 Mm HEPES, Ph 7.5, 5 mM CaCl2) before use.
The deposit of the enzyme is diluted with buffer
(50 mM HEPES, pH 7.5, 5 mM CaCl2, 0.02% Brij) for the desired final concentration. The buffer, the enzyme, the vehicle or the inhibitor, and the DTNB / substrate are added in this order to a 96-well plate
(total reaction volume of 200 μl) and the increase in color is monitored spectrophotometrically for 5 minutes at 405 nm on a reading plate and the increase in color for a time is plotted as a line or linear trace. Alternatively, a fluorescent peptide substrate is used. In this test procedure, the peptide substrate contains a fluorescent group and a rapidly cooling group. After separation of the substrate by an MMP, the fluorescence that is generated is quantified in the fluorescence plate reader. The assay is run in an HCBC assay buffer (50 mM HEPES, pH 7.0, 5 mM Ca + 2, 0.02% Brij, 0.5% Cysteine), with MMP-1, MMP-9, or recombinant human MMP-13 . The substrate is dissolved in methanol and stored frozen in 1 mM aliquots. For the assay, the substrate and the enzymes are diluted in HCBC buffer for the desired concentrations. The compounds are added to the 96-well plate containing the enzyme and the reaction is stored by the addition of the substrate. The reaction is read (excitation 340 nm, emission 444 nm) for 10 minutes and the increase in fluorescence for a time is plotted as a linear trace. For any of the fluorescent or thiopeptide peptide test procedures, the slope of the line is calculated and represents the reaction rate. The linearity of the reaction rate is confirmed (r2> 0.85). The means (x ± sem) of the control rate is calculated and compared by statistical significance (p <0.05) with drug-treated rates using the Dunnett's multiple comparison test. Dose response ratios can be generated using multiple doses of drugs and IC50 values with 95% CI are estimated using linear regression.
Test Procedure for Measurement of TACE Inhibition Using 96-well dark microtiter plates, each well receives a solution composed of 10 μl of TACE (final concentration 1 μg / ml), Tris buffer 70 μl, pH 7.4 containing glycerol to 10% (final concentration of 10 mM), and 10 μl of the test compound solution in DMSO (final concentration of 1 μM, DMSO concentration of <1%) and incubated for 10 minutes at room temperature. The reaction is initiated by the addition of a fluorescent peptidyl substrate (final concentration of 100 μM) to each well and then by agitation on a shaker for 5 seconds. The reaction is read (excitation 340 nm, emission 420 nm) for 10 minutes and the increase in fluorescence for a time is plotted as a linear trace. The inclination of the line is calculated and represents the reaction speed. The linearity of the reaction rate is confirmed (r2> 0.85). The means (x + sem) of the control rate is calculated and compared by statistical significance (p <0.05) with drug-treated rates using the Dunnett's multiple comparison test. Dose response ratios can be generated using multiple doses of drugs and IC50 values with 95% CI are estimated using linear regression.
Cell Differentiation Test of Human Monocitic THP-1 for Soluble Proteins (THP-1 Soluble Protein Assay) Mitogenic stimulation of THP-1 cells causes differentiation into macrophages as cells with concomitant tumor necrosis factor (TNF-) secretion a) and the TNF receptor (TNF-R p75 / 80 and TNF-R p55 / 60) and Interlecin-8 (IL-8), among other proteins. In addition, unstimulated THP-1 cells are scattered or spilled in both p75 / 80 and p55 / 60 receptors for a time. The release of TNF-α bound to the membrane and possibly TNF-R p75 / 80 and TNF-R p55 / 60, but without IL-8, is measured by an enzyme called the enzyme that converts to TNF-a or TACE. This assay can be used to demonstrate either an effect of the inhibitor or stimulator compound on this TACE enzyme and any cytotoxic consequence of such a compound. THP-1 cells (from ATCC) are a human monocytic cell line obtained from the peripheral blood of a one-year-old male with acute monocytic leukemia. They can be developed in cultures and differentiated into macrophages as cells by stimulation with mitogens.
For the assay, THP-1 cells were seeded from an ATCC reservoir that was previously developed and frozen before at 5 x 106 / ml / vial. One vial is seeded in a T25 flask with 16 ml of RPMI-1640 with a glutamax medium (Gibco) containing 10% fetal bovine serum, penicillin 100 units / ml, streptomycin 100 μg / ml, and mercapto-ethanol 5 x 10"5 M 2 (THP-1 medium) Each vial of cells are cultured for approximately two weeks before being used and then used for a trial for only 4 to 6 weeks for protection compounds. they are subcultured on Monday and Thursday at a concentration of 1 x 105 / ml. To perform a test, THP-1 cells are co-incubated in a 24-well plate with 50 ml / well of a 24 mg / well reservoir ml of Lipopolysaccharides (LPS) (Calbiochem Lot # B13189) at 37 ° C in 5% C02 at a concentration of 1091 x 106 cells / ml (1.1 ml / well) for a total of 24 hours. 50 ml / well of drug, vehicle or THP-1 medium in appropriate wells to give a final volume of 1.2 ml / well. elve in DMSO at a concentration of 36 mM and diluted from here to the appropriate concentrations in the THP-1 medium and added to the wells at the beginning of the incubation period to give final concentrations of 100 mM, 30 mM, mM, 3 M, 1 mM, 300 nM and 100 nM. Cell exposure to DMSO was limited to 0.1% of the final concentration. The positive control wells were included in the experiment that has added the mitogen but not the drug. The vehicle control wells are also included, which were identical to the positive control wells, except that DMSO was added to give a final concentration of 0.083%. Negative control wells were included in the experiment that added the vehicle but not the mitogen or drug to the cells. Compounds can be evaluated for their basic (not stimulated) efflux of the recipients by replacing the LPS with 50 ml / well of the THP-1 medium. The plates were placed in a fixed incubator in C02 at 5% and at 37 ° C. After 4 hours of incubation, 300 ml / well of TCS tissue culture supernatant was removed for use in an ELISA test of TNF-α. After 24 hours of incubation, 700 ml / well of TCS was removed and used for analysis in the ELISA tests of TNF-R p75 / 80, TNF-R p55 / 60 and IL-8.
In addition, within 24 hours, the cells for each treatment group were harvested by resuspension in 500 μl / well of the THP-1 medium and transferred to a FACS tube. Two ml / tube was added from a 0.5 mg / ml deposit of propidium iodide (Pl) (Boerhinger Mannheim cat. # 1348639). The samples were run on a Becton Dickinson FaxCaliber FLOW cytometric machine and the amount of dye absorbed by each cell is measured at the deep red wavelength (FL3). Any of the cells with compromised membranes (dead or dying) can absorb Pl. The percentage of living cells is calculated by the number of cells not stained with Pl, it is divided by the total number of cells in the sample. The calculated viability values for the drug-treated groups are compared to the calculated viability value for the mitogen-stimulated vehicle-treated group ("vehicle positive control") to determine the "control percentage change". This value of the "control percentage change" is an indicator of the drug's toxicity. The amount of soluble TNF-α, TNF-R p75 / 80 and TNF-R p55 / 60 and IL-8 in TCS of THP-1 cell cultures are obtained with the commercially available ELISA tests of R & amp; amp; amp;; D Systems, by extrapolating a standard curve generated with standard equipment. The number of cells that absorb or exclude either Pl are measured by the FLOW cytometric machine and visualized by histograms using cytological software commercially available for each treatment group including all controls. The biological variability in the magnitude of the cell culture response of THP-1 requires that the experiments be compared on the basis of the percentage change of the "vehicle positive control" for each drug concentration. The percentage change in each soluble protein evaluated from the "vehicle positive control" is calculated for each concentration of compound with the following formula:
% (_atbio = pg / ml (csrpuesto) - pg / ml (ccptrol positive vehicle) x 100 pg / ml (centro! positive efe vehicle) - pg / ml (negative control of vehicle
For studies of soluble protein
(TNF-α, p75 / 80, p55 / 60, IL-8) under stimulated conditions, the pg / ml media of duplicate wells were determined and the results expressed as percentage changes of the "positive vehicle control". For studies of the soluble protein (receptors of p75 / 80 and p55 / 60) under no stimulated conditions, the pg / ml media of duplicate wells were determined and the results expressed as percentage changes of the "positive vehicle control" using the following formula:
% C = rrbio = pgftí (artarl nacptivo del caipLesto) - pg (cp ± rbL a i ce vé? üo) x 100 pg / frü. (negative control of vehicle)
The IC50 values for each compound are calculated by non-linear regression analysis using software adapted using the JUMP statistical package. For cell viability studies, the viabilities (Pl exclusion) of combined duplicate wells and the results expressed as change of% of the "positive vehicle control" were determined. The viability values calculated for the compound of the treated groups were compared for the viability value calculated for the "positive vehicle control" to determine the "control percentage change" as follows. This "percentage change of control" value is an indicator of the drug's toxicity.
% of Change% of living cells (compound) - 1 X 100
% of living cells (positive vehicle control)
References: Bjornberg, F., Lantz, M., Olsson, I., and Gullberg, U. Mechanisms involved in the processing of tumor necrosis factor (TNF) receptors from p55 and p75 to soluble receptor forms. Lymphokine Cytokine Res. 13: 203-211, 1994. Gatanaga, T., Hwang, C., Gatanaga, M., Cappuccini, F., Yamamoto, R., and Granger, G. Regulation of the mRNA synthesis of the TNF, membrane expression and release by human monocytic THP-1 cells stimulated with PMA and LPS in vi tro. Cellular Immun. 138: 1-10, 1991. Tsuchiya, S., Yamabe, M., Yamagughi, Y., Kobayashi, Y., Konno, T., and Tada, K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. Cancer. 26: 1711-176, 1980. The results of the inhibition of the metalloproteinase matrix in the above, the inhibition of TACE and the standard pharmacological test procedures of THP are given in Table 1 below.
Table 1
a is% @ 10 μM or IC50 (nM), unless otherwise specified b is THP (change of stock)
Based on the results obtained in the standard pharmacological test procedures described in the foregoing, the compounds of this invention were shown to be inhibitors of the enzymes MMP-1, MMP-9, MMP-13 and the enzyme that converts to TNF- (TACE) and are therefore useful in the treatment of disorders such as arthritis, tumor metastasis, tissue ulceration, scarring of abnormal wounds, disease, periodontal, graft rejection, insulin resistance, bone disease and HIV infection . The compounds of this invention are also useful in the treatment and inhibition of pathological changes mediated by metalloproteinase matrixes such as atherosclerosis, atherosclerotic plaque formation, reduction of coronary thrombosis from rupture of the atherosclerotic plaque, restenosis, mediated osteopenias. by MMP, inflammatory diseases of the central nervous system, skin aging, angiogenesis, tumor metastasis, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, proteinuria, aneurysmal aortic disease, degenerative cartilage loss followed by injury traumatic joint, demyelinating diseases of the nervous system, liver cirrhosis, glomerular kidney disease, premature rupture of the fetal membranes, inflammatory bowel disease, age-related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy due to prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, angiogenesis / neovascularization of the eye and rejection of cornea graft. The compounds of this invention can be administered pure or with a pharmaceutical carrier to a patient in need thereof. The pharmaceutical carrier can be solid or liquid. Applicable solid carriers may include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid that is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the desired shape and size. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidine, low melting waxes, and ion exchange resins. Liquid carriers can be used in the preparation of solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier may contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as in the above, for example, cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, example glycols) and their derivatives, and oils (for example, fractionated coconut oil and peanut oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in compositions of sterile liquid form for parenteral administration. Liquid pharmaceutical compositions which are sterile solutions or suspensions may be used, for example, by intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered in ravenously. The oral administration may be in the form of a liquid or solid composition. The compounds of this invention can be administered rectally in the form of a conventional suppository. For intranasal administration or intrabronchial inhalation or insufflation, the compounds of this invention can be formulated in an aqueous or partially aqueous solution, which can then be used in the form of an aerosol. The compounds of this invention can also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non-toxic to the skin, and allows the delivery of the agent by systemic absorption into the skin. the bloodstream via the skin. The carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments can be viscous or semi-solid liquid emulsions of any type of oil in water or water in oil. Pastes that consist of absorbent powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the bloodstream such as a semipermeable membrane that covers a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature. The dose that is used in the treatment of a specific patient suffering from a condition dependent on MMP or TACE must be subjectively determined by the attending physician. The variables involved include the severity of the dysfunction, and the size, age, and response pattern of the patient. The treatment will usually start with small doses less than the optimal dose of the compound. Therefore, the dose is increased to the optimum effect under the circumstances achieved. The precise doses for oral, parenteral, nasal, or intrabronchial administration will be determined by the physician administering them based on the experience of the individual treated subject and the standard medical principles. Preferably the pharmaceutical composition is in the unit dosage form, for example as tablets or capsules. In such manner, the composition is sub-divided into unit doses containing appropriate amounts of the active ingredient; the unit dosage form can be in packaged compositions, for example packaged powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.
Claims (10)
1. A compound of the formula I characterized in that: Ri is hydrogen, aryl, heteroaryl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms or cycloheteroalkyl with 5-carbon atoms. to 8 carbon atoms having 1 to 2 heteroatoms selected from N, NR7, S and O; R2 and R are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH; R5 is hydrogen, alkyl of 1-8 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, heteroaryl, or cycloheteroalkyl with 4 to 8 carbon atoms; R7 is hydrogen, aryl, aralkyl, alkyl of 1-6 carbon atoms, or cycloalkyl of 3-6 carbon atoms, oxy, alkanoyl with 1 to 8 carbon atoms, C00R5, C0R5, -S02-alkyl with 1 to 8 carbon atoms, -S02-aryl, -S02-heteroaryl, -CO-NHRi; R8, R9, R7 and Rn are each, independently, hydrogen, aryl, aralkyl, 5-10 heteroaryl members having 1-3 heteroatoms selected from N, NR7, O and S, heteroalkyl having from 1-3 heteroatoms selected from N, NR7, O and S, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl with 4 to 8 carbon atoms having 1-3 heteroatoms selected from N, NR7, 0 and S, alkyl of 1-18 atoms of carbon, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; R12 is hydrogen, aryl or 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, NR7, S and O, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl having 5 to 8 carbon atoms having 1 to 2 heteroatoms selected from N, NR7, S and O, or alkyl of 1-6 carbon atoms; A is O, S, SO, S02, NR7, or CH2; X is O, S, SO, S02, NR7, or CH2; And it is aryl or heteroaryl, with the proviso that A and X are not attached to adjacent atoms of Y; and n is 0 -2; or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, characterized in that Y is phenyl, pyridyl, thienyl, furanyl, imidazolyl, triazolyl or iadiazolyl.
3. A compound according to claim 1 or claim 2, characterized in that R2 and R3 are each, independently, hydrogen or alkyl of 1-6 carbon atoms.
4. A compound according to any of claims 1 to 3, characterized in that R2 and R are each, independently, hydrogen or alkyl of 1-6 carbon atoms.
5. A compound according to any of claims 1 to 4, characterized in that R 2 is hydrogen.
6. A compound according to claim 1, characterized in that it is selected from the group consisting of: 2- (4-But-2-ynyloxy-benzenesulfonyl) -N-hydroxy-2-methyl-3-pyridin-3-yl- propionamide; 2- (4-But-2-ynyloxy-benzenesulfonyl) -N-hydroxy-2-methyl-3- [4- (2-pyridin-1-yl-ethoxy) -phenyl] -propionamide; 3-Biphenyl-4-yl-2- (4-but-2-ynyloxy-benzenesulfonyl) -N-hydroxy-2-methyl-propionamide; 2- (4-But-2-ynyloxy-phenyl-sulfanyl) -octanoic acid hydroxyamide; 2- (But-2-ynyloxy-benzenesulfonyl) -octanoic acid hydroxyamide; 2- [(R) - (4-Butyl-2-ynyloxy) -sulfinyl-N-hydroxy-octanamide; 2- [(S) - (4-Butyl-2-ynyloxy) -sulfinyl-N-hydroxy-octanamide; 3- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-propionamide; 4- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-but-iramide; 2- (4-But-2-ynyloxy-phenoxy) -N-hydroxy-acetamide; 4- (4-But-2-ynyloxy-phenyl) -N-hydroxy-butyramide; [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxy-carbamoyl-1-pentyl] -amide of quinoline-2-carboxylic acid; Hydroxyamide 2- (4-but-2-ynyloxy-phenylsulfanyl) -6- [2- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid hydroxyamide; N- [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentyl] -2-phenethyl-benzamide; 2- (4-But-2-ynyloxy-phenylsulfanyl) -6- [2- (3, 4-dichloro-phenyl) -acetylamino] -hexanoic acid hydroxyamide; [5- (4 -But -2-loxy-phenylsulfanyl) -5-hydroxy-carbamoyl-pentyl] -amide of quinoline-3-carboxylic acid; 2- (4-But-2-ynyloxy-phenylsulfanyl) -6- (-thiophen-2-yl-butyrylamino) -hexanoic acid hydroxyamide; [5- (4 -But -2-ynyloxy-phenylsulfanyl) -5-hydroxy-carbamoyl-pentyl] -amide of 9H-Xanthen-9-carboxylic acid; 2- (4-But-2-ynyloxy-phenylsulfanyl) -6-diphenylacetylaminohexanoic acid hydroxyamide; [5- (Isobutyl-1-carboxylic acid-5- (-But-2-ynyloxy-phenylsulfanyl) -5-hydroxy-carbamoyl-1-pentyl] -amide; Hydroxyamide 6- (2-benzo [b] t -pheno-3-yl-acetylamino) -2- (4-bt-2-ynyloxy-phenyl-sulfanyl) -hexanoic acid hydroxyamide; [5- (4 -But-2-quinloxy-benzenesulfinyl) -5-hydroxy-carbamoyl-pentyl] -amide of quinoline-2-carboxylic acid; 2- (4-But-2-ynyloxy-benzenesulfinyl) -6- [2- (1, 3-dioxo-1,3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid hydroxyamide; N- [5- (4-But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentyl] -2-phenethyl-benzamide; Hydroxyamide 2- (butyl-2-inyloxy-benzenesulfinyl) -6- [2- (3,4-dichloro-phenyl) -acetyl-amino] -hexanoic acid hydroxyamide; [5- (4 -But-2-yl loxi-benzenesulfinyl) -5-hydroxy-ca rbamoi-pentyl] -amide of quinoline-3-carboxylic acid; Hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfinyl) -6- (4-thiophen-2-yl-butyrylamino) -hexanoic acid; [5- (4 -But-2-aminoloxy-benzenesulfinyl) -5-hydroxy-carbamoyl-pentyl] -amide of 9H-Xanthen-9-carboxylic acid; Hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfinyl) -6-diphenylacetylamino-hexanoic acid [5- (4 -But-2-linoxy-benzenesulfinyl) -5-hydroxy-carbamoyl-1- pentyl] - isoquinoline-1-carboxylic acid amide; Hydroxyamide 6- (2-benzo [b] thiophen-3-yl-acetylamino) -2- (4-but-2-ynyloxy-benzenesulfinyl) -hexanoic acid hydroxyamide; 2- (4-But-2-ynyloxy-benzenesulfinyl) -6- (2-lH-indol-3-yl-acetylamino) -hexanoic acid hydroxyamide; [5- (4 -But-2 -i or loxi-benzenesulfinyl) -5-hydroxy-ca rbamoi-pentyl] -aminoquin-2-carboxylic acid amide; Hydroxyamide 2- (4-but-2-ynyloxy-benzenesulfonyl) -6- [2- (1,3-dioxo-1,3-dihydro-isoindol-2-yl) -acetylamino] -hexanoic acid hydroxyamide; . N- [5- (4-But-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-1-pentyl] -2-phenethyl-benzamide; Hydroxyamide 2- (butyl-2-ynyloxy-benzenesulfonyl) -6- [2- (3,4-dichloro-phenyl) -acetyl-amino] -hexanoic acid hydroxyamide; [5- (4-But-2-ynyloxy-benzenesulfonyl) -5-5-hydroxycarbamoyl-pentyl] -amide of quinoline-3-carboxylic acid; [5- (4-But-2-ynyloxy-benzenesulfonyl) -5-hydroxy-carbamoyl-pentyl] -amide of 9H-Xanthen-9-carboxylic acid; Hydroxyamide 2- (4-but-2-ynyloxy-benzenesulfonyl) -6-diphenylacetylaminohexanoic acid hydroxyamide; [5- (4 -But-2-aminoloxy-benzenesulfonyl) -5-hydroxy-carbamoyl-1-pentyl] -aminoquinoline-1-carboxylic acid amide; Hydroxyamide 6- (2-benzo [b] thiophen-3-yl-acetylamino) -2- (4-but-2-ynyloxy-benzenesulfonyl) -hexanoic acid hydroxyamide; . { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} -quinoline-2-carboxylic acid amide; 2- (4-But-2-ynyloxy-phenylsulfanyl) -6- acid hydroxyamide. { 2- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] acetylamino} hexanoic; N-. { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentyl-carbamoyl] -methyl} -2-phenethylbenzamide; Hydroxyamide 2- (4-but-2-ynyloxy-phenylsulphyl) -6- acid. { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acetylamino} -hexanoic; . { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} quinoline-3-carboxylic acid amide; . { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} 9H-Xant en-9-carboxylic acid amide; 2- (4-But-2-ynyloxy-phenyl-sulfanyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic acid hydroxyamide; . { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} isoquinoline-1-carboxylic acid amide; . { [5- (4-But-2-ynyloxy-phenylsulfanyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} l-methyl-lH-pyrrole-2-carboxylic acid amide; Hydroxyamide of 6- f 2- (2-benzo [b] t -pheno-3-yl-acetylamino) -acetylamino] -2- (4-but-2-ynyloxy-phenylsulfanylhexanoic acid; { [5- (4 -But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -met-yl.} - quinoline-2-carboxylic acid amide; 2- (butyl-2-ynyloxy-benzene) hydroxyamide; sulfinyl) -6-. {2- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -acetylamino}. -hexanoic; N- { [ 5- (4-But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl -pentyl-carbamoyl] -methyl} -2-phenethyl-benzamide; 2- (4-but-2-ynyloxy) hydroxyamide -benzene-sulfinyl) -6- { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acet-ylamino} -hexanoic; {. [5- (4 -But-2 - inyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} -quinol in-3 -carboxylic acid; hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfinyl) -6- [2- (4-thiophen-2-yl-butyrylamino) -acetylamino] -hexanoic; {. [5- (4 -Bu t-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} -amide of acid 9H-Xanten-9-carboxylic acid; 2- (4-But-2-ynyloxy-benzenesulfinyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic acid hydroxyamide; . { [5- (4-But-2-ynyloxy-benzenesulfinyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} -amide of acid 1-methyl-lH-pyrrole-2-carboxylic acid; Hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfonyl) -6- acid. { 2- [2- (1, 3-dioxo-l, 3-dihydro-isoindol-2-yl) -acetylamino] -acetylamino} -hexanoic; N-. { [5- (4-but-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} -2-phenethylbenzamide; Hydroxyamide of 2- (4-but-2-ynyloxy-benzenesulfonyl) -6- acid. { 2- [2- (3,4-dichloro-phenyl) -acetylamino] -acetylamino} -hexanoic; . { [5- (4-but-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} quinoline-3-carboxylic acid amide; . { [5- (4-But-2-linoxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -met-il} -amide of acid 9H-Xanten-9-carboxylic acid; 2- (4-But-2-ynyloxy-benzenesulfonyl) -6- (2-diphenylacetylamino-acetylamino) -hexanoic acid hydroxyamide; . { [5- (4-But-2-ynyloxy-benzenesulfonyl) -5-hydroxycarbamoyl-pentylcarbamoyl] -methyl} isoquinoline-1-carboxylic acid amide; Hydroxyamide 6- [2- (2-benzo [b] t -pheno-3-yl-acetylamino) -acetylamino] -2- (4-but-2-ynyloxybenzenesulfonylhexanoic acid; 2- (4-buty) hydroxyamide -2-inyloxy-benzenesulfonyl) -6- [2- (2-lH-indol-3-yl-acetylamino) -acetylamino] -hexanoic acid; 2- {[[4- (2-butynyloxy) phenyl]] sulphonyl} -N-hydroxy -4 - {4- [2- (1-piperidinyl) -ethoxyphenyl} butanamide; 2- {[[4- (2-butynyloxy) phenyl] sulfonyl}. -7-cyano-N-hydroxy-heptanamide; • 2- {[[4- (2-butynyloxy) phenyl] sulfanyl} -2-cyclohexyl-N-hydroxyacetamide; 2 - { [4- ( 2-butynyloxy) phenyl] sulfinyl.} -2-cyclohexyl-N-hydroxyacetamide; 2- {[[4- (2-butynyloxy) phenyl] sulfonyl} -2-cyclohexyl-N-hydroxyacetamide; {. [4- (2-Butynyloxy) phenyl] sulfanyl.} - N-hydroxy-2- (4-methoxyphenyl) acetamide; (2R) -2- { [4- (2-butynyl loxi) phenyl] sulfanyl) -N-hydroxy-2- (4-methoxyphenyl) ethanamide; (2S) -2- [4- (2-butyloxy) phenyl] sulfanyl} -N-hydroxy-2 - (-methoxyphenyl) ethanamide; 2-. { [4- (2-Butynyloxy) phenyl] sullyl} -N-hydroxy -2- (4-methoxyphenyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (4-chlorophenyl) N-hydroxyacetamide; 2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -2- (4-chlorophenyl) N-hydroxyacetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulphonyl} -2- (4-chlorophenyl) N-hydroxyacetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (3-chlorophenyl) N-hydroxyacetamide; 2-. { [4- (2-butynyl loxy) phenyl] sulphonyl} -2- (3-chloro phenyl) N-hydroxyacetamide; 2- (4-bromo-phenyl) -2-. { [4- (2-Butynyloxy) phenyl] sulfanil} N-hydroxyacetamide; (2S) -2- (4-bromo phenyl) -2-. { [4- (2-Butynyloxy) phenyl] -sulfinyl} -N-hydroxyacetamide; (2R) -2- (4-bromophenyl) -2-. { [4- (2-butyloxy) phenyl] -sulfinyl} -N-hydroxyacetamide; - (-bromophenyl) -2-. { [4- (2-Butynyloxy) phenyl] -sulfonyl} -N-Hydroxyacetamide; -. { [4- (2-butynyl loxy) phenyl] sulfanil} -N-hydroxy -2- [4- (2-thienyl) phenyl] -acetamide; (2R) -2-. { [4- (2-butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- [4- (2-thienyl) -phenyl] ethanamide; 2-. { [4- (2-butynyl oxy) phenyl] sulfonyl} -N-hydroxy -2- [4 ' (2-thienyl) phenyl] -acetamide; 2- . { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-2- (1-naphthyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -N-hydroxy-2- (1-naphthyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulphonyl} -N-hydroxy -2- (1-naphthyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -2- (4- fluorophenyl) -N-hydroxy-2- (l-naphthyl) acetamide; 2- . { [4- (2-butynyloxy) phenyl] sulfinyl} -2- (4- fluorophenyl) -N-hydroxyacetamide; 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (4- fluorophenyl) -N-hydroxyacetamide; 2- (2-methoxyphenyl) -2-. { [4- (2-butyloxy) phenyl] -sulfanyl} -N-hydroxyacetamide; 2- (2-methoxyphenyl) -2-. { [4- (2-butynyloxy) phenyl] -sulfinyl} -N-hydroxyacet amide; 2-. { [4- (2-butynyloxy) phenyl] sulfanyl-N-hydroxy-2- (4-ethoxyphenyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfinyl-N-hydroxy-2- (4-ethoxyphenyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulphonyl-2- (4-chlorophenyl) N-hydroxyacetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanyl-N-hydroxy-2- (3-bromophenyl) acetamide; (2R) -2-[[4- (2-butynyloxy) phenyl] sul-finyl-N-hydroxy-2- (3-bromophenyl) acetamide; (2S) -2-. { [4- (2-butynyloxy) phenyl] sulfinyl-N-hydroxy-2- (3-bromophenyl) acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -2- (3-phenyl bromide; N-hydroxyacetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfanil} -N-hydroxy-acetamide; R-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-isopropyl-N-hydroxyacetamide; S-2-. { [4- (2-Butynyloxy) phenyl] sulfinyl} -2-isopropyl-N-hydroxyacetamide; 2- ([4- (2-Butynyloxy) phenyl] sulfonyl} -2-isopropyl-N-hydroxyacetamide; 2- [4- (2-Butynyloxy) phenyl] sulfanyl} -2-phenyl-N-hydroxyacetamide; R-2- { [4- (2-Butynyloxy) phenyl] sulfinyl.} -2- phenyl-N-hydroxyacetamide; S-2-Í [4- (2-butynyloxy) phenyl] sulfinyl. -2-phenyl-N-hydroxyacetamide; 2- {[[4- (2-Butynyloxy) phenyl] sulphonyl} -2- (2-naphthyl) -N-hydroxyacetamide; 2-[[4- (2-butyl) phenyl] sulfinyl} -2- (2-naphthyl) - - hydroxyacetamide; 2-[[4- (2-butynyloxy) phenyl] sulfonyl} -2- (2-naphthyl) -N-hydroxyacetamide; 4- [1-. { [4- (2-butynyloxy) phenyl] sulfonyl} -2- (hydroxyamino) -2-oxoethyl] -1-piperidinecarboxylate terbutyl; 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -N-hydroxy -2- (4-piperidinyl) acetamide; 2-. { [4- (2-butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- [1- (4-methoxybenzyl) -4-piperidinyl] acetamide; 2- (l-benzoyl-4-piperidinyl) -2-. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -N-hydroxy-acetamide; 2- (l-acetyl-4-piperidinyl) -2-. { [4- (2-Butynyloxy) -phenyl] sulfonyl} -N-hydroxy-acetamide, • 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2-tetrahydro-2H-pyran-4-yl-acetamide; 2-[[4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2-tetrahydro-2H-thiopyran-4-yl-acetamide; 2-. { [4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1-oxidotetrahydro-2H-thiopyran-4-yl) -acetamide; and 2-[[4- (2-Butynyloxy) phenyl] sulfonyl} -N-hydroxy-2- (1, 1-dioxidotetrahydro-2H-thiopyran-4-yl) -acetamide.
7. A method for the inhibition of pathological changes mediated by the enzyme (TACE) that converts TNF-a into a mammal in need thereof, characterized in that it comprises administering to the mammal a therapeutically effective amount of a compound having the formula: wherein: Ri is hydrogen, aryl, heteroaryl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms or cycloheteroalkyl with 5-carbon atoms. to 8 carbon atoms having 1 to 2 heteroatoms selected from N, NR7, S and 0; R2 and R3 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH; R5 is hydrogen, alkyl of 1-8 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, heteroaryl, or cycloheteroalkyl with 4 to 8 carbon atoms; R7 is hydrogen, aryl, aralkyl, alkyl of 1-6 carbon atoms, or cycloalkyl of 3-6 carbon atoms, oxy, alkanoyl with 1 to 8 carbon atoms, C00R5, C0R5, -S02-alkyl with 1 to 8 carbon atoms, -S02-aryl, -S02-heteroaryl, -CO-NHRi; R8, Rg, Rio and Rii are each, independently, hydrogen, aryl, aralkyl, 5-10 heteroaryl members having 1-3 heteroatoms selected from N, NR7, O and S, heteroalkyl having from 1-3 selected heteroatoms of N, NR7, O and S, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl with 4 to 8 carbon atoms having 1-3 heteroatoms selected from N, NR7, O and S, alkyl of 1-18 carbon atoms. carbon, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; R12 is hydrogen, aryl or 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, NR7, S and O, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl having 5 to 8 carbon atoms having 1 to 2 heteroatoms selected from N, NR7, S and O, or alkyl of 1-6 carbon atoms; A is 0, S, SO, S02, NR7, or CH2; X is O, S, SO, S02, NR7, or CH2; And it is aryl or heteroaryl, with the proviso that A and X are not linked to adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof.
8. The method according to claim 7, characterized in that the condition treated is rheumatoid arthritis, rejection of the graft, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory disease of the intestine or HIV infection.
9. A pharmaceutical composition, characterized in that it comprises a compound having the formula: wherein: Ri is hydrogen, aryl, heteroaryl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 atoms, carbon or cycloheteroalkyl with 5 to 8 carbon atoms having from 1-2 heteroatoms selected from N, NR7, S and 0; R2 and R3 are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH; R5 is hydrogen, alkyl of 1-8 carbon atoms, cycloalkyl of 3-6 carbon atoms, aryl, heteroaryl, or cycloheteroalkyl with 4 to 8 carbon atoms; R7 is hydrogen, aryl, aralkyl, alkyl of 1-6 carbon atoms, or cycloalkyl of 3-6 carbon atoms, oxy, alkanoyl with 1 to 8 carbon atoms, COOR5, COR5, -S02-alkyl with 1 to 8 carbon atoms, -S02-aryl, -S02-heteroaryl, -CO-NHRi; Rs, Rg, Rio and Rii are each, independently, hydrogen, aryl, aralkyl, 5-10 heteroaryl members having 1-3 heteroatoms selected from N, NR7, O and S, heteroalkyl having from 1-3 selected heteroatoms of N, NR7, O and S, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl with 4 to 8 carbon atoms having 1-3 heteroatoms selected from N, NR7, 0 and S, alkyl of 1-18 carbon atoms. carbon, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; R12 is hydrogen, aryl or 5-10 membered heteroaryl having 1-3 heteroatoms selected from N, NR7, S and O, cycloalkyl of 3-6 carbon atoms, cycloheteroalkyl having 5 to 8 carbon atoms having 1 to 2 heteroatoms selected from N, NR7, S and 0, or alkyl of 1-6 carbon atoms; A is O, S, SO, S02, NR7, or CH2; X is 0, S, SO, S02, NR7, or CH2; Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
10. Processes for the preparation of a compound of the formula I according to claim 1, characterized in that the processes comprise one of the following: a) reacting a compound of the formula wherein n, X, Y, A, Ri, R2, R3, Rs, R9, ior and R11 are as defined in claim 1 or a reactive derivative thereof, with a compound of the formula R12NHOH wherein Ri2 is as defined in claim 1, to give a compound of the formula I; or b) deprotect a compound of the formula: wherein n, X, Y, A, Rlr R2, R3, R8, R9, R10 RX1 and R12 are as defined in claim 1, and R30 is a suitable protecting group such as t-butyl, benzyl, and tri- alkylsilyl, to give a corresponding compound of the formula I or c) to remove a supported hydroxamate derivative with resin containing the group wherein n, X, Y, A, Ri, R 2, R 3, R 8, R 9, Rio, and R 11 are as defined in claim 1 to give a compound of formula I wherein R 2 is hydrogen; or d) dissolving a mixture (e.g. racemate) of optically active isomers of a compound of formula I to isolate an enantiomer or diastereomer substantially free of the other enantiomer or diastereomers; or e) acidifying a basic compound of formula I with a pharmaceutically acceptable acid to give a pharmaceutically acceptable salt; or f) converting a compound of the formula I having a reactive substituent group or site to a compound of the formula I having a different substituent group or site.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/239,088 | 1999-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01007649A true MXPA01007649A (en) | 2002-05-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6340691B1 (en) | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | |
AU746877B2 (en) | Acyclic metalloprotease inhibitors | |
JP2001519777A (en) | N-hydroxy-2- (alkyl, aryl or heteroarylsulfanyl, sulfinyl or sulfonyl) -3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | |
JP2002535382A (en) | Sulfonamidohydroxamic acid TACE inhibitors based on acetylene α-amino acids | |
EP1147080B1 (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors | |
US6197770B1 (en) | Alkenyl- and alkynl-containing metalloprotease inhibitors | |
EP1169031A1 (en) | Antimicrobial agents | |
MXPA02009309A (en) | CARBOCYCLIC SIDE CHAIN CONTAINING, Nminus;SUBSTITUTED METALLOPROTEASE INHIBITORS. | |
MXPA02003811A (en) | Beta disubstituted metalloprotease inhibitors. | |
MXPA01007649A (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors | |
JP2002535383A (en) | Acetylene β-sulfonamide and phosphinamide hydroxamic acid TACE inhibitors | |
CA2356313A1 (en) | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors | |
JP2002535399A (en) | Heteroarylacetylenesulfonamide and phosphinamide hydroxamic acid TACE inhibitors | |
MXPA01007465A (en) | ACETYLENIC&bgr;-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | |
MXPA01007470A (en) | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors | |
MXPA01007579A (en) | ACETYLENIC&agr;-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | |
MXPA02009310A (en) | Carbocyclic side chain containing metalloprotease inhibitors. | |
MXPA01007513A (en) | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |